Drug, bio-affecting and body treating compositions inventions 05/09

20090136417 - Glycerol ester derivative having metal chelate structure: wherein R1 and R2 represent an alkyl group or alkenyl group; X1 and X2 represent —O—, or —N(Z)-; Z represents hydrogen atom, or an alkyl group; L represents a divalent bridging group comprising an alkylene group, an alkenylene group, —CO—, —O— and the like wherein number of atoms constituting a... Agent: Sughrue Mion, PLLC

20090136418 - Peptides specific for hepatocellular carcinoma cells and applications thereof: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. Novel treatment strategies derived from increased knowledge of molecular oncology are constantly being developed to cure this disease. Here, we used phage display to identify novel peptides, including (SP94), which binds specifically to HCC cells. In vitro, the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090136419 - High dose radionuclide complexes for bone marrow treatment: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such... Agent: Schwegman, Lundberg & Woessner, P.A.

20090136420 - Neoplasm-specific polypeptides and their uses: The present invention features novel polypeptides and methods of using these polypeptides in the diagnosis, detection, monitoring, and treatment of neoplasms in a mammal, e.g., a human.... Agent: Clark & Elbing LLP

20090136421 - Pai-2 conjugates for the treatment and imaging of cancer: A method is described for detecting, visualizing, or treating cells, particularly cancerous cells, that express a uPA/uPAR complex. The method employs a PAI-2 conjugate molecule that comprises PAI-2 or a functional derivative, homologue, analogue, chemical equivalent or mimetic thereof, which PAI-2 is bound, linked, or otherwise associated with a toxin... Agent: Foley And Lardner LLP Suite 500

20090136422 - Radioactive surface source and a method for producing the same: A method for preparing a radioactive surface source for radiotherapy is disclosed. The method comprises: (a) providing a structure having a surface; (b) positioning the structure in a flux of at least one radionuclide so as to collect atoms of the at least one radionuclide on or beneath the surface;... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090136425 - Contrast agents: The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing an aliphatic central moiety containing urea or urethane functions allowing for the arrangement of three iodinated phenyl... Agent: Ge Healthcare, Inc.

20090136426 - Contrast media for using in medical and diagnostic procedures and methods of using the same: The present invention relates to contrast media having a low concentration of contrast agent (active ingredient) and/or low Hounsfield value for use in medical or diagnostic procedures, or for therapeutic use. In one alternative embodiment, the contrast media are comprised of a contrast agent, alone or in combination with a... Agent: Alston & Bird LLP

20090136423 - Methods for assessing psychotic disorders: This invention relates to the assessment of individuals with first-episode psychosis (FEP) or an at risk mental state (ARMS) using visuospatial associative learning tests such as paired associates learning (PAL). Visuospatial associative learning ability as determined by such tests may be prognostic of the severity of psychosis in FEP patients... Agent: Wolf Greenfield & Sacks, P.C.

20090136424 - Rotanone analogs: method of preparation and use: The present invention provides rotenone analogs and methods of making and using them. Labeled with single photon and positron emitting isotopes, the rotenone analogs of the present invention are useful in, for example, clinical imaging applications as tracers to measure cardiac blood flow and detect regions of ischemia.... Agent: Lawrence Berkeley National Laboratory

20090136428 - High throughput genetic screening of lipid and cholesterol processing using fluorescent compounds: The present invention utilizes fluorescent lipids, particularly quenched phospholipid or cholesterol analogues, to facilitate screening for phenotypes representing perturbations of lipid and/or cholesterol processing in a vertebrate; screening for genetic mutations that lead to disorders of phospholipid and/or cholesterol metabolism; and screening of compounds designed to treat disorders of phospholipid... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20090136427 - Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment: Methods of treating inflammatory conditions, disease and disorders are provided. Method include, for example, contacting or administering a sufficient amount of a LIGHT inhibitor to a subject to treat the inflammatory condition, disease or disorder.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090136429 - Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory disease: The present invention relates to a combination of an inhaled/oral PDE 4 inhibitor in combination with inhaled anticholinergic bronchodilators (muscarinic receptor antagonists), preferentially Roflumilast or AWD-12-281 and R, R-glycopyrrolate, for symptomatic or prophylactic treatment of respiratory diseases, especially those accompanied by obstruction or inflammation such as chronic obstructive pulmonary disease... Agent: Venable LLP

20090136430 - Antihistamine/corticosteroid preparations for the treatment of atopic dermatitis: It has been found that the combination of an antihistamine with a corticosteroid is more effective in the treatment of atopic dermatitis than either one used separately. The synergistic effect in some cases results in the disappearance of the atopic dermatitis lesion within one to five days with little or... Agent: Omri M. Behr

20090136431 - Stilbene like compounds as novel hdac inhibitors: The present invention relates to novel stilbene like compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel stilbene like compounds of the general formula (I). Also included is... Agent: Oliff & Berridge, PLC

20090136432 - Oral stannous compositions: e

20090136437 - Cosmetic and dermatological formulations including isononyl benzoate: wherein R1 is an unbranched or branched C9-alkyl radical to at least one component selected from the group of an emollient, emulsifier, surfactant, thickener, viscosity regulator, stabilizer, UV light protection filter, antioxidant, hydrotropic agent, filler, film-forming agent, pearlescent additive, deodorant active compound, antiperspirant active compound, insect repellent, self-tanning agent, preservative,... Agent: Scully Scott Murphy & Presser, PC

20090136436 - Fragrancing composition comprising the combination of a hydroxyaminobenzophenone screen a, a cinnamate screen b and a piperidinol, benzotriazole or dibenzoylmethane compound c: e

20090136435 - Medicated skin care preparation for promoting wound healing: Herbal skin care compositions for the promotion of wound healing is provided.... Agent: Dann, Dorfman, Herrell & Skillman

20090136434 - Tyrosinase enzyme inhibitors from fungal hydroxylation of tibolone: Seven new and one known metabolites of tibolone were obtained by incubation of tibolone with various fungi. Their structures were elucidated by means of a homo and heteronuclear 2D NMR and by HREI-MS techniques. The relative stereochemistry was deduced by 2D NOESY experiment. These metabolites of tibolone were strong inhibitors... Agent: Sarfaraz K. Niazi

20090136433 - Use of hydrophobin-polypeptides and conjugates from hydrophobin-polypeptides having active and effect agents and the production thereof and use thereof in the cosmetic industry: v

20090136438 - Photo-protective dermatological formulations and methods of using the same: It is described a dermatological formulation comprising: one or more amino acid-based antioxidants in an amount effective to reduce or repair photodamage to skin exposed to UV radiation; and a dermatologically acceptable carrier, and methods of using the same.... Agent: Seed Intellectual Property Law Group PLLC

20090136439 - Cosmetic composition capable of imparting exceptional curl-retention properties: The present invention is directed to a composition and method of making-up eyelashes involving applying onto the lashes a cosmetic composition containing: (a) at least one bimodal polymer having both anionic and cationic functionalities; (b) an aqueous microdispersion of at least one wax; (c) at least one coloring agent; (d)... Agent: L'oreal Usa/ Patent Department

20090136440 - Mixtures of phosphorus-containing compounds, a process for their preparation, and their use as flame retardants: R3, R4, R5 are identical or different and, independently of one another, are CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2(CH2)2CH3, CH2Ch(CH3)2, C(CH3)3, C6H5, and/or CH2—C6H5 and where at least 2 compounds of the formulae (I), (III), (IV), or (V) are simultaneously present in the mixture; to a process for their preparation, and... Agent: Clariant Corporation Intellectual Property Department

20090136441 - Method of fabricating nano-antifouling boat paint: A nano-scaled antifouling paint for boat is fabricated. A few hydrophobic nano-particles are added into the paint to obtain a nanostructure and a low surface energy. Thus, sea creatures are hard to adhere on the boat or are easily removed. Moreover, owing to a low wettability of the paint, a... Agent: Troxell Law Office PLLC

20090136442 - Erythropoietin receptor peptide formulations and uses: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages... Agent: Darby & Darby P.C.

20090136443 - Drug carrier: The present invention has an object of providing a drug carrier capable of controlling in vivo pharmacokinetics. The present invention is directed to a drug carrier comprising a molecular assembly having a drug incorporated therein, and the above object can be achieved by a part of the amphiphilic molecules included... Agent: Birch Stewart Kolasch & Birch

20090136444 - molecule and chimeric molecules thereof: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule in or related to the IL-6 protein family such as G-CSF, IL-11, IL-6, LIF or chimeric molecules thereof, comprising at least a portion of the protein... Agent: Seed Intellectual Property Law Group PLLC

20090136446 - Induction of regulatory t cell-resistant helper cd4+ t cells: The invention relates to stimulation of immune responses against antigen(s) and overcoming regulatory T cell suppression of such immune responses against antigen(s).... Agent: Wolf Greenfield & Sacks, P.C.

20090136447 - Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor: The invention involves the discovery that if dendritic cells loaded with a tumor antigen are cultured in interleukin-15 (IL-15), or if T cells activated by the dendritic cells are cultured in IL-15, Treg activity that is specific for the tumor antigen is reduced. This reduction in Treg activity results in... Agent: Mctavish Patent Firm

20090136445 - Sustained release eye drop formulations: This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably α-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents.... Agent: Nixon Peabody, LLP

20090136448 - Antiviral 2-carboxy-thiophene compounds: i

20090136449 - Tetracyclic indole derivatives as antiviral agents: The present invention relates to tetracyclic indole derivatives of formula (I); wherein Ar, D1, D2, D3, D4, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.... Agent: Merck And Co., Inc

20090136450 - Therapy for neurological diseases: The present invention relates to compositions and methods for treating neurological diseases in a subject. More specifically, the invention relates to combination therapies for treating such diseases, using a c-kit inhibitor and a neuroactive compound. The invention may be used against a variety of demyelinating diseases, including multiple sclerosis, in... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090136451 - Humanised baculovirus: We describe a modified baculovirus that has increased specific cell targeting and decreased non-specific targeting by mutation of a heparin sulphate binding motif.... Agent: Marshall, Gerstein & Borun LLP

20090136453 - Methods for treating pain: Methods of treating pain by delivery of anti-inflammatory cytokines, proinflammatory cytokine antagonists, and agents that act to reduce or prevent proinflammatory cytokine actions, to the nervous system are described. These agents can be delivered using gene therapy techniques. Alternatively, the agents can be delivered in protein compositions.... Agent: Robins & Pasternak LLP

20090136452 - Targeting of herpes simplex virus to specific receptors: The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a... Agent: Marshall, Gerstein & Borun LLP

20090136467 - Apolipoprotein analogues: The invention relates to a pharmaceutical composition comprising an apolipoprotein construct, to an apolipoprotein construct, a nucleic acid sequence encoding the apolipoprotein construct, a vector comprising the nucleic acid sequence, a method for producing the apolipoprotein construct, and a method of treatment comprising administering the apolipoprotein construct. The presented data... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090136464 - Methods and compositions for cell therapy: Improved methods of cell therapy are provided using cells and tissues that are histocompatible with a human or non-human transplant recipient. The cells and tissues for transplant produced by the present invention exhibit a youthful state and can be committed to specific cell lineages to better infiltrate and proliferate at... Agent: Ropes & Gray LLP

20090136466 - Methods for making skin cell derived stem cells: The present invention relates to methods of deriving a stem cell from a skin cell.... Agent: Polsinelli Shughart PC

20090136465 - Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof: The present invention relates to methods and compositions for treating, ameliorating or preventing a disease or disorder in a subject by introducing into cells of the subject a therapeutic gene switch construct that controls expression of one or more therapeutic products.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090136454 - Anti-inflammatory activity from lactic acid bacteria: In the present invention, lactic acid bacteria produce soluble factors (such as peptides or proteins) that block inflammatory responses in a mechanism that depends on G proteins and is post-transcriptional to effectively block protein production or secretion by cells.... Agent: Lynn E Barber

20090136455 - Canine probiotic bifidobacteria pseudolongum: According to the invention there is provided a strain of lactic acid bacteria of the species Bifidobacteria pseudolongum obtainable by isolation from resected and washed canine gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Bifidobacteria pseudolongum of the present invention are also provided.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090136468 - Peri-operative composition comprising lactobacillus rhamnosus: The present invention relates to the field of human health and uses of L. rhamnosus strains for the preparation of pharmaceutical and nutritional compositions.... Agent: Foley And Lardner LLP Suite 500

20090136469 - Formulation for oral administration with beneficial effects on the cardiovascular system: Formulation for oral administration, in the form of tablets or of powder for extemporaneous use, able to exert a beneficial effect on the cardiovascular system and having eulipidaemic activity, cholesterol-lowering and triglyceride-lowering activity, antioxidant activity, and a protective action on the vasal endothelium, comprising berberine in combination with a policosanol... Agent: Sughrue Mion, PLLC

20090136459 - Compositions for preventing or treating skin defects and methods of use thereof: Described herein are compositions and methods that treat or prevent skin defects in a subject.... Agent: Gardner Groff Greenwald & Villanueva. PC

20090136456 - Methods of treating neurodegenerative disorders: The present invention provides a selected population of neural cells, including neural stem cells, neural progenitor cells, neural precursor cells, and progeny thereof, which neural cells are selected for an apoE4− phenotype. In some embodiments, the neural cells are further selected for an apoE3+ phenotype. The selected population of neural... Agent: Bozicevic, Field & Francis LLP

20090136457 - Methods of treating spinal cord injury and minimizing scarring: The invention is directed to methods of promoting the healing of spinal cord injury. The invention is further directed to methods of minimizing the extent of scarring following spinal cord injury. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS... Agent: Linda O. Palladino

20090136461 - Neuronal differentiation method of adult stem cells using small molecules: The present invention relates to a neuronal differentiation method of adult stem cells using small molecules, more particularly to a method for inducing differentiation of adult stem cells into nerve cells using small molecules, which enables effective differentiation into nerve cells and, thus, is useful in treating intractable CNS disorders... Agent: Frommer Lawrence & Haug LLP

20090136458 - Renal carcinoma cell line and uses thereof: The present invention relates to a renal carcinoma cell line capable of activating the immune system in an antigen-specific manner. According to a further aspect, the invention also includes derivatives of the cell line that maintain said activation capacity. The invention also comprises a method for targeting and activating immune... Agent: Mellen & Carrool

20090136463 - Schwann cell bridge implants and phosphodiesterase inhibitors to stimulate cns nerve regeneration: The use of a composition that elevates intracellular levels of cyclic nucleotide cyclases in combination with phosphodiesterase inhibitors and cell grafts to restore function after CNS injury.... Agent: Venable LLP

20090136462 - Tumor associated antigen peptides and use of same as anti-tumor vaccines: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA),... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090136460 - Use of adenosine receptor ligands to promote cell adhesion in cell-based therapies: Intracoronary delivery of endothelial progenitor cells (EPCs) is an emerging concept for the treatment of cardiovascular disease, and enhancement of EPC adhesion to vascular endothelium should improve cell retention within targeted organs, as well as vascular development. The present inventors have shown that stimulation of adenosine receptors (AdoR) in murine... Agent: Fulbright & Jaworski L.L.P.

20090136470 - Regulatory t cells and methods of making and using same: Methods of stimulating or increasing differentiation to regulatory T cells, cultures of regulatory T cells and methods of reducing or decreasing an immune response, inflammation or an inflammatory response, among other things, are provided. Methods include, among other things, contacting blood cells or T cells with an amount of TGF-beta... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090136471 - Treatment of premature birth complications: The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood... Agent: Jones Day

20090136473 - Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders: e

20090136472 - Use of thiazole derivatives and analogues in disorders caused by free fatty acids: X, T, Y, W, A1, A2, R1, R5 and R6 have meanings given in the description, for the manufacture of a medicament for the treatment of a disorder or condition caused by, linked to, or contributed to by, free fatty acids, such as hyperinsulinemia and associated conditions, including type 2... Agent: Morgan Lewis & Bockius LLP

20090136474 - Stabilized protease composition:

20090136475 - Immunokinases: A synthetic, soluble, endogenous complex formed from at least one component A and at least one component B, whereby component A comprises a binding domain for extra-cellular surface structures that internalize upon binding of component A of said complex, and component B has a constitutive catalytic kinase activity and effects... Agent: Dardi & Associates, PLLC

20090136476 - Arabinofuranosidases: The present invention relates to isolated polypeptides having alpha-L-arabinofuranosidase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the polypeptides.... Agent: Novozymes North America, Inc.

20090136477 - Methods of generating and screening for proteases with altered specificity: Disclosed herein are methods for generating proteases with altered specificity for the target molecules they cleave. The invention further discloses methods of using these proteases to treat diseases in which the target proteins are involved with. Cleaving certain target proteins at certain substrate sequences with a protease is a method... Agent: K&l Gates LLP

20090136478 - Methods for using enzymes to disintegrate cancerous tumors in vivo: Methods to disintegrate cancerous tissue in vivo, using proteolytic enzyme compound for the digestion of the cancer cells. These methods exploit the fact that there is a significant difference in the strength and layout of the protein fraction between the normal and the cancer cells.... Agent: Alon Shomer

20090136486 - Biomarkers for human papilloma virus-associated cancer: Cervical cancer cells and HPV+ head and neck cancer cells express three testis-specific genes not normally expressed in somatic cells: testicular cell adhesion molecule 1 (TCAM1), synaptonemal complex protein 2 (SYCP2) and stromal antigen 3 (STAG3). Among the three markers, TCAM1 and SYCP2 are early detection markers. Various methods for... Agent: Quarles & Brady LLP

20090136487 - Bmx mediated signal transduction in irradiated vascular endothelium: Provided are methods for modulating the proliferation of cells and tissues. In some embodiments, the methods include administering to a subject an effective amount of a modulator of a biological activity of a bone marrow X kinase (Bmx) gene product. Also provided are methods for increasing the radiosensitivity of a... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090136483 - Compositions and methods for binding lysophosphatidic acid: Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described.... Agent: Biotechnology Law Group 12707 High Bluff Drive

20090136482 - Drug target protein and target gene, and screening method: The present invention provides target proteins and target genes for bioactive substances such as drugs, and means that enable the development of novel bioactive substances using the same. More specifically, the present invention provides target proteins and target genes for bioactive substances; screening methods for substances capable of regulating bioactivities;... Agent: Leydig Voit & Mayer, Ltd

20090136488 - Inhibition of cancer metastasis: P-Selectin on platelets and endothelium binds cell surface chondroitin sulfate (CS) proteoglycans, which are abundantly and stably expressed on the surface many cancer cells. Binding of the cancer cells through the CS moieties may be blocked to inhibit the interaction of cancer cells with platelets and endothelium. The present inventors... Agent: Hugh Mctavish Mctavish Patent Firm

20090136485 - Methods and compositions for inhibiting cd32b expressing cells: The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090136489 - Methods for the treatment, diagnosis, and prognosis of cancer: We have discovered that antizyme inhibitor (AZI) is expressed at increased levels in highly proliferating cells. We have also discovered that inhibiting antizyme inhibitor, including inhibiting its expression, reduces the growth of cancer cells. The present invention is directed to the use of inhibitors of antizyme inhibitor for the treatment... Agent: David S. Resnick

20090136484 - Novel antibody molecules and nucleic acids: An scFv peptide comprising a VH domain and a VL domain linked by an amino acid spacer is disclosed. The VH domain comprises a sequence with at least 80% sequence identity to the sequence of SEQ ID NO. 64. The VL domain comprises a sequence with at least 80% sequence... Agent: Novartis Corporate Intellectual Property

20090136480 - Transcutaneous immunostimulation: Transcutaneous immunostimulation administers at least one adjuvant by transcutaneous immunization to a subject who has undergone, is undergoing, or will undergo conventional vaccination or another immune response. A subject is selected for treatment to stimulate the immune response to a conventional vaccine or other immuno-therapy. A suspicion, medical history, or... Agent: Morgan Lewis & Bockius LLP

20090136479 - Ubiquitin-like protein isg15 for hiv inhibition: The instant invention provides methods for the treatment and prevention of viral infection, e.g., HIV infection, based on the discovery that viral replication utilizes the ubiquitination pathway of the host cell to replicate. Specifically, the invention provides methods for the treatment and prevention of viral infection, e.g., HIV infection, by... Agent: Edwards Angell Palmer & Dodge LLP

20090136481 - Use of myostatin (gdf-8) antagonists for treatment of sarcopenia (age-related muscle-wasting): The present invention relates to a method of treating sarcopenia in a human or animal patient by inhibiting the activity of myostatin using one or more myostatin antagonists.... Agent: Nixon & Vanderhye, PC

20090136495 - Anti-hepcidin antibodies and uses thereof: Monoclonal antibodies are provided that selectively bind human hepcidin-25 and are characterized as having high affinity for human hepcidin-25 and strong human mature hepcidin neutralizing properties. The antibodies of the invention are useful therapeutically for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a... Agent: Eli Lilly & Company

20090136496 - Chronic lymphocytic leukemia prognosis and treatment: Provided herein are methods for identifying a subject afflicted with chronic lymphocytic leukemia who is responsive to treatment with a chemotherapeutic agent by detecting the presence or absence of at least one APOE4 allele in the subject, the presence of an APOE4 allele identifying the subject as responsive to the... Agent: Myers Bigel Sibley & Sajovec

20090136494 - Combination therapies employing gitr binding molecules: The present invention provides combination therapies that employ a GITR binding molecule in combination with one or more additional agents.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090136491 - Il-17 homologous polypeptides and therapeutic uses thereof: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090136498 - Method for manufacturing recombinant polyclonal proteins: The invention relates to a method for manufacturing a recombinant polyclonal protein composition, in particular a recombinant polyclonal antibody composition. The method comprises obtaining a collection of cells transfected with a library of variant nucleic acid sequences, wherein each call in the collection is transfected with and capable of expressing... Agent: Edwards Angell Palmer & Dodge LLP

20090136497 - Methods for inhibiting cutaneous inflammation and hyperpigmentation: This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis... Agent: Cooper & Dunham, LLP

20090136493 - Modified fusion molecules for treatment of allergic disease: The present invention comprises a fusion molecule comprising a Fcε fragment sequence including functionally active CH2, CH3 and CH4 domains of the constant region of an IgE heavy chain (CHε2-CHε3-CHε4 sequence) linked at its C-terminus to the N-terminus of a second polypeptide including functionally active hinge, CH2 and CH3 domains... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090136490 - Ovr110 antibody compositions and methods for use: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another... Agent: Licata & Tyrrell P.C.

20090136499 - Raf inhibitors and uses thereof: The present invention provides imidazooxazole and imidazothiazole compounds and their synthesis. The compounds of the present invention are capable of inhibiting the activity of RAF kinase, such as B-RAFV600E. The compounds are useful for the treatment of cell proliferative disorders such as cancer.... Agent: Bromberg & Sunstein LLP

20090136492 - Therapy of ocular disorders: The present application describes therapy of ocular disorders using antagonists, such as antibodies, that bind to CD20.... Agent: Genentech, Inc.

20090136500 - Humanized pai-1 antibodies: The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy... Agent: Wilson Sonsini Goodrich & Rosati

20090136501 - Compositions and methods for treating coagulation related disorders: Disclosed are methods for preventing or treating sepsis, a sepsis-related condition or an inflammatory disease in a mammal. In one embodiment, the method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to tissue factor (TF)... Agent: Morrison & Foerster LLP

20090136502 - Preventives/remedies for cancer: The present invention provides a drug containing a substance that inhibits a function of RET, such as an antibody against RET. In addition, the present invention provides a drug containing a substance that inhibits a function of GDNF, such as an antibody against GDNF. Moreover, the present invention provides a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090136503 - Trail receptor-binding agents and uses of the same: This invention relates generally to the preparation of TRAIL receptor-binding agents and uses of the same. In particular, the present invention relates to the preparation of anti-TRAIL receptor antibodies which recognize a common antigen determinant (i.e., epitope) shared by TRAIL-R1 and TRAIL-R2 receptors and their use for TRAIL receptor detection... Agent: Foley & Lardner LLP

20090136506 - Conserved membrane activator of calcineurin (cmac), a novel therapeutic protein and target: The invention discloses the first known function and biological activity of the hypothetical protein MGC14327, now designated cMAC, which is herein identified as an important controller of T-cell activation. It is contemplated herein that cMAC is a suitable drug target for the development of new therapeutics to treat cMAC-associated disorders.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090136504 - Diagnostic and therapeutic target prkx proteins for neurodegenerative diseases: The present invention discloses a dysregulation of a PRKX gene and the protein products thereof in Alzheimer's disease patients and individuals being at risk of developing Alzheimer's disease. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090136507 - Hbm variants that modulate bone mass and lipid levels: The present invention relates to methods and materials used to express an HBM-like polypeptide derived from HBM, LRP5 or LRP6 in animal cells and transgenic animals. The present invention also relates to transgenic animals expressing the HBM-like polypeptides. The invention provides nucleic acids, including coding sequences, oligonucleotide primers and probes,... Agent: Drinker Biddle & Reath (dc)

20090136510 - Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof: The invention provides antibodies or fragments thereof, including human antibodies, specific for Macrophage-Stimulating Protein Receptor (MSP-R or RON), which inhibit RON activation. Also provided are methods to inhibit RON, particularly the use of RON antibodies to treat diseases such as cancer.... Agent: Imclon Lerner, David, Littenberg, Krumholz & Mentlik, LLP

20090136505 - Intranasal administration of active agents to the central nervous system: Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are provided. The polypeptide can be a catalytically active protein or an antibody, antibody fragment or antibody fragment fusion protein. The polypeptides are formulated with one or more specific agents.... Agent: Philip S. Johnson Johnson & Johnson

20090136508 - Method of diagnosing colon and gastric cancers: Objective methods for detecting and diagnosing Colorectal and gastric carcinomas are described herein. In one embodiment, the diagnostic method involves the determining a expression level of colon or gastric cancer-associated gene that discriminate between colon or gastric cancer and normal cell. The present invention further provides methods of screening for... Agent: Townsend And Townsend And Crew, LLP

20090136509 - Use of toll-like receptor 4 antagonists for the treatment or prevention of osteoarthritic conditions: Methods for treating or preventing osteoarthric conditions using Toll-Like Receptor 4 (TLR4) antagonists are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20090136513 - Bicyclo-pyrazoles active as kinase inhibitors: A compound having formula (I): wherein: R, A, R1 and R2, are as defined in the specification, and pharmaceutical formulas thereof, and methods of use thereof, as Kinase inhibitors.... Agent: Scully Scott Murphy & Presser, PC

20090136512 - Cxcl13 antagonists and their use for the treatment of inflammatory diseases: Methods of treating disorders related to CXCL13 activity utilize CXCL13 antagonists and, optionally, TNFα antagonists, such as antibodies, including specified portions or variants, polypeptides, polynucleotides, siRNA, shRNA, ribozymes, and DNAzymes. Disorders related to CXCL13 activity include inflammatory disorders, such as pulmonary disorders, for example, asthma, emphysema, and COPD, and systemic... Agent: Philip S. Johnson Johnson & Johnson

20090136511 - Interleukin-15 antagonist peptide: t

20090136514 - Tetracyclines for treating ocular diseases and disorders: Methods and compositions are disclosed for treating a patient suffering from a condition associated with a retinal and/or choroidal disease or disorder of the eye involving endothelial cell dysfunction, especially vascular endothelial cells of the eye, and especially before or in the absence of neovascularization. The therapeutic method involves administering... Agent: Ropes & Gray LLP

20090136515 - Methods of diagnosing, preventing and treating infection with hepatitis c virus: The present invention provides a method for diagnosing hepatitis C virus (HCV) infection, a preventive agent for and a prevention method for HCV infection, a method for treating HCV infection, and a method for screening anti-HCV drug candidates. The HCV diagnostic method of the present invention comprises the detection of... Agent: Kratz, Quintos & Hanson, LLP

20090136516 - Cd-20 specific antibodies and methods of employing same: The present invention provides monoclonal antibodies and antigen-binding fragments thereof that specifically bind to CD20, as well as pharmaceutical compositions comprising the same. The invention further provides methods of using the monoclonal antibodies, antigen-binding fragments, and pharmaceutical compositions, for example, in methods of depleting B cells or in treating B... Agent: Ropes & Gray LLP

20090136517 - Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit: The present invention provides a composition and a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and a KIT kinase inhibitors, with or without additional agents or treatments,... Agent: Osi Pharmaceuticals, Inc.

20090136518 - Compositions and methods to reduce mutagenesis: The present invention provides methods and compositions for said inhibition of drug resistance. In one embodiment, said invention provides methods and compositions for said inhibition of antibiotic resistance. The invention generally involves said administration of achaogens, agents that inhibit said mutational process, to inhibit said evolution of drug resistance. Also,... Agent: Quine Intellectual Property Law Group, P.C.

20090136520 - Mitochondrial localization of muc1: The invention provides methods of identifying and making compounds that inhibit the interaction between MUC1 and either or both of HSP70 and HSP90. Also embraced by the invention are in vivo and in vitro methods of inhibiting such an interaction.... Agent: Fulbright & Jaworski L.L.P.

20090136519 - Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof: The present invention is directed methods for identifying compounds that have a tissue protective activity using a heteromultimer receptor complex that mediates the tissue protective activities. The complex consists of at least one EPO-R in complex with at least one βc Receptor. These compounds used in the assays to identify... Agent: Frederick J Hamble Warren Pharmaceuticals Inc

20090136521 - Method for selectively depleting hypoxic cells: An improved method for selectively depleting hypoxic cells within the bone marrow is disclosed. The method can be used to enhance engraftment of hematopoietic stem cells (HSCs) in the bone marrow of a host subject. Also disclosed is a method for treating a cancer within the bone marrow of a... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090136522 - Multivalent immunogen: The present invention relates, in general, to HIV and, in particular, to immunogens that present epitopes located in the membrane external proximal region (MPER) of HIV-I envelope gp41 in multivalent form and to methods of using same.... Agent: Nixon & Vanderhye, PC

20090136523 - Anti-cd26 antibodies and methods of use thereof: The present invention provides novel anti-CD26 antibodies and other, related polypeptides, as well as novel polynucleotides encoding the antibodies and polypeptides. The invention also provides methods of making the antibodies and polypeptides. Compositions and cells comprising the antibodies or polypeptides are further provided. Methods of using the antibodies and/or polypeptides,... Agent: Morrison & Foerster LLP

20090136524 - Compositions and methods for diagnosis and treatment of tumors: Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating... Agent: Klarquist Sparkman, LLP

20090136525 - Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform: Compositions and methods for producing compositions comprising immunoglobulins or immunoglobulin fragments having an N-linked glycosylation pattern consisting predominantly of the GlCNAcMan3GlcNAc2 N-glycan structure are disclosed. The GlCNAcMan3GlcNAc2 N-glycan structure effects an increase in binding to the FcγRiπ receptors and a decrease in binding to the FcγRH receptors.... Agent: Merck And Co., Inc

20090136526 - Cd19 binding agents and uses thereof: This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.... Agent: Townsend And Townsend And Crew LLP

20090136529 - Compositions and methods for treatment, research and therapeutic applications for malaria: The present invention provides anti-Plasmodium immunogenic compositions comprising EVP1 (PFD0495c) or an antigenic portion thereof, as well as methods of immunizing against malaria employing these compositions. In other embodiments, the present invention provides methods of identifying Plasmodium infection employing agents that bind to EVP1 or an antibody generated thereto.... Agent: Casimir Jones, S.c.

20090136530 - Influenza hemagglutinin and neuraminidase variants: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.... Agent: Medimmune, LLC Jonathan Klein-evans

20090136528 - Novel immunogenic epitope for immunotherapy: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090136527 - Retro-inverso gonadotropin-releasing hormone peptide and vaccine composition: The invention describes a retro-inverso (RI) gonadotropin-releasing hormone (GnRH) peptide which is capable of eliciting an immune response directed against GnRH, the peptide having the amino acid sequence GPRLGYSWHX, wherein the amino acids are D-amino acids and X is any amino acid. More particularly, X is E, Q, P or... Agent: Morrison & Foerster LLP

20090136531 - Hpv e6 protein t cell epitopes and uses thereof: The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes are identified based on their ability to induce... Agent: Benjamin Aaron Adler Adler & Associates

20090136532 - Vaccine for avian influenza and methods of use: The subject invention pertains to influenza vaccines and particularly avian influenza vaccines (AIV). The invention includes methods for preparing transgenic plant cells to express know HA1 polypeptides having specified homologies that are used to prepare vaccine compositions and methods for inducing protective immunity in an individual, animal, mammal or human.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090136533 - Polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates... Agent: Fulbright & Jaworski L.L.P.

20090136535 - Adjuvant activities of mutants of lt-iia and lt-iib enterotoxin lacking binding to ganglioside: The present invention describes the adjuvant activity of mutants of LT-IIa and LT-IIb enterotoxin which lack ganglioside binding activity. The adjuvant activity of the LT-IIb(T13I) mutant is comparable to that of the wild type LT-IIb. The adjuvant activity of LT-IIa(T34I) mutant is also described which exhibits a late onset adjuvant... Agent: Hodgson Russ LLP The Guaranty Building

20090136534 - Novel recombinant bcg tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease: A vaccine against Mycobacteria tuberculosis (Mtb) is provided. The vaccine comprises a recombinant Bacille Calmette-Guerin (BCG) subunit-based vaccine in which one or more Mtb antigens and one or more Mtb resuscitation or reactivation antigens are overexpressed, and in which at least a portion of the DosR regulon is up-regulated. The... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20090136537 - Lipopeptide compositions and methods of use therof: Compositions comprise lipopeptides, antigens and emulsifying agents. The compositions are used to stimulate an immune response in a subject.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090136536 - Recombinant subunit vaccine: A method is provided of producing an immunogenic complex comprising a heat shock protein (hsp) coupled to a heterologous antigenic polypeptide, which method comprises: (a) expressing the antigenic polypeptide in a cell which cell has been subjected to a stimulus which causes the induction of a heat shock response in... Agent: Marshall, Gerstein & Borun LLP

20090136538 - Stable vaccine formulation: m

20090136540 - Anti-aging composition and collagen production promoting composition: There are provided an anti-aging composition, a collagen production promoting composition, a collagen gel contraction promoting composition, and an integrin production promoting composition for promoting integrin production in fibroblasts/epidermal cell, which have improved collagen production promotion effect and are effective for preventing or reducing wrinkle and/or sagging caused by aging.... Agent: Foley And Lardner LLP Suite 500

20090136539 - Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols: A composition for treating insulin-dependent diabetes, reducing body fat, improving insulin sensitivity, reducing hyperglycemia, and reducing hypercholesterolemia with at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol is disclosed. A method of treating a subject suffering from insulin-dependent diabetes by administering a composition that includes... Agent: Knobbe Martens Olson & Bear LLP

20090136541 - Immunogenic composition: The present application discloses an immunogenic composition comprising at least 2 different N. meningitidis capsular saccharides, wherein one or more is/are selected from a first group consisting of MenA, MenC, MenY and MenW which is/are conjugated to a protein carrier(s) wherein the saccharide:protein ratio (w/w) is between 1:2-1:5, and one... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090136542 - Immunogenic composition and method of developing a vaccine based on portions of the hiv matrix protein: The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one covalent binding site of myristate (SEQ ID NOS: 1-3) on the HIV matrix protein. The present invention contemplates three categories of embodiments: protein or... Agent: Williams Mullen

20090136543 - Vaccine: The present invention provides an immunogenic influenza composition in a dose volume suitable for human use, comprising an influenza virus antigen or antigenic preparation thereof and an adjuvant composition comprising an oil-in-water emulsion, wherein said oil-in-water emulsion comprises a metabolisable oil at a level of below 11 mg and an... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090136544 - Interfering rnas targeting the morbillivirus nucleoprotein gene: The invention relates to interfering RNAs (siRNAs, shRNAs or pre-miRNAs) directed against conserved regions of the mRNA of the N gene encoding the morbillivirus nucleoprotein. The invention also relates to the use of said interfering RNAs for the production of medicaments for use in the treatment or prevention of a... Agent: Morgan Lewis & Bockius LLP

20090136545 - Porcine rotavirus reassortant compositions: The present invention provides rotavirus reassortant immunogenic compositions based on a porcine rotavirus. In particular, porcine rotavirus Gottfried strain-based single VP7 or VP4 gene substitutions which can provide (i) an attenuation phenotype of a porcine rotavirus in humans and (ii) antigenic coverage for G serotypes 1, 2, 3, 4, 5,... Agent: Townsend And Townsend And Crew, LLP

20090136546 - Immunomodulating compositions and uses therefor: The present invention discloses the use of an inhibitor of IL-10 function and an immune stimulator that stimulates the priming of an immune response to a target antigen, in methods and compositions for stimulating and prolonging host immune responses to the target antigen. The methods and compositions of the present... Agent: Seed Intellectual Property Law Group PLLC

20090136548 - Multiple antigenic peptides immunogenic against streptococcus pneumonia: The invention provides a nucleic acid encoding the 37-kDa pneumococcal surface adhesion A protein (PsaA) from Streptococcus pneumoniae. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising unique fragment of at least 10 nucleotides of the 37-kDa protein.... Agent: Klarquist Sparkman, LLP

20090136547 - Zwitterionization of capsular saccharides: Capsular saccharides are typically anionic. In the invention, however, cationic groups are introduced, such that the modified saccharide has a repeating unit which includes both cationic and anionic groups. These cationic and anionic groups can be balanced to give a zwitterionic repeating unit. These modifications can convert a saccharide that... Agent: Novartis Vaccines And Diagnostics Inc.

20090136549 - Transdermal patch containing rasagiline for treatment or prophylaxis of nervous system disease and its preparation process: The present invention relates to a rasagiline transdermal patch for treatment or prophylaxis of nervous system diseases, in which the patch comprises an inert backing layer chemically inert to substrate ingredients, a substrate layer comprising rasagiline or a pharmaceutically acceptable salt thereof, and a protective layer to be peeled off... Agent: Merchant & Gould PC

20090136550 - Modified release formulations of diltiazem: Modified release diltiazem compositions and associated methods of preparation and administration are provided.... Agent: Townsend And Townsend And Crew, LLP

20090136551 - Substituted dicyanoalkanes for combating animal pests: Dicyanoalkane compounds of formula (I), wherein R1, R2, R3, R4 and A are defined as in the description, or the enantiomers or diastereomers or salts thereof are subject matter of the present invention. Further also processes and intermediates for preparing the compounds of formula (I), as well as pesticidal compositions... Agent: Brinks, Hofer, Gilson & Lione

20090136552 - Growth factors nsg28, nsg30, and nsg32: Disclosed are NsG28, NsG30, NsG32 polypeptides, nucleic acids encoding NsG28, NsG30, NsG32 polypeptides, and antibodies that bind to NsG28, NsG30, NsG32 polypeptides as well as methods of making and using the same.... Agent: Ivor R Elrifi Mintz, Levin, Chon,frris, Glovsky And Popeo, PC

20090136555 - Process for the preparation of a hot-melt extruded laminate: A process for the preparation of a bioadhesive laminate comprising a hot-melt extruded reservoir layer and a hot-melt extruded backing layer is provided. The reservoir layer comprises a thermoplastic bioadhesive composition containing an active agent. An active agent-containing thermoplastic bioadhesive hydrophilic composition is hot-melt coextruded with a hydrophobic composition to... Agent: Ratnerprestia

20090136556 - System and method for coating implantable devices: A method and system of coating an implantable device, such as a stent, are provided.... Agent: Squire, Sanders & Dempsey LLP

20090136554 - Transdermal sustained release drug delivery: Provided herein are microprojections and microprojection arrays for delivering biologically active agents. Also provided herein are compositions suitable for coating such microprojections and microprojection arrays.... Agent: Edwards Angell Palmer & Dodge LLP

20090136553 - Triggerably dissolvable hollow fibers for controlled delivery: Provided are tubular structures of a biocompatible, triggerably-dissolvable material such as cellulose or a copolymer having an LCST below physiological temperatures. The structures may be embedded within a cell growth scaffold. The tubular structures are useful in growing 3-dimensional tissue structures because nutrients, cytokines or other cell growth and/or differentiation... Agent: Jesse A. Hirshman, Esq.

20090136558 - Anti-restenosis coatings and uses thereof: The present invention provides coatings or coating compositions for implantable or insertable medical devices containing one or more polymers and a combination of an immunosuppressant agent and an anti-neoplastic agent. In some embodiments, the coatings or coating compositions of the invention control sustained-release of the immunosuppressant agent and the anti-neoplastic... Agent: Choate, Hall & Stewart LLP

20090136559 - Chondrocyte differentiation from human embryonic stem cells and their use in tissue engineering: Methods for inducing differentiation of human embryonic stem cells into chondrocytes for use in tissue engineering applications are provided. One example of a method is a method for inducing differentiation of human embryonic stem cells into chondrocytes comprising aggregating undifferentiated human embryonic stem cells to form embryoid bodies; and culturing... Agent: Baker Botts, LLP

20090136560 - Coated medical device: A coated medical device (10) including a structure (12) adapted for introduction into a passage or vessel of a patient. The structure is formed of preferably a non-porous base material (14) having a bioactive material layer (18) disposed thereon. The medical device is preferably an implantable stent or balloon (26)... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20090136557 - Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots: It has now been discovered that certain mutant forms of pro-urokinase (“pro-UK”), such as so-called pro-UK mutant “M5” (Lys.sup.300.fwdarw.His)-, perform in the manner of pro-UK in lysing “bad” blood clots (those clots that occlude blood vessels), while sparing hemostatic fibrin in the so-called “good” blood clots (those clots that seal... Agent: Medlen & Carroll, LLP

20090136561 - Non-peptidyl agents with phsp20-like activity, and uses thereof: The present invention provides compositions and methods for modulating smooth muscle cells. The present invention also provides methods of identifying small molecule candidate therapeutic agents for modulating smooth muscle.... Agent: Ropes & Gray LLP

20090136562 - Hemostatic material: The present invention relates to hemostatic fabric materials, and to the methods for making and using such materials. In particular, the present invention relates to hemostatic fabric materials made from chemically treated cellulose, where the hemostatic material can be soluble on wound surfaces.... Agent: Kirton And Mcconkie

20090136563 - Method for coating particle with lipid film: A method for coating an object, i.e. a particle, with two sheets of lipid film having a space formed there between. In the method for coating a particle having a positive electrostatic-charging property with two sheets of lipid film, the particle having a positive electrostatic-charging property is brought into contact... Agent: Edwards Angell Palmer & Dodge LLP

20090136565 - Methods of treating neurological diseases by regulating migration of neuroblasts in the adult nervous system with tenascin-r: This invention provides a method for regulating migration of neuronal progenitor cells in the nervous system of a mammal. The method comprises providing a mammal with TNR, a biologically active fragment of TNR, or a TNR agonist in an amount sufficient to direct migration of the neuronal progenitor cells. The... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090136564 - Micelles: The present invention provides micelles, solutions comprising micelles, methods for preparing micelles, and methods for delivering micelles to patients. The micelles have fixed, preselected hydrodynamic diameters and are formed from basic or acidic amphiphilic compounds.... Agent: Lahive & Cockfield, LLP/eisai Floor 30, Suite 3000

20090136566 - Therapeutic triterpenoids: The present invention relates generally to compositions that can be obtained by extraction of birch bark, methods of using such compositions (e.g., methods of medical use, cosmetic use and/or pharmaceutical use), food products and methods of manufacturing such compounds. The compositions are triterpenes, triterpene alcohols, or derivatives of triterpene alcohols.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090136567 - Adhesin-enterotoxin chimera based immunongenic composition against enterotoxigenic escherichia coli: The inventive subject matter relates to an immunogenic composition composed of a chimeric molecule including a conformationally stable adhesin from Escherichia coli fused to a bacterial toxin A subunit, such as cholera toxin A subunit or heat-labile Escherichia coli toxin A subunit. The invention also relates to the adhesin-toxin chimera... Agent: Naval Medical Research Center Attn: (code 00l)

20090136569 - Rapidly disintergrating tablet in oral cavity: When a rapidly disintegrating tablet in an oral cavity is produced, the bitter taste of a drug is suppressed by utilizing (a) a granule which contains a drug having a bitter taste and an excipient and in which the bitter taste has not been suppressed and (b) a granule containing... Agent: Birch Stewart Kolasch & Birch

20090136568 - Tabletting process: A process for producing a compressed solid dosage form containing an active ingredient. The process includes a step of preparing core elements containing the active ingredient. Optionally the core elements are coated with a pharmaceutically acceptable coating layer to form coated pellets. The core elements or pellets are treated with... Agent: Birch Stewart Kolasch & Birch

20090136571 - Pharmaceutical formulations containing irbesartan: The present invention relates to pharmaceutical compositions and formulations for the oral administration of Irbesartan, one of its pharmaceutically acceptable salts or its polymorphs, optionally combined with a diuretic and to a process for the manufacture of said composition.... Agent: Moore & Van Allen PLLC

20090136570 - Taste-masked tablets and granules: Orally administered, taste-masked tablets and granules contain (a) a hydroxypyrimidinone carboxamide, a hydroxy-tetrahydropyridopyrimidinone carboxamide, or a related carboxamide compound, or a pharmaceutically acceptable salt thereof, (b) a taste-masking polymer, (c) a superdisintegrant, and optionally other excipients. The carboxamide compound is an HIV integrase inhibitor, and the tablets and granules are... Agent: Merck And Co., Inc

20090136574 - Compositions comprising at least one aqueous phase and at least one fatty phase which comprises avermectin compounds: Pharmaceutical/dermatological emulsions containing at least one avermectin compound, notably ivermectin, include at least one fatty phase and at least one aqueous phase, the at least one avermectin compound being solubilized in the fatty phase, which emulsions are useful for the treatment of a variety of dermatological conditions/afflictions, in particular rosacea.... Agent: Buchanan, Ingersoll & Rooney PC

20090136572 - Emulsified composition for dilution and cancer vaccine composition: The present invention relates to an emulsified composition for diluting a cancer antigen peptide or a dimer thereof, comprising a particular ester, a particular surfactant, a particular emulsifier, and a water phase. The present invention also relates to a cancer vaccine composition or specific CTL inducer obtained by freshly diluting... Agent: Leydig Voit & Mayer, Ltd

20090136573 - Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof: The present invention provides methods for making, delivering and using formulations that combine a therapeutically active agent(s) (such as for example a Rho antagonist(s)) and a flowable carrier component capable of forming a therapeutically acceptable matrix in vivo (such as for example tissue adhesives), to injured nerves to promote repair... Agent: Fish & Richardson P.C.

20090136575 - Protein formulation: The present invention relates to a new and improved low-concentration formulation of an active enamel substance, such as an enamel matrix, enamel matrix derivative and/or an enamel matrix protein, intended to be used as therapeutic, as propylacetic and/or as cosmetic agent. In the present invention, said active enamel substance is... Agent: Rissman Jobse Hendricks & Oliverio, LLP

20090136576 - Biocompatible composition for replacing/regenerating tissues: A biocompatible composition for replacing/regenerating articular tissues, in particular tissues of the nucleus pulposus but also not articular tissues such as bony tissues, providing a hydrogel matrix comprising a first and a second natural polymer, cells adapted to regenerate the tissue of the disc core, a cross linking agent suitable... Agent: Dennison, Schultz & Macdonald

20090136581 - Copper-based fungicide/bactericide: The present invention discloses an improved copper-based fungicide/bactericide composition. The improved composition offers higher biological activity over typical copper-based products, while requiring significantly less copper in the composition. The present invention also discloses methods of making the improved copper-based fungicide/bactericide composition. The present invention further discloses methods of using the... Agent: Duane Morris LLP (bos)IPDepartment

20090136577 - Intestinal absorptive anti-tumor agent: An objective of the present invention is to provide intestinal absorptive antitumor agents with an excellent intestinal absorptive effect by using injectable antitumor agents. In the intestinal absorptive pharmaceutical agents of the present invention, antitumor components that can be used only as injections are supported by hydroxyapatite particles.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090136579 - Nanoparticles comprising a pdgf receptor tyrosine kinase inhibitor: in which the symbols and substituents have the meanings as given herein above, in free form or in pharmaceutically acceptable salt form; to the intracellular delivery of PDGF receptor tyrosine kinase inhibitors such as Imatinib with bio-absorbable polymeric nanoparticles; the use of such nanoparticles in the manufacture of a pharmaceutical... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090136578 - Pharmaceutical composition comprising perindopril or its salts: The present invention relates to a stable pharmaceutical composition of the ACE inhibitor perindopril or its salts having a defined particle size distribution.... Agent: Arent Fox LLP

20090136580 - Preferential killing of cancer cells and activated human t cells using zno nanoparticles: Here we disclose the response of normal human cells to ZnO nanoparticles under different signaling environments and compare it to the response of cancerous cells. ZnO nanoparticles exhibit a strong preferential ability to kill cancerous T cells (˜28-35X) compared to normal cells. Interestingly, the activation state of the cell contributes... Agent: Pedersen & Company, PLLC

20090136582 - Colloidal magnetic nanobioparticles for cytotoxicity and drug delivery: The present invention provides systems that include magnetic colloidal particles of differing elemental compositions with differing morphologies. The colloidal particles comprise a magnetic material and a shell that surrounds the magnetic material. The colloidal particles can be inductively heated using a magnetic field. The present invention also provides applications of... Agent: Warf/bhgl

20090136583 - Sol-gel phase-reversible hydrogel templates and uses thereof: Discrete microstructures of predefined size and shape are prepared using sol-gel phase-reversible hydrogel templates. An aqueous solution of hydrogel-forming material is covered onto a microfabricated silicon wafer master template having predefined microfeatures, such as pillars. A hydrogel template is formed, usually by lowering the temperature, and the formed hydrogel template... Agent: James H. Meadows And Medicus Associates

20090136584 - Toothpaste: A toothpaste filled in a container which has two chambers and is capable of simultaneously discharging two different compositions filled respectively in the two chambers when the main body of the container is pressed, wherein a ratio of a storage modulus GA′ of Composition (A) filled in one chamber to... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090136585 - Surface-modified nanoparticles for intracellular delivery of therapeutic agents and composition for making same: Surface-modified polymeric nanoparticles (NPs), compositions for making them, and their use in drug delivery are disclosed.... Agent: Dann, Dorfman, Herrell & Skillman

20090136586 - Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood: The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an... Agent: Birch Stewart Kolasch & Birch

20090136587 - Pharmaceutical composition for the treatment of nerve damage comprising blood plasma or serum: The present invention relates to a pharmaceutical composition for the treatment of nerve damage, and more particularly to a pharmaceutical composition for the treatment of nerve damage, which contains blood plasma or serum as an active ingredient. The inventive composition regenerates nerve cells after spinal nerve damage and provides complete... Agent: Intellectual Property / Technology Law

20090136588 - Methods for altering food intake, modifying nutrient digestibility and altering stool quality and/or stool frequency: The invention encompasses methods for altering food intake, modifying nutrient digestibility and altering stool quality and/or stool frequency in an animal by adjusting the balance of metabolizable cations to metabolizable anions consumed by the animal.... Agent: Colgate-palmolive Company

20090136589 - Methods for sealing fluid leaks in lung tissue: A method for reducing leakage of bodily fluids or air through lung tissue within a patient is provided. In one embodiment, the method comprises applying, to an appropriate area of lung tissue, an adhesive composition that is derived from a mixture of KH2PO4, metal oxide, a calcium compound, and water,... Agent: Traves Crabtree

20090136590 - Anti-tumoral, antibacterial and antiviral pharmaceutical composition (variants): The inventive pharmaceutical compositions relate to medicine and veterinary sciences, in particular to agents which exhibit a combined anti-tumoral, antibacterial and antiviral activity and can be used for producing medicinal and veterinary formulations. In the first variant, the composition contains in mass %: 0.016-1.6 silver nitrate, 0.07-0.7 alpha-asparaginic acid, 0.07-0.7... Agent: Houston Eliseeva

20090136591 - Metallothionein as an early biomarker for death secondary to septic shock and as a novel therapeutic target for septic shock: A set of signature genes that predict the severity of septic shock, as well as methods of diagnosing and treating septic shock. The genes and methods are particularly useful for the identification of individuals who are at a high risk of death from septic shock.... Agent: Knobbe Martens Olson & Bear LLP

20090136592 - Vitamin preparation: s

20090136593 - Mazindol combination in the treatment of attention deficit/hyperactivity: The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.... Agent: Foley And Lardner LLP Suite 500

20090136594 - Functionalization of micro-and nano particles for selective attachment to calcium biomineral surfaces: The present invention includes compositions, methods, devices and kits for magnetizing a biological particle by contacting a biological particle with a ferrous or magnetic particle that is able to specifically bind the biological particle and reacting the biological particle with the ferrous or magnetic particle under physiological conditions, wherein the... Agent: Chalker Flores, LLP

20090136595 - Anti-wrinkle cosmetic composition: The present invention relates to a composition for treating skin comprising an acylated short chain bioactive peptide and fulvic acid, and optionally colloidal gold. The invention further relates to a method for topically administering the composition in an amount therapeutically effective to reduce wrinkles by building the dermal fibroblast matrix.... Agent: K.f. Ross P.C.

20090136596 - P38 inhibitors and methods of use thereof: This invention relates to inhibitors of p38 and methods of utilizing the inhibitors and pharmaceutical compositions thereof in the treatment and prevention of various disorders mediated by p38.... Agent: Viksnins Harris & Padys Pllp

20090136597 - Cyclic process for the efficient generation of chlorine dioxide in dilute solutions: An efficient cyclic process and related compositions for the in-situ generation of chlorine dioxide from dilute solutions of chlorite anions at near neutral pH. The cyclic process provides a means of safe and effective use of chlorine dioxide with reduced concern of chlorite accumulation in the aqueous system. The disclosed... Agent: Roy W. Martin

20090136598 - Compositions for the treatment and prevention of eyelid swelling: The invention features topical formulations comprising an osmotically active agent and/or a vasoconstrictor and/or an astringent agent for the treatment and prevention of eyelid swelling, and methods of use thereof.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090136599 - Homeopathic composition and kit therefore: The present invention refers to homeopathic medicine compositions, developed from seven chemical elements which are submitted to successive homeopathic dilutions by means of a specific process in order to provide precise sequence for administration to the patient within given time intervals. The present invention also refers to medicinal kits containing... Agent: Duane Morris LLP - PhiladelphiaIPDepartment

20090136600 - Method for alleviating chemotherapy side effects using extract of dioscorea sp.: Extract fractions of Dioscorea sp. and methods of preparing the extract fractions are disclosed. The extract fractions enhance the proliferation and differentiation of bone marrow cells. Also described are a method for treatment of osteoporosis and a method for alleviation of side effects caused by chemotherapy by using the extract... Agent: Panitch Schwarze Belisario & Nadel LLP

20090136601 - Anti-itch formulations for canines & methods of use thereof: Anti-itch formulations for canines comprised of natural homeopathic ingredients. The formulation includes a combination of oil extracts and other natural ingredients typically characterized as spices or food enhancers. The formulation can be applied to a canine as an itch deterrent in addition to secondary beneficial effects.... Agent: Loza & Loza LLP

20090136602 - Natural immunostimulant compositions, methods for obtaining the same and pharmaceutical formulations thereof: A natural immunostimulant composition for the treatment of immunodeficiency, the composition comprising extract of plant Symplocos racemosa and/or plant Prosopis glandulosa and a pharmaceutically acceptable carrier is disclosed. Also disclosed are methods for obtaining the plant extract, methods for preparing the composition and methods of treating diseases related to immunodeficiency.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090136603 - Active component fraction of high antiviral activity: A method of producing active component fractions from dried and ground root material of a species of the rheum family by extraction with ethanol, removal of lipophilic minor components and methanol, followed by shaking in ethyl acetate and separating the combined ethyl acetate phase into a limited number of fractions... Agent: Law Offices Of Karl Hormann

20090136604 - Bacterial extracts cultured in thermal waters for treating sensitive skin, mucous membranes and scalps: Sensitive skin, mucous membranes and scalps are treated by administering to individuals in need of such treatment, thus effective amounts of at least one extract of a non-photosynthetic and non-fruiting filamentous bacterium cultured in a medium which includes at least one non-sulfurous mineral and/or thermal water, e.g., an extract derived... Agent: Buchanan, Ingersoll & Rooney PC

20090130017 - Targeted short-lived drug delivery: An aspect of the disclosure includes a system for delivering therapeutic agents. In an embodiment, the system includes an implantable medical device comprising at least one reservoir that holds at least one therapeutic agent. Additionally the device includes a delivery mechanism that provides non-systemic in vivo delivery of the at... Agent: Searete LLC Clarence T. Tegreene

20090130018 - Supramolecular aggregates containing chelating agents and bioactive peptides as effective and selective delivery tools for drugs and contrast agents in mri or nuclear medicine: The invention relates to supramolecular aggregates obtained by coaggregation of two monomers: —a first monomer containing a paramagnetic or radioactive metal ion complexed by a chelating agent having a lipophilic moiety, —a second monomer containing a bioactive peptide linked to a lipophilic moiety through an organic spacer. The aggregates are... Agent: Steinfl & Bruno

20090130019 - Methods of perispinal extrathecal administration of large molecules for diagnostic use in mammals: This application concerns novel methods which enable or improve the ability of molecules, particularly large molecules, to cross the blood-brain barrier, the blood-eye barrier, and/or the blood-nerve barrier and therefore be of improved diagnostic and/or therapeutic use in humans and other mammals. These methods involve perispinal administration of imaging agents... Agent: Ezra Sutton, P.A.

20090130020 - Diagnostic agents for positron emission imaging using f-18 radio-labeled amino-alcohols: This invention relates to novel compounds F-18 radio-labeled amino-alcohols suitable for labeling or already labeled by 18F methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).... Agent: Millen, White, Zelano & Branigan, P.C.

20090130021 - Methods, products and uses involving platelets and/or the vasculature: The present disclosure relates to agents which interfere with the binding of GPVI to various components. Agents which interfere with GPVI interaction with one or both of fibronectin and vitronectin or sequences thereof are also disclosed. Methods of treating disorders or diseases which involve pathological, dysfunctional or non-pathological interaction of... Agent: Klarquist Sparkman, LLP

20090130022 - Mri contrast medium containing liposomes: A liposome containing a phosphatidylcholine and a phosphatidylserine in combination as membrane components at a phosphatidylcholine:phosphatidylserine molar ratio of 3:1 to 1:2, and said liposome containing superparamagnetic particles having a mean particle size not less than 1 nm and not more than 50 nm. A means for selectively accumulating an... Agent: Sughrue Mion, PLLC

20090130023 - Multiple contrast agent injection for imaging: MRI based molecular imaging is strongly supported by the accurate quantification of contrast agents. According to an exemplary embodiment of the present invention, contrast agent is applied on the basis of a multiple injection application scheme, during which changes in relaxation rate are determined. This may provide for an accurate... Agent: Philips Intellectual Property & Standards

20090130025 - Apparatus and methods for the production of ultrasound contrast agents: Disclosed is a method of making gas bubbles in a liquid, the bubbles having substantially uniform size suitable for responding to ultrasound or other diagnostic tools. Gas (P2) is forced through one or more pores or nozzles, into the liquid (P1), the nozzles or pores being of substantially uniform diameter,... Agent: Philips Intellectual Property & Standards

20090130024 - Biocompatible n, n-disubstituted sulfonamide-containing fluorescent dye labels: This invention relates to new fluorescent chemical entities, especially fluorescent molecules that comprise biocompatible N,N-disubstituted sulfonamide fluorochromes. This invention also relates to the corresponding reactive versions of such molecules. This invention also relates to the corresponding conjugates with moieties such as peptides, proteins, various biomolecules, carbocyclic and heterocyclic compounds, sugars,... Agent: Goodwin Procter LLP Patent Administrator

20090130027 - Compositions and methods for treating purpura: Embodiments of the present invention are directed to compositions and methods for the treatment of purpura. Preferred compositions comprise an α adrenergic receptor agonist selected from selective α1 adrenergic receptor agonist, selective α2 adrenergic receptor agonist, non-selective α1/α2 adrenergic receptor agonist, agents with α2 adrenergic receptor agonist activity and combinations... Agent: Pepper Hamilton LLP

20090130026 - Pharmaceutical solution formulations for pressurised metered dose inhalers: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090130028 - Cosmetic composition comprising a cationic polyurethane and a silicone, to be applied during hair dressing: e

20090130029 - Glycerol ethers vehicle and pharmaceutical compositions thereof: The present disclosure teaches unique foamable vehicles or carriers comprising at least one glycerol ether, a stabilizer, and water; pharmaceutical and cosmetic compositions with potentially enhanced skin delivery and their uses.... Agent: Wilmerhale/boston

20090130031 - Diamond, precious and semi-precious dust polishing agent for dental veneers and teeth: A diamond dust polishing agent for home use and professional use in the care of natural tooth enamel and dental veneers comprised of a quantity of diamond dust coated with a lubricant in conjunction with a paste for carrying the lubricant coated diamond dust, or other semi-precious, non-toxic abrasive dust,... Agent: James D. Fornari C/o Gersten Savage LLP

20090130030 - Plural activating optical change toothpastes, stimuli and elements: Optical change toothpaste compositions (as well as methods for making and using the same), and methods for inducing and stimulating optical changes and associated elements for imparting optical changes are provided. Optical change toothpastes can possess a plurality of visual and reporting properties and find use in a variety of... Agent: Bozicevic, Field & Francis LLP

20090130032 - Dental appliance cleanser: This invention relates to a dental appliance cleanser which is a metastable emulsion comprising about 50-99% w/w of an aqueous phase, about 1-50% w/w of a water immiscible oily phase, the oily phase having a combination of a one or more immiscible oils and one or more flavor oils. The... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090130033 - Dendrimer-aminobuadiene-based uv screens: The invention relates to UV-absorbing polymers, said UV-absorbing polymer comprising a synthetic amine rich polymer to which is covalently linked to an aminobutadiene represented by the general formula (I) wherein the UV-absorbing polymer has a number average molecular weight Mn of 1000 g/mol to 100.000 g/mol; and said UV-absorbing polymer... Agent: Foley And Lardner LLP Suite 500

20090130034 - Re-engineered uv damage endonuclease, compositions and methods: Provided are methods and compositions for reducing damage to skin by ultraviolet light and other agents that cause distortion to double stranded DNA and methods for reducing damage to other organs due to such DNA distortion. These compositions comprise a novel truncated UV damage endonuclease (a truncated derivative of Uvde... Agent: Greenlee Winner And Sullivan P C

20090130036 - Self tanning product having slimming, firming and toning properties associated therewith: A sunless or self-tanning composition having slimming, firming and toning properties associated therewith. The composition is an emulsion containing safe effective amounts of sunless tanning agents and slimming, firming and toning constituents. A method for preparing such composition is disclosed.... Agent: Dunlap Codding, P.C.

20090130035 - Stabilized preparations comprising phenolic compounds and benzophenones: s

20090130038 - Cosmetic compositions comprising at least one cationic polymer and at least one ester of a c8-c24 fatty acid and oxyethylenated sorbitan comprising 2 to 10 oxyethylene motifs, and cosmetic treatment methods employing said compositions:

20090130037 - Method of applying makeup to a surface and a kit for implementing such a method: b) applying a magnetic field to the deposit to modify the orientation and/or displace at least some of said particles with non-zero magnetic susceptibility.... Agent: Oliff & Berridge, PLC

20090130040 - Cosmetic rinsable mask type composition for skin care:

20090130039 - Gel composition and pack cosmetic using the same: The present invention has an object to provide a gel composition which has an excellent skin whitening effect and shows high storage stability even when ascorbic acid, a salt of ascorbic acid, an ascorbic acid derivative, and a salt of an ascorbic acid derivative is blended, and to provide a... Agent: Trexler, Bushnell, Giangiorgi, Blackstone & Marr, Ltd.

20090130041 - Hydrocarbon-terminated polyether-polyamide block copolymer and uses thereof: A composition comprising (a) a resin composition comprising a block copolymer of the formula hydrocarbon-polyether-polyamide-polyether-hydrocarbon; and (b) a polar liquid. The block copolymer may be prepared by a process comprising reacting together reactants comprising dimer acid, diamine, and a polyether having termination at one end selected from amine, hydroxyl and... Agent: Arizona Chemical Company C/o Bo Segers

20090130043 - Patchouli odorant: c

20090130042 - Topical composition: The invention is directed to a topical composition suitable to control sweat. The composition comprises a low HLB lipid and a silicone oil whereby the composition has at least one metastable phase formed during topical application to the skin. The composition does not interfere with thermoregulation of the body, and... Agent: Unilever Patent Group

20090130045 - Nitrosulfide dyes: Disclosed are nitro-sulfide dyes of formula (1), their salts, isomers, hydrates and other solvates, wherein R1, R2, R3, independently from each other are hydrogen; C1-C20alkyl or C1-C20alkoxy, which may be substituted by one or more C1-C5alkoxy, halogen, —NH2, mono-C1-C5alkylamino, di-C1-C5alkylamino, —NO2 or hydroxy; C3-C6cycloalkyl; —C(O)H; —C(O)—C1-C5alkyl; —C(O)OH; —C(O)O—C1-C5alkyl; halogen; NO2;... Agent: Joann Villamizar Ciba Corporation/patent Department

20090130044 - Skin care method using wax and the apparatus thereof: A skin-treatment method using wax is provided, which includes preheating a skin-treatment wax filled in containers with nozzles in a heating device to melt the wax into a liquid wax capable of being sprayed, and spraying the liquid wax filled in the containers with nozzles in the heating device on... Agent: Pearne & Gordon LLP

20090130046 - Concentrated fragrance composition provided in metered aerosol spray: An aerosol fragrance composition for air freshening is disclosed, wherein the composition comprises a fragrance, one or more organic solvents, a propellant, and other optional ingredients. In use, the composition may be included in an aerosol device having a metered valve for delivering a predetermined dose to the air. Preferably,... Agent: S.c. Johnson & Son, Inc.

20090130047 - Reduction of airborne malodors using hydrogen peroxide and a catalyst-coated media: Compositions, methods and apparatuses for reducing or eliminating malodors from indoor air are described. A method is provided for the reduction or elimination of malodors from indoor air using vapor phase hydrogen peroxide generated from either evaporation from a pH neutral to mildly acidic aqueous-based liquid composition or sublimation from... Agent: S.c. Johnson & Son, Inc.

20090130048 - Topical composition for treating pain: Topical compositions having as the active ingredient a hydrophilic material, such as a polyalkylene oxide homopolymer or copolymer, and methods of use, have been developed for the amelioration or prevention of pain or the sequelae of pain. The composition may be in the form of a cream, gel, lotion, spray,... Agent: Morrison & Foerster LLP

20090130050 - Titanium oxide composite particles, dispersion liquid thereof, and process for producing them: Disclosed are titanium oxide composite particles and a dispersion of the titanium oxide composite particles, which can improve retentivity in blood and accumulation in cancer cells while satisfactorily developing the catalytic activity of titanium oxide particles to be excited upon exposure to ultrasonic waves or ultraviolet light. The titanium oxide... Agent: Carrier Blackman And Associates

20090130049 - Self-sterilizing products: Self-sterilising products, and in particular novel products comprising phthalocyanine derivatives bound to polymers, a process for the preparation of said products and their use for preparing self-sterilising industrial and medical articles or devices, are described.... Agent: Knobbe Martens Olson & Bear LLP

20090130051 - Flavonoid compounds and uses thereof: Novel flavonoid compounds having anti-oxidant activity are described. The compounds and compositions have been shown to exhibit anti-oxidant properties and are particularly useful in the treatment of ischemia and reperfusion injuries. The invention also describes a method to chemically synthesize such flavonoid compounds and test their efficacy. Such compounds and... Agent: Nixon & Vanderhye, PC

20090130052 - Biocide, in particular an agent with fungicidal activity: The invention relates to a polymeric condensation product which can be obtained by reacting guanidine or its salt with an alkylene diamine and an oxyalkylene diamine. Said condensation product has biocidal, in particular fungicidal, activity and is usable as a plant protection product.... Agent: Knobbe Martens Olson & Bear LLP

20090130053 - Natural method of killing bacteria and pathogens in animal scents: The present invention relates to a composition for killing the bacteria and the pathogens that are present in animal scent attractants or animal scent repellents, including a plant derivative and an animal scent. Additionally, the present invention relates to a composition that enhances the scent emitted by animal scents, while... Agent: The Webb Law Firm, P.C.

20090130054 - Apc activators in combination with a cytokine-secreting cell and methods of use thereof: The present invention relates to a method of enhancing anti-tumor protection in a mammal. More particularly, the invention is concerned with combinations comprising antigen presenting cell (APC) activators and a cytokine-secreting cell and methods of administering the combination for enhanced immune response to tumor cells in a patient with a... Agent: Jones Day

20090130056 - Compounds for the treatment of hepatitis c: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090130057 - Compounds for the treatment of hepatitis c: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090130055 - Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha: The invention relates to the use of at least one cytokine from the IL-6 family −gp130, preferably selected from among IL-11, the leukaemia inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin-1, ciliary neurotrophic factor (CNTF), the cardiotrophin-like cytokine (CLC) and combinations thereof or a DNA sequence encoding same, in the preparation... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090130058 - Biologically active composition comprising ethylcellulose: A biologically active composition comprising an ethylcellulose, a polyethylene oxide and a biologically active ingredient, wherein the amount of ethylcellulose is at least about (15) percent, based on the total weight of the composition, can be used in melt-extrusion processes to produce pharmaceutical dosage forms.... Agent: The Dow Chemical Company

20090130059 - Tetrazolyl macrocyclic hepatitis c serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090130061 - Adenovirus vectors containing cell status-specific response elements and methods of use thereof: The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A “cell status” is generally a reversible physiological and/or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using... Agent: Ropes & Gray LLP

20090130060 - Modified vitamin k dependent polypeptides: The present invention relates to modified cDNA sequences coding for vitamin K-dependent polypeptides, in particular human Factor VII, human Factor VIIa, human Factor IX and human protein C and their derivatives with improved stability and extended plasma half life, recombinant expression vectors containing such cDNA sequences, host cells transformed with... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090130062 - Novel application of heparin-binding epidermal growth factor-like growth factor for medical purposes: The present invention provides an agent for protecting the liver and/or promoting liver regeneration, which contains a heparin-binding EGF-like growth factor-like growth factor (HB-EGF) or a partial peptide thereof, or a nucleic acid that encodes same, and an agent for the prophylaxis or treatment of liver diseases. The present invention... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090130070 - Method of treatment: The present invention discloses the use of fetuin and fetuin producing agents in methods and compositions for treating burn injuries in animals.... Agent: Proskauer Rose LLP

20090130071 - Soybean plant and seed corresponding to transgenic event mon87701 and methods for detection thereof: The present invention provides a transgenic soybean event MON87701, and cells, seeds, and plants comprising DNA diagnostic for the soybean event. The invention also provides compositions comprising nucleotide sequences that are diagnostic for said soybean event in a biological sample, probes and primers for use in detecting nucleotide sequences that... Agent: Howrey LLP

20090130069 - Thymidine kinase: A polynucleotide comprising a nucleotide sequence encoding a thymidine kinase wherein at least one of the nucleotides corresponding to the splice donor site nucleotides is replaced by another nucleotide and wherein the nucleotides of the splice acceptor sites are not altered.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090130073 - Microorganisms inhibiting the formation of foot malodor: Described are microorganisms which are able to inhibit the formation of foot malodor by skin microorganisms. Also described are compositions comprising such microorganisms as well as the use of such microorganisms in cosmetic, prophylactic or therapeutic applications.... Agent: Connolly Bove Lodge & Hutz, LLP

20090130072 - Use of lactobacillus kefiranofaciens as a probiotic and a synbiotic: In accordance with the present invention, there is provided a probiotic composition comprising an effective amount of Lactobacillus kefiranofaciens in association with a suitable carrier. The probiotic composition has many probiotic effects such as intestinal adherence, intestinal persistence, positive modulation of the intestinal microflora, protection against intestinal pathogens, immunomodulation, protection... Agent: Calfee Halter & Griswold, LLP

20090130063 - Process for separating and determining the viral load in a pancreatin sample: Processes for separating a viral load from a pancreatin sample and for quantitatively determining the viral load in a pancreatin sample with high sensitivity are described herein.... Agent: Mayer Brown LLP

20090130067 - Cell population having immunoregulatory activity, method for isolation and uses: The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-γ) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune... Agent: Moore & Van Allen PLLC

20090130064 - Differentiation of stem cells and stabilization of phenotypical properties of primary cells: Methods of inducing differentiation of stem cells and stem cells obtained are disclosed. A method for stabilizing the phenotype of isolated primary cells in vitro is disclosed. In both methods, a central role is played by histone deacetylase inhibitors.... Agent: Knobbe Martens Olson & Bear LLP

20090130065 - Multipotent adult stem cells: Isolated human multipotent adult stem cell and isolated populations of cells that include human multipotent adult stem cells are disclosed. Human hair-follicle derived multipotent adult stem cells and methods of preparing isolated populations of cells that include human multipotent adult stem cells are disclosed. Isolated human hair-follicle derived multipotent adult... Agent: Dann, Dorfman, Herrell & Skillman

20090130068 - Oral tissue regeneration and repair: A method for treating an oral condition of a subject by grafting cultured tissue constructs to the oral tissue. The cultured tissue constructs comprise cultured cells and endogenously produced extracellular matrix components without the requirement of exogenous matrix components or network support or scaffold members. Some tissue constructs of the... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090130074 - Preparation of antigen-presenting human gamma delta t cells and use in immunotherapy: Cytotoxic αβ T cells form an essential component in immunity to infections and tumors, and are also implicated in host defense against these challenges. The present disclosure demonstrates the ability of activated γδ T cells to cross-present exogenous antigens to CD8+ αβ T cells, a process previously thought to be... Agent: King & Schickli, PLLC

20090130075 - Energy generating composition: The present invention is drawn to an ephedra- and artificial stimulant-free energy promoting composition, comprising effective amounts of a magnesium amino acid chelate, a B vitamin, a pyruvate salt, and rhodiola. These ingredients work synergistically together to provide energy, without the use of artificial stimulants, caffeine, or ephedrine. Additional amino... Agent: Thorpe North & Western, LLP.

20090130077 - Substituted benzoazole pde4 inhibitors for treating inflammatory, cardiovascular and cns disorders: e

20090130076 - Substituted benzoazole pde4 inhibitors for treating pulmonary and cardiovascular disorders:

20090130078 - Treatment for cardiovascular disease: This invention relates to a method for treating and preventing hypertension by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment. Additionally, the scope of the invention includes a method of treating coronary heart disease by administering... Agent: Mcdermott, Will & Emery

20090130079 - Intraventricular enzyme delivery for lysosomal storage diseases: Lysosomal storage diseases can be successfully treated using intraventricular delivery of the enzyme which is etiologically deficient in the disease. The administration can be performed slowly to achieve maximum effect. Surprisingly, effects are seen on both sides of the blood-brain barrier, making this an ideal delivery means for lysosomal storage... Agent: Genzyme Corporation Legal Department

20090130080 - Placental alkaline phosphatase to control diabetes: The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens may... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20090130082 - Compositions and methods for the treatment and prevention of infections caused by staphylococcus aureus bacteria: The present invention relates to antimicrobial deoxyribonuclease-based compositions that inhibit growth and proliferation of Staphylococcus aureus bacteria. The present invention also relates to methods of administering the compositions in the treatment and prevention of S. aureus infections. The present invention also relates to methods of administering the compositions in the... Agent: Barbara V. Maurer University Of Medicine And Dentistry Of New Jersey

20090130081 - Method for treating pervasive development disorders: A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD,... Agent: Duane Morris LLP - San Diego

20090130084 - Tagged iga1 proteases: The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are... Agent: Choate, Hall & Stewart LLP

20090130083 - Therapeutic agents targeting the ncca-atp channel and methods of use thereof: The present invention is directed to therapeutic compositions targeting the NCCa-ATP channel of an astrocyte, neuron or capillary endothelial cell and methods of using same. More specifically, agonists and antagonists of the NCCa-ATP channel are contemplated. The therapeutic compositions are used to treat cancer, more specifically, a metastatic brain tumor,... Agent: Fulbright & Jaworski, LLP

20090130085 - Amidino-compounds for stabilizing factor vii polypeptide formulations: The invention relates to novel compounds of the formula (I) and their use in stabilization of Factor Vila or other Factor VII polypeptides, particularly in aqueous liquid compositions thereof.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090130086 - Fxiii variants with improved properties: The present invention concerns variant factor XIII, wherein the rate of activation of said variant by thrombin is faster than for wild type FXIII. Methods for enhancing fibrin clot formation, pharmaceutical compositions and the use for the manufacture of medicaments wherein the variant factor XIII is applied are disclosed.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090130087 - Method for measuring the content of a botulinum toxin in a formulation: A method of measuring the concentration of a bioactive agent is disclosed.... Agent: Squire, Sanders & Dempsey L.L.P.

20090130066 - Augmentation and repair of sphincter defects with cells including muscle cells: An embodiment of the invention includes methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or... Agent: Dardi & Associates, PLLC

20090130093 - Binding member for gm-csf receptor: Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFRα), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.... Agent: Klarquist Sparkman, LLP

20090130088 - Compositions and methods for regulating rna translation via cd154 ca-dinucleotide repeat: Compositions and methods for regulating CD154 gene expression are provided that rely on the interaction of hnRNP L with the CA-dinucleotide rich sequence of the 3′-untranslated region of CD154.... Agent: Licata & Tyrrell P.C.

20090130091 - Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies: Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in hematopoietic malignancy cells, and determined to be associated with growth and proliferation of the malignancy cells. Accordingly, methods are provided for treating a hematopoietic cell malignancy associated with elevated Hh pathway activity by reducing or inhibiting... Agent: Dla Piper LLP (us)

20090130090 - N-amide derivatives of 8-azabicyclo[3.2.1]oct-3-yl as ccr1 antagonists: New antagonists of the interaction between the CCR1 Chemokine receptor and its ligands, including MIP-1α (CCL3), represented by formula (I) are disclosed, as well as pharmaceutical compositions comprising them and their use in therapy for the treatment of pathological conditions or diseases susceptible of being improved by antagonism of the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090130092 - Nucleotide phosphate dissipation as a treatment for vascular disorders: The present invention provides a method of treating or preventing immunoinflammatory, vascular, thrombotic or ischemic disorders in a subject, the method comprises administering to the subject an agent which dissipates nucleotide phosphates or generates a product which stimulates adenosine receptors. The present invention also provides a method of treating or... Agent: Butzel LongIPDocketing Dept

20090130089 - Anti-cd20 antibodies and methods of use: Compositions and methods are provided for treating diseases associated with CD20, including lymphomas, autoimmune diseases, and transplant rejections. Compositions include anti-CD20 antibodies capable of binding to a human CD20 antigen located on the surface of a human CD20-expressing cell, wherein the antibody has increased complement-dependent cell-mediated cytotoxicity (CDC) that is... Agent: Alston & Bird LLP

20090130094 - Cytotoxic antibodies directed against antibodies inhibiting factor viii: The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human factor VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70%... Agent: Birch Stewart Kolasch & Birch

20090130101 - Anti-cancer therapy with an extract of scutellaria barbata: Methods of treating cancer with a combination of an extract of Scutellaria barbata D. Don and at least one additional anticancer chemotherapeutic agent are provided. Also provided are kits comprising an extract of Scutellaria barbata D. Don and at least one additional anticancer chemotherapeutic agent.... Agent: Wilson Sonsini Goodrich & Rosati

20090130095 - Anti-cd40 antibodies capable of blocking b-cell activation: Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the... Agent: Alston & Bird LLP

20090130096 - Gene signature of early hypoxia to predict patient survival: The present invention provides methods and compositions for predicting patient responses to cancer treatment using hypoxia gene signatures. These methods can comprise measuring in a biological sample from a patient the levels of gene expression of a group of the genes designated herein. The present invention also provides for microarrays... Agent: Siemens Corporation Intellectual Property Department

20090130099 - Humanized antibodies and compositions for binding sphingosine-1-phosphate: The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P.... Agent: Biotechnology Law Group 12707 High Bluff Drive

20090130102 - Methods for humanizing antibodies and humanized antibodies made thereby: Disclosed herein is the use of three-dimensional structure information to guide the process of modifying antibodies with amino acids from one or more templates or surrogates such that the antigen binding properties of the parent antibody are maintained and the immunogenicity potential is reduced when administered as a therapeutic in... Agent: Burns & Levinson, LLP

20090130100 - Methods of using humanized antibodies and compositions for binding sphingosine-1-phosphate: The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P.... Agent: Biotechnology Law Group 12707 High Bluff Drive

20090130097 - Quinazolinone compounds and methods of use thereof: The present invention relates to quinazolinone compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the quinazolinone compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a... Agent: Bromberg & Sunstein LLP

20090130098 - Specific therapy using integrin ligands for treating cancer: The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered consecutively with said ligands, such as chemotherapeutic agents and or radiation therapy. The therapy... Agent: Arent Fox LLP

20090130104 - Fusion proteins for inhibition and dissolution of coagulation: Fusion proteins containing a ligand which specifically binds to a selected vascular bed linked to an anti-thrombotic molecule are provided. Also provided are methods for use of these fusion proteins to prevent coagulation, to dissolve blood clots and to protect against the risk of iatrogenic side effects including those arising... Agent: Howson & Howson LLP

20090130103 - Purification and protective efficacy of monodisperse and modified yersinia pestis capsular f1-v antigen fusion proteins for vaccination against plague: This disclosure concerns compositions and methods for the treatment and inhibition of infectious disease, particularly bubonic and pneumonic plague. In certain embodiments, the disclosure concerns immunogenic proteins, for instance substantially monodisperse F1-V fusion proteins, that are useful for inducing protective immunity against Y. pestis.... Agent: Klarquist Sparkman, LLP

20090130105 - Compositions that bind multiple epitopes of igf-1r: The instant invention is based, at least in part on the finding that binding molecules which bind to different epitopes within IGF-1R result in improved IGF-1 and/or IGF-2 blocking capabilities when compared to binding molecules that bind to a single IGF-1R epitope. The instant invention provides compositions that bind to... Agent: Lahive & Cockfield, LLP / Biogen Idec Floor 30, Suite 3000

20090130106 - Demibodies: dimerization-activated therapeutic agents: The present invention relates generally to a set of synthetic immunointeractive molecules referred to herein as “demibodies” which are useful in targeting particular cells in a subject. More particularly, the present invention provides a set of demibodies wherein at least two molecules from within the set, each specific for a... Agent: Knobbe Martens Olson & Bear LLP

20090130107 - Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders: The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090130108 - N-cadherin and ly6 e: targets for cancer diagnosis and therapy: The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that overexpress N-cadherin and Ly6-E, including prostrate and bladder cancers. The invention further provides methods of drug discovery to identify pharmaceutical agents that inhibit or prevent the binding of N-cadherin and... Agent: Townsend And Townsend And Crew, LLP

20090130115 - Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use: The present invention provides MSCRAMM® proteins from S. aureus which are putative highly-expressed antigens from methicillin-resistant S. aureus, including communit-associated MRSA (CA-MRSA), and these antigens can thus be utilized in methods of generating antibodies capable of binding these antigens which can be useful in methods of treating or preventing infection... Agent: Stites & Harbison PLLC

20090130113 - Compositions and methods for use for antibodies against sclerostin: The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat disease related to bone abnormalities such as osteoporosis. An embodiment of the invention herein provides an antibody or a functional protein comprising an antigen-binding portion of said antibody for a target... Agent: Novartis Institutes For Biomedical Research, Inc.

20090130109 - Dcl-1 and uses thereof: The present invention relates generally to a novel lectin and to derivatives, homologues, analogues, chemical equivalents and mimetics thereof and, more particularly, to a novel type I C-type lectin, herein referred to as “DCL-1”. In particular, the present invention relates to the use of DCL-1 in therapeutic, prophylactic and diagnostic... Agent: Knobbe Martens Olson & Bear LLP

20090130110 - High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies: The present embodiments are related to high-affinity antibodies directed to IL-8, methods of making and characterizing such antibodies and uses of such antibodies. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the... Agent: Knobbe Martens Olson & Bear LLP

20090130111 - Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells: The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored immunoglobulins and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to... Agent: Medimmune, LLC Jonathan Klein-evans

20090130112 - Spatial for altering cell proliferation: This disclosure provides methods useful for altering cell proliferation by modifying SPATIAL activity in cells. In some methods, thymocyte numbers in subjects with disease-associated immunodeficiencies are increased by administering an agent that inhibits SPATIAL activity. Also provided are methods useful for increasing thymocyte number in a subject by administering an... Agent: Klarquist Sparkman, LLP

20090130114 - Wise binding agents and epitopes: The present invention relates to binding agents for WISE, and includes for their manufacture and use.... Agent: Amgen Inc.

20090130118 - Scutellaria barbata extract and combinations for the treatment of cancer: An extract of Scutellaria barbata D. Don is effective in the arrest of cancer cell growth in the G1 phase, the induction of apoptosis in cancer cells and the shrinking of solid cancers. The extract may be prepared as a pharmaceutical composition for administration to mammals for the treatment of... Agent: Wilson Sonsini Goodrich & Rosati

20090130117 - Substituted tetrazole compounds and uses thereof: The present invention provides tetrazole compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the tetrazole compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically... Agent: Bromberg & Sunstein LLP

20090130116 - Use of ceacam8-specific substances for treating autoimmune diseases and a method for screening substances which induce apoptosis: The invention relates to the use of substances which are specific to CEACAM8 for the manufacture of a medicament for the prophylactic or therapeutic treatment of human autoimmune diseases and/or gout. Another object of the invention concerns the use of CEACAM8-specific substances for apoptosis induction in-vitro. The invention also relates... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20090130119 - Anti-ctla-4 antibody compositions: The present invention provides for novel compositions of anti-CTLA-4 antibodies comprising a chelating agent. Also provided are method of treating diseases and conditions with novel compositions of CTLA-4 antibodies, including various neoplasia conditions.... Agent: Pharmacia Corporation Global Patent Department

20090130120 - Anti-rsv g protein antibodies: Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections.... Agent: Morrison & Foerster LLP

20090130122 - Methods for treating rheumatoid arthritis using il-17 antagonists: A method of treating a mammal afflicted with rheumatoid arthritis comprising administering a soluble form of IL-17 receptor is disclosed.... Agent: Immunex Corporation Law Department

20090130121 - Synthetic peptide copolymers for treatment and prevention of cardiovascular disorders: The present invention relates to the use of random or ordered copolymers including the known copolymer glatiramer (also known as Copolymer 1) and Copolymer 1-related heteropolymers or ordered peptides, for treating or preventing cardiovascular diseases and disorders.... Agent: Cooper & Dunham, LLP

20090130123 - Antibodies to west nile virus polypeptides: The present invention relates to anti-West Nile virus E protein (WNE) antibodies, including human antibodies, and antigen-binding portions thereof. In particular, the invention relates to such antibodies and portions that prevent, inhibit, or treat a flavivirus infection, including a West Nile Virus infection. The invention also relates to antibodies that... Agent: Ropes & Gray LLP

20090130124 - Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration: The present invention satisfies the need in the art by providing methods for altering hematopoietic progenitor cell adhesion and/or migration to a target tissue, and for altering hematopoietic progenitor cell differentiation into a second cell type. The invention also provides methods for screening test compounds for altering the level of... Agent: Medlen & Carroll, LLP

20090130125 - Combination of tumor-associated surface protein antigens and tumor-associated sugars in the treatment and diagnosis of cancer: The invention relates to a kit for the combined use for the treatment of cancer patients, which set comprises an antigen of a cellular surface protein, or an antibody directed against the cellular surface protein, and an antigen of an aberrant glycosylation, or an antibody directed against the aberrant glycosylation.... Agent: Birch Stewart Kolasch & Birch

20090130127 - Adjuvant or pharmaceutical preparation for transdermal or transmucousal administration: An adjuvant for transdermal or transmucosal administration which comprises at least one substance selected from an aliphatic alcohol, a free fatty acid and a fatty acid derivative but does not contain a substance represented by the following formula: wherein R3 and R4 may together form a cyclic ring, and R1... Agent: Licata & Tyrrell P.C.

20090130128 - Antiinfective proanthocyanidin compounds and methods of use thereof:

20090130126 - Dna expression vectors: The invention relates to DNA vectors containing a transcription regulatory sequence derived from Human Cytomegalovirus major immediate early gene that includes exon 1, but not intron A. Vectors, host cells, pharmaceutical and vaccine compositions comprising such host cells and vectors are contemplated.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090130132 - Anti-caveolin-1 polyclonal antibody, and antigen peptide sequence and method for preparing the same: The present invention provides a highly specific anti-Caveolin-1 polyclonal antibody, which is prepared by the following steps: (1) providing an antigen comprising a fragment of Caveolin-1 peptide sequence SEQ ID NO: 1; and (2) subcutaneously injecting said antigen into a rabbit to produce the anti-Caveolin-1 polyclonal antibody. The present invention... Agent: Bacon & Thomas, PLLC

20090130131 - Antigen-drug vehicle enabling switch from selective production of iga antibody to production of both of iga and igg antibodies and transnasal/mucosal vaccine using the same: In the aim of practical utilization of a safe and effective transnasal/inactivated/mucosal vaccine and establishment of a technology for imparting capacity of producing both of IgA and IgG antibodies to a conventional inactivated vaccine, toxoid; allergen, or the like, a means for prevention and treatment of allergy, and the like,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090130133 - Immunogenic polypeptide composed of tumor antigen-derived optimized cryptic peptides, and uses thereof: The present invention pertains to the field of anti-cancer vaccines. More particularly, the invention concerns an optimized polypeptide, which comprises three cryptic tumor peptides with enhanced immunogenicity and comprises the amino acids sequence YLQVNSLQTVYLEYRQVPVYLEEITGYL, for use in an anti-cancer vaccine. Nucleic acids encoding such a polypeptide, as well as complexes... Agent: Alston & Bird LLP

20090130129 - Melanoma-associated endogenous retrovirus (merv) derived peptide sequences and their therapeutic/diagnostic use: The present invention provides antigenic polypeptides derived from the melanoma-associated endogenous retrovirus (MERV). These antigens are useful compounds for the detection of cancerous cells and melanoma-diagnosis as well as melanoma-prognosis. Furthermore these antigenic polypeptides of the present invention form the basis for anti-cancer vaccines.... Agent: Fulbright & Jaworski L.L.P.

20090130130 - Mutant allergen(s): There is provided an isolated polypeptide, derivative, isoform and/or fragment thereof, wherein the polypeptide is a mutant of a Group 5 allergen. There are also provided pharmaceutical compositions(s) and vaccine(s) for the treatment of subjects allergic to at least one Group 5 allergen.... Agent: Volpe And Koenig, P.C.

20090130134 - T cd4+ epitopes of type i and ii latency antigens of the epstein-barr virus, which can be recognized by the majority of individuals in the caucasian populations and applications thereof: The invention relates to immunogenic peptides from EBV type I and II latency antigens, comprising at least one T CD4+ epitope which can be recognized by the majority of individuals in the Caucasian population. The invention also relates to the diagnostic and therapeutic applications of same.... Agent: Morgan Lewis & Bockius LLP

20090130135 - Hcv vaccines: Disclosed are methods and compositions for inducing immune responses against Hepatitis C virus (HCV). The compositions comprise one or more epitope from a hotspot epitope. In certain embodiments, an HCV vaccine comprising at least two epitopes, each from a different hotspot epitope, is provided.... Agent: Fulbright & Jaworski L.L.P.

20090130136 - Chondroitin sulphate a binding domains: The invention is related to the identification of CSA binding domains in var2CSA homologs from different parasite strains and furthermore to an isolated polypeptide comprising a CSA-binding domain sequence substantially as shown in SEQ ID NO:1, or functional equivalent thereof, or the corresponding portion of PfEMP1 from a strain of... Agent: Knobbe, Martens, Olson & Bear, LLP

20090130137 - Multivalent pneumococcal polysaccharide-protein conjugate composition: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic... Agent: Alston & Bird LLP

20090130138 - Antiviral and antibacterial activity from medicinal mushrooms: Compounds having unique antiviral and antibacterial properties are prepared from medicinal mushroom mycelium, extracts and derivatives. The compositions are derived from Fomitopsis, Piptoporus, Ganoderma, Inonotus, Trametes, Pleurotus, and blends of medicinal mushroom species and are useful in preventing and treating viruses including Poxyiridae and Orthopox viruses, flu viruses including bird... Agent: William R. Hyde

20090130139 - Cosmetic active ingredient composed of arginine ferrulate and a microalgae extract and its uses: The invention relates to a novel cosmetic active ingredient composed of a microalgae extract and arginine ferrulate, its uses for activating proteasome and the production of thioredoxin, a cosmetic composition containing it and the use of such a cosmetic composition for combating skin ageing.... Agent: Leyendecker & Lemire, LLC

20090130140 - Capsular polysaccharide solubilisation and combination vaccines: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The... Agent: Novartis Vaccines And Diagnostics Inc.

20090130141 - Compositions and methods for stimulating an immune response against infectious agents: The invention provides for oral compositions for safely stimulating an immune response to mucoadhesive antigens for protection against infectious agents, particularly influenza viruses using heat-labile, mutant Escherichia coli enterotoxins and antigen. Methods of stimulating immune responses and for eliciting IgA antibodies are also provided.... Agent: Novartis Vaccines And Diagnostics Inc.

20090130142 - Streptococcus phocae vaccine: The present invention relates to the use of bacteria of the species Streptococcus phocae for the manufacture of a vaccine, to methods for the production of such vaccines, to bacteria of the species Streptococcus phocae for use in a vaccine and to methods for the combating of Streptococcus phocae infection... Agent: Intervet/schering-plough Animal Health Patent Department

20090130143 - N protein mutants of porcine reproductive and respiratory syndrome virus: The present invention provides a genetically modified PRRS virus, methods to make it and related polypeptides, polynucleotides and various components. Vaccines comprising the genetically modified virus and polynucleotides are also provided.... Agent: Pharmacia & Upjohn

20090130144 - Direct vaccination of the bone marrow: The present invention provides methods for eliciting an effective immune response against a weakly immunogenic disease or for priming T cells to become memory T cells against a weakly immunogenic disease by directly vaccinating into the bone marrow of the patient an antigen associated with the weakly immunogenic disease. Also... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090130145 - Vaccine: The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090130146 - Combination vaccine: The present invention relates to the combination of antigens directed against bacteria and viruses, their uses and the preparation of medicaments in order to confer protection against infectious diseases. In particular, the invention relates to a combination vaccine comprising at least one antigen of Clostridium tetani, at least one antigen... Agent: Novartis Vaccines And Diagnostics Inc.

20090130147 - Capsular polysaccharide solubilisation and combination vaccines: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The... Agent: Novartis Vaccines And Diagnostics Inc.

20090130148 - Mycoplasma bovis vaccine and methods of use thereof: The present invention relates to new attenuated M. bovis bacteria strains. Moreover, the present invention also provides immunogenic compositions comprising live bacteria of an of those attenuated M. bovis bacteria strain, their manufacture and use for the treatment and prophylaxis of M. bovis infections.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090130149 - Bioactive copepod-compositions, processes for the production thereof, and use thereof to prevent or treat hosts infested by phylogenetically similar ectoparasites: The present invention relates to novel compositions comprising copepods, such as marine Calanus species, process for the production thereof and use of said compositions in the prevention and/or treatment of ectoparasite infestations in animals. Further the invention relates to methods for prevention and/or treatment of ectoparasite infestations in aquatic animals,... Agent: Christian D. Abel

20090130150 - Biologically active nanoparticles a carbonate-substituted hydroxyapatite, process for their preparation and compositions incorporating the same: The biologically active nanoparticles of the invention find a preferred use in oral or dental hygiene applications and may be formulated as compositions for oral or dental hygiene such as, for example, solutions, suspensions, oils, gels or other solid products. Other aspects of the invention include a process for preparing... Agent: Steinfl & Bruno

20090130152 - Cosmetic composition comprising an oil: The present invention relates to a composition for making up or caring for the skin having a volatile fraction, a non-volatile fraction and comprising at least one dispersed solid phase and a liquid fatty phase comprising: —at least one oil chosen from dry oils chosen from oils with a viscosity... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090130151 - Dispersion of natural oils and/or synthetic essential oils in water: The invention relates to process for the production of an emulsion, comprising combining an aqueous liquid with a non-aqueous liquid mixture to form a combination, removing dissolved gases from both the aqueous liquid and the non-aqueous liquid mixture and agitating the combination sufficient to form the emulsion. The non-aqueous liquid... Agent: Darby & Darby P.C.

20090130153 - Emulsifier combination, emulsion containing the emulsifier combination, and a process for its production: An emulsifier concentrate containing: (a) a C8-14 alkyl oligoglycoside, (b) a polyol hydroxystearate; (c) a C6-22 acyl glutamate; (d) water; and (e) optionally, at least one auxiliary component, and wherein the composition is ethoxylate-free.... Agent: Fox Rothschild LLP

20090130154 - Topical delivery of biological and cosmetic agents by zeolites: The present invention discloses certain di- and polyvalent metal zeolite compounds (formula I) for topical delivery of biological and skin and hair care agents. The method of treating skin and hair condition via topical application of said zeolite compounds is also disclosed. The said method provides a treatment for topical... Agent: Shyam K. Gupta Bioderm Research

20090130157 - Antimicrobial adhesive films: A multi-layer film for reducing microbial contamination on a surface. The multi-layer film can include a core layer having a first surface and a second surface opposite the first surface, an adhesive layer disposed adjacent the first surface of the core layer, and an antimicrobial layer disposed adjacent the second... Agent: 3m Innovative Properties Company

20090130155 - Biologically active formulation: The present invention provides a formulation characterised by the simultaneous presence in cyclodextrin based supramolecular complexes, of two components, one of which possesses insecticidal, acaricidal, fungicidal, snailcidal or vermicidal activity and the other possesses an activity synergistic with the first, enhancing its effectiveness. The biologically active substance is chosen from... Agent: Knobbe Martens Olson & Bear LLP

20090130156 - Innovative formulation: The present invention relates to a new formulation characterised by the presence of two components, one of which (A) possesses insecticidal, acaricidal, fungicidal, snailcidal or vermicidal activity and the other (B) exhibits synergistic activity with the first by enhancing its effectiveness, and in which the average release time of component... Agent: Knobbe Martens Olson & Bear LLP

20090130158 - Polymer composite film with barrier functionality: Polymer composite material with barrier functionality, in particular for the use in fumigation methods, comprising at least one base polymer compound and at least one barrier functional layer, wherein the barrier functional layer comprises at least one binder that is cross-linkable and after cross-linking capable of water absorbing and gel-forming.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090130159 - Water-dispersible nanoparticle containing microbicide: It is an object of the present invention to provide a nanoparticle containing a microbicide and a biodegradable polymer, which is safe and excellent in terms of dispersion stability and has high transparency and good absorbability due to its small particle size. The present invention provides a water-dispersible nanoparticle, which... Agent: Sughrue Mion, PLLC

20090130160 - Fiber for wound dressing: The invention provides a fluid-wicking, antimicrobial fiber formed of a grooved fiber comprising an antimicrobial material. Fabrics and products comprising the fluid-wicking, antimicrobial fiber are also provided. A medical device of the invention, for example a wound dressing, demonstrates antibacterial and optionally antifungal properties, depending on the selection of the... Agent: Alston & Bird LLP

20090130161 - Material compositions for microbial and chemical protection: An antimicrobial and chemical deactivating composition for use in a liquid medium or for incorporation into a coating, structural plastic materials, thin microporous membranes, textiles and sponges. The composition includes macrosize or submicron particles of silver, platinum with silver and their salts with parabens, oxide, salicylate, acetate, citrate, benzoate and... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20090130170 - Agent eluting bioimplantable devices and polymer systems for their preparation: Bioimplantable devices comprising a polyetherurethane modified by admixture with siloxane surface modifying additive that may be loaded with a therapeutic agent are provided.... Agent: Woodcock Washburn LLP

20090130168 - Ceramic/structural protein composites and method of preparation thereof: Ceramic/structural protein composite scaffolds and their preparation in a simple one-step process are shown.... Agent: Cantor Colburn, LLP

20090130167 - Drug delivery device and method for use with prosthetic device implantation: Implantable drug delivery devices are provided which are adapted to be installed adjacent to at least a portion of an orthopedic prosthetic device implanted on a surgically prepared bone section of a patient. For example, the prosthetic device may be a hip joint replacement or knee joint replacement. The drug... Agent: Sutherland Asbill & Brennan LLP

20090130163 - Drugs with improved hydrophobicity for incorporation in medical devices: The invention provides a medical device comprising a hydrophobic analog of a medicament known to inhibit cell proliferation and migration. The invention also provides a method of treating a narrowing in a body passageway comprising placing an implantable medical device comprising a hydrophobic analog of a medicament known to inhibit... Agent: Leydig Voit & Mayer, Ltd

20090130171 - High concentration gentian violet containing medical devices and methods of making same: Implantable medical devices, such as catheters, treated with a high concentration of gentian violet, and methods of preparing these medical devices are provided.... Agent: Amster, Rothstein & Ebenstein LLP

20090130164 - Method to control cell adhesion and growth on biopolymer surfaces: Methods for treating surfaces of polymeric substrates (as used in medical implants) with inert plasmas to promote the growth of bioentities (such as cells) on these surfaces is disclosed. The treated surfaces are subsequently exposed to an environment to form functionalities associated with enhanced growth of the bioentity on the... Agent: Townsend And Townsend And Crew, LLP

20090130165 - Mif inhibitors: The present invention relates to the use of specific benzimidazolone analogues and derivatives to inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF), and diseases or conditions wherein MIF cytokine or biological activity is implicated. Novel benzimidazole analogues and derivatives are also provided.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090130169 - Sterilizing compositions comprising phosphors for converting electromagnetic radiation to uvc radiation and methods for using the same: There is disclosed a composition for converting electromagnetic energy to ultraviolet C (UVC) radiation or radiation of a shorter wavelength, the composition comprising at least one phosphor capable of converting an initial electromagnetic energy (A) to an electromagnetic energy (B) comprising UVC radiation or radiation of a shorter wavelength, and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090130166 - System for providing implant compatibility with recipient: A system for providing or enhancing compatibility between an implant and a recipient. The system includes a recipient, typically a living biological organism, that further includes a target region; an implant having a first attraction means; and a plurality of cells. The cells are compatible with the target region and... Agent: Calfee Halter & Griswold, LLP

20090130162 - Implantable tissue compositions and method: Novel implantable tissue fixation methods and compositions are disclosed. Methods and compositions of tissue, fixed using polymeric and/or variable length crosslinks, and di- or polymercapto compounds are described. Also described are the methods and compositions wherein the tissue is fixed using biodegradable crosslinkers. Methods and compositions for making radio-opaque tissue... Agent: Dardi & Associates, PLLC

20090130173 - Bone matrix compositions and methods: Osteoinductive compositions and implants having increased biological activities, and methods for their production, are provided. The biological activities that may be increased include, but are not limited to, bone forming; bone healing; osteoinductive activity, osteogenic activity, chondrogenic activity, wound healing activity, neurogenic activity, contraction-inducing activity, mitosisinducing activity, differentiation-inducing activity, chemotactic... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090130175 - Composite injectable and pre-fabricated bone replacement material and method for the production of such bone replacement material: A bone replacement material and methods for making and using the same are disclosed. In one embodiment, the bone replacement material comprises a viscous component. The bone replacement material also comprises a plurality of biodegradable inclusions, wherein the inclusions comprise polymers. The inclusions can comprise polymers with therapeutic agents. In... Agent: Conley Rose, P.C.

20090130172 - Modular bioresorbable or biomedical, biologically active supramolecular materials: The present invention relates to a modular supramolecular bioresorbable or biomedical material comprising (i) a polymer comprising at least two 4H-units and (ii) a biologically active compound. Optionally, the supramolecular bioresorbable or bio medical material comprises a bioresorbable or biomedical polymer as third component to tune its properties (mechanical and... Agent: Foley And Lardner LLP Suite 500

20090130174 - Poly (ester urethane) urea foams with enhanced mechanical and biological properties: A biodegradable polyurethane scaffold that includes a HDI trimer polyisocyanate and at least one polyol; wherein the density of said scaffold is from about 50 to about 250 kg m-3 and the porosity of the scaffold is greater than about 70 (vol %) and at least 50% of the pores... Agent: Stites & Harbison PLLC

20090130176 - Intraocular lens with drug delivery system attached thereto: The present invention relates to a device comprising an intraocular lens and a drug delivery system attached thereto, wherein said drug delivery system is or can be loaded with one or more therapeutic agents. Preferably, said drug delivery system comprises a biodegradable matrix material wherein said biodegradable matrix material is... Agent: Birch Stewart Kolasch & Birch

20090130177 - Dental implant and production method for said implant: The invention relates to a dental implant, which comprises a coating at least in those surface areas that come into contact with hard and/or soft tissue when implanted. To ensure that the active ingredient contained in the coating (bisphosphonate) is released into the surrounding tissue or can act in the... Agent: Sughrue Mion, PLLC

20090130179 - Confectionery compositions including markings for delivery of actives: The present invention relates to a confectionery composition including a confectionery region and a marking on the exterior surface of the region, where the marking includes at least one active agent. A method of manufacturing the confectionery composition and of delivering an active agent using the confectionery composition is also... Agent: Hoffmann & Baron, LLP

20090130178 - Formulation for decreasing tobacco, alcohol, drug or food consumption: Formulations have been developed which assist individuals having an addiction such as smoking to reduce or quit engaging in the addictive behavior. Representative behaviors include smoking, excessive alcohol or food ingestion, drug addiction, and ingestion of caffeine or junk food providing quick “highs”. The formulations assist the smoker to become... Agent: Morrison & Foerster LLP

20090130181 - Antibacterial surface treatments based on silver cluster deposition: r

20090130183 - Bilayer composition for the sustained release of acetaminophen and tramadol: The invention relates to a bilayer composition for the delivery of acetaminophen and tramadol over at least a twelve hour period following initial administration. A single administration of the bilayer composition can provide analgesia starting in less than half an hour to about one hour after initial administration with a... Agent: Goodwin Procter LLP Patent Administrator

20090130184 - Compositions and methods for preventing or reducing postoperative ileus and gastric stasis: Disclosed are compositions and methods for preventing or reducing postoperative ileus and gastric stasis. Such compositions comprise a combination of an oxidized regenerated cellulose component and a non-steroidal anti-inflammatory drug (NSAID) which functions as an inhibitor of cyclooxygenase enzyme (Cox) activity. Such methods comprise administering an effective amount of the... Agent: Roberts Mlotkowski Safran & Cole, P.C. Intellectual Property Department

20090130180 - Preparation for external use: A preparation for external use which, even when ingredients such as a drug, absorption accelerator, and plasticizer are contained therein in a large amount, is excellent in pressure-sensitive adhesive properties including cohesive force and which, when a drug is contained therein, enables the drug to have excellent percutaneous absorbability. The... Agent: Licata & Tyrrell P.C.

20090130182 - Topical compositions for treating pain: Topical compositions having as the active ingredient a hydrophilic material, such as a polyalkylene oxide homopolymer or copolymer, and methods of use, have been developed for the amelioration or prevention of pain or the sequelae of pain. The composition may be in the form of a cream, gel, lotion, spray,... Agent: Morrison & Foerster LLP

20090130185 - Anti-microbial compositions comprising a cationic peptide and a glycylglycine endopeptidase: There is provided an anti-microbial composition comprising a cationic peptide and a glycineglycine endopeptidase. The composition has been found to be synergistic against bacteria, especially Gram positive bacteria such as Staphylococcus aureus MSSA or MRSA. In one embodiment the composition comprises ranalexin, dermaseptin, magainin or mixtures thereof together with lysostaphin.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090130186 - Wound dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan and incorporating silver nanoparticles: Silver nanoparticles are mixed with a chitosan solution, to form a chitosan/silver nanoparticle dispersion, which is then subjected to a freeze-drying process, to form a chitosan/silver nanoparticle matrix suitable for use as a wound dressing.... Agent: Ryan Kromholz & Manion, S.c.

20090130187 - Covalent conjugates of cotton and substitutes (viscose, modal cotton) with bioactive substances having antiseptic, sanitizing, acaricidal and insect repellent activity, and a method for obtaining them: The present invention concerns covalent conjugates of cotton and substitutes (viscose, modal cotton) with bioactive substances having antiseptic, sanitizing, acaricidal and insect repellent activity, as well as a new process for obtaining aforesaid conjugates in common equipment of the textile industry, without compromising the marketable and organoleptic properties of the... Agent: Abelman, Frayne & Schwab

20090130188 - Acrylic pressure sensitive adhesives: Solution acrylic polymers suitable for dispersing drugs are particularly useful in transdermal drug delivery applications.... Agent: National Starch And Chemical Company

20090130189 - Means for transdermal administration of nicotine: Devices for transdermal administration of nicotine, which provide for basic as well as additional user activatable administration of nicotine, as well as use of such devices.... Agent: Philip S. Johnson Johnson & Johnson

20090130190 - Transdermal system for the delivery of sufentanil and its analogs: Methods and systems for the transdermal delivery of sufentanil and its analogs are described, from patches having a unique pharmacodynamic profile that can be used to treat persistent pain over extended periods and acute pain episodes of limited duration.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20090130192 - Class iii slrp agonists for the reduction of blood vessel formation: The invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the inhibition of blood vessel formation. In addition the invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a... Agent: Michael Best & Friedrich LLP

20090130193 - Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally: One aspect of the invention relates to methods of treating cancer in a patient comprising administering intraperitoneally to a patient in need thereof a cancer treating effective amount of a composition comprising a lipid-complexed platinum compound wherein the concentration of the platinum compound of the lipid-complexed platinum compound composition is... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090130194 - Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously: In one aspect, the present invention relates to methods of treating cancer in a patient comprising administering intravenously to a patient in need thereof a cancer treating effective amount of a lipid-complexed platinum compound composition wherein the concentration of the platinum compound of the lipid-complexed platinum compound composition is greater... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090130191 - Osteoclast growth inhibitor, oral composition, and preventive or therapeutic agent for bone diseases, containing liposome-encapsulated lactoferrin: A growth of osteoclasts is inhibited by orally administering a liposomal lactoferrin. Thus a bone disease in which the osteoclast is involved is effectively prevented or treated by orally administering the liposomal lactoferrin. The present invention provides an osteoclast growth inhibitor, an oral composition and a preventive and therapeutic agent... Agent: Sughrue Mion, PLLC

20090130195 - Prostate carcinogenesis predictor: A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-ι and (c) comparing the expression level in (b) to a... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090130196 - Bacteriophage composition: Bacteriophage compositions, and methods for preparing bacteriophage compositions are provided. The method for producing an antibacterial composition involves adsorbing an aqueous solution of one or more bacteriophages, or one or more phage components, onto a matrix to produce a composition, and drying the composition to produce the antibacterial composition. An... Agent: Brinks, Hofer, Gilson & Lione

20090130197 - Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt: An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090130198 - Pharmaceutical composition with enhanced bioavailability: The invention pertains to a self-emulsifying pharmaceutical composition containing a lipophilic drug, a surfactant, and a hydrophilic carrier. The invention also provides a method for making the pharmaceutical composition for increasing the bioavailability of a drug by self-emulsification.... Agent: Wpat, PC Intellectual Property Attorneys

20090130199 - Preparations, methods and kits useful for the treatment of cough: The invention relates to a respiratory preparation providing cough relief in a human comprising: a film forming agent; a thickening agent; and the respiratory preparation provides on demand relief. Additionally, the invention relates to a method of providing cough relief in a human comprising: the steps of administering to a... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090130203 - Extracts of chenopodium ambrosioides l., the compositions comprising said extracts, the preparing process and application thereof: The present invention relates to plant extracts, specifically, the extracts of Chinese medicine Chenopodium ambrosioides L. and the composition comprising thereof. The extracts of Chinese medicine Chenopodium ambrosioides L. are prepared by conventional methods for the extraction of volatile oil, and can be used to treat Helicobacter Pylori-induced diseases of... Agent: Evan Law Group LLC

20090130200 - Granules for controlled release of tamsulosin: Granules for controlled release of Tamsulosin, the granules including Tamsulosin and a carrier matrix. The carrier matrix includes a) 2 to 25% by weight of an alginate and b) 30 to 70% by weight of a macromolecular substance selected from the group consisting of: methacrylic acid/ethyl acrylate 1:1 copolymer, methacrylic... Agent: Brinks Hofer Gilson & Lione

20090130202 - Pharmaceutical compositions: Sustained release pharmaceutical compositions contain a drug; microcrystalline cellulose; a diluent (such as starch); a glidant (such as talc); and one or more of ethylcellulose, stearic acid and a salt of stearic acid. Preferred drugs include those that exhibit a low degree of solubility combined with a high potency, particularly... Agent: Panitch Schwarze Belisario & Nadel LLP

20090130201 - Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin δ and rifaximin ε useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090130204 - Dosage form comprising therapeutic formulation: A dosage form is disclosed comprising a semipermeable walled container that houses a capsule, which capsule comprises a drug formulation, a piston, and an osmotic composition. The dosage form delivers the drug formulation through a passageway at a controlled rate over a sustained-release period of time up to 24 hours.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090130205 - Solid pharmaceutical composition comprising donepezil hydrochloride: The invention relates to a solid pharmaceutical composition comprising donepezil hydrochloride hydrate and a process for its preparation. In particular it relates to a composition and a process wherein the donepezil hydrochloride retains its polymorphic form and is therefore highly stable against conversion into other polymorphic forms.... Agent: Swanson & Bratschun, L.L.C.

20090130206 - Controlled release compositions of an antidepressant agent: The present invention relates to controlled release compositions comprising an anti-depressant compound. More particularly, the present invention relates to controlled release compositions comprising paroxetine hydrochloride.... Agent: Jay Akhave

20090130208 - Modified release niacin formulations: Modified release niacin formulations, methods for making the formulations, and methods of using the formulations.... Agent: Townsend And Townsend And Crew, LLP

20090130207 - Pharmaceutical tablets having a relatively inactive segment: An immediate release drug containing pharmaceutical tablet adapted for accurate breaking which has two or more segments with at least one segment containing a drug.... Agent: Accu-break Technologies, Inc.

20090130209 - Novel pyridazinone derivatives:

20090130210 - Pharmaceutical compositions of sirolimus: A pharmaceutical composition of sirolimus comprising an inert core and a sugar overcoat, wherein said sugar overcoat comprises sirolimus, a poloxamer other than poloxamer 188, microcrystalline cellulose and binder has been developed.... Agent: Jayadeep R. Deshmukh, Esq. Ranbaxy Inc.

20090130212 - Composition and improved method for preparation of small particles: The present invention relates to a novel method of loading drug molecules into small pores, along with the composition so produced. In a preferred embodiment, the drug is dissolved in a suitable solvent (which may or may not be biocompatible), and the solution is allowed to move into the pores... Agent: Hoffmann & Baron, LLP

20090130211 - Gelled colloidal emulsion for appetite suppression: Disclosed is a composition and method for producing individual dosages of chewable snack of gelled-colloidal-emulsion containing a large dose of hydrophilic and lipophilic neutraceutical and pharmaceutical preparations and in particular to the administration of edible composition having appetite reduction benefits with desirable eating characteristics for mammals.... Agent: Aly Gamay

20090130213 - Rapidly disintegrating solid oral dosage form: Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, or less than about 2000 nm.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20090130217 - Cosmetic composition containing nanoparticulate a-alumina: Cosmetic or dermatological preparations which contain modified or unmodified nanocrystalline a-alumina having particle sizes of from 10 to 100 nm and d50 values of from 30 to 60 nm are described.... Agent: Clariant Corporation Intellectual Property Department

20090130214 - Gemcitabine derivatives nanoparticles: The invention concerns a 2′,2′-difluoro-2′-deoxycytidine derivative of general formula (I), wherein: R1, R2 and R3, identical or different, represent independently of one another, a hydrogen atom or an at least C18 hydrocarbon acyl radical and of such conformation that it is capable of providing the compound of general formula (I),... Agent: Young & Thompson

20090130215 - Granular preparation containing biguanide compound: A granular preparation containing a biguanide compound and a solidification-preventive agent does not solidify during storage and can avoid the difficulty in dosing.... Agent: Leydig Voit & Mayer, Ltd

20090130216 - Multimodal particulate formulations: Multimodal particulate formulations of medicaments and methods for their use, e.g. by nasal or pulmonary administration for the treatment of various medical conditions, are provided.... Agent: Wilson Sonsini Goodrich & Rosati

20090130218 - Association of oleaginous substance with a mixture of at least two cyclodextrins: The invention concerns a mixture of inclusion complexes comprising or consisting of (1) at least two different cyclodextrins selected among alpha-, beta- and gamma cyclodextrin and/or derivatives thereof, in particular derivatives thereof modified by primary and/or secondary hydroxyl groups, and (2) at least one oleaginous substance, in particular selected among... Agent: Harness, Dickey & Pierce, P.L.C

20090130219 - Composition for improving lipid metabolism: e

20090130220 - Cosmetic composition having pomace olive oil: A cosmetic composition is provided. The cosmetic composition may include pomace olive oil and a first moisturizing oil. The first moisturizing oil may be safflower oil, mango butter, or hemp seed oil. A second oil can also be included and may be coconut oil or grape seed oil. A bacterial... Agent: J. Bennett Mullinax, LLC

20090130221 - Decellularisation of tissue matrices for bladder implantation: The invention provides an improved method of producing a natural, acellular matrix scaffold for subsequent use in tissue-engineered replacement of tissues such as the bladder. Decellularisation is carried out on an expanded or distended bladder and the product retains the strength and compliance of natural material. The invention also provides... Agent: Myers Bigel Sibley & Sajovec

20090130222 - Methods for predicting urine ph: The invention provides methods for predicting urine pH for an animal by determining the amount of selected cations, anions, and sulfur-containing amino acids in a food for consumption by the animal and predicting urine pH using a formula that equates the amount of such cations, anions, and sulfur-containing amino acids... Agent: Colgate-palmolive Company

20090130223 - Cosmetic preparation with aquaporin stimulators and the use thereof: The development relates to cosmetic and dermatological preparations containing aquaporin stimulators, in particular glyceryl glycosides, and their use to improve the moisturizing of the skin.... Agent: Greenblum & Bernstein, P.L.C

20090130224 - Granular bleach-activating mixtures: e

20090130225 - Macrolides derivatives as antibacterial agents: The present invention provides macrolide derivatives, which can be used as antibacterial agents. Compounds described herein can be used for treating or preventing conditions caused by or contributed to by gram-positive, gram-negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp., Chlamydia spp., Mycoplasm, Legionella... Agent: Ranbaxy Inc.

20090130226 - Method of producing biomaterials and biomaterials produced by the same: A biomaterial producing method and a biomaterial produced by the same are disclosed. The method includes preparing an electrolyte by dissolving monobasic potassium phosphate (KH2PO4) and calcium chloride (CaCl2) in distilled water placed in an electrolytic bath, adjusting a concentration of calcium chloride (CaCl2) in the electrolyte, immersing titanium (Ti)... Agent: Volpe And Koenig, P.C.

20090130227 - External preparation for skin: The present invention provides an external preparation for skin which contains 5-aminolevulinic acids as active components and which is excellent in skin-beautifying effects such as prevention/amelioration of skin roughness, dry skin, wrinkles, sagging and flecks of skin, and improvement of turnover of corneum; and in an ameliorating effect on skin... Agent: Morgan & Finnegan Transition Team C/o Locke Lord Bissell & Liddell

20090130229 - Antitumor uses of compound: The use of an arylidene 2-indolinone derivative for treating tumors involving Met, PDGF-R, FGF-RI, FGF-R3 or Kit tyrosine kinases, or a Ret oncoprotein which includes a MEN2-associated mutation is disclosed.... Agent: Seed Intellectual Property Law Group PLLC

20090130228 - Pharmaceutical combination for the treatment and or chemosensibilization of refractory tumors to anticancer drugs: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide,... Agent: Hoffmann & Baron, LLP

20090130230 - Silicate containing compositions and methods of treatment: The present invention relates to compositions comprising a silicate and methods of use thereof. In particular, the compositions of the present invention are suitable for treating inflammatory conditions, cancer, bacterial and viral infections, and infected and uninfected wounds. The compositions of the present invention can also be useful in treating... Agent: Foley And Lardner LLP Suite 500

20090130231 - Pharmaceutical formulation for treating tinea of feet and hands and preparation thereof: A pharmaceutical formulation for treating tinea of feet and hands is disclosed, which is composed of Fructus Gleditsia, Alumen and Borneol. Also disclosed is a cream preparative method of the pharmaceutical formulation, which comprises Fructus Gleditsia is decocted with water, and the decocted liquid is dried under decompression into powder,... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090130232 - Composition and method for treatment of oral inflammation an ulceration: p

20090130233 - Two part lotion: The present invention provides a composition, substantially a lotion, containing a source of nitrite ions and water. The composition, substantially a lotion, is preferably provided in two distinct and separate formulations. One of these formulations may or may not contain a source of nitrite ions. The composition is easily washed... Agent: Klauber & Jackson

20090130236 - Anti-microbial agent and anti-microbial composition: The present invention relates to an anti-tetanic agent comprising a Sasa extract; an anti-fungal agent comprising a Sasa extract and an organic acid; an anti-viral agent comprising a Sasa extract; an anti-microbial agent comprising Sasa tannin; and an anti-microbial composition comprising a Sasa extract and an organic acid.... Agent: Sughrue Mion, PLLC

20090130234 - Composition for the treatment of diabetic periodontitis: The invention refers to the use of an extract of a part of a Solidago species, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active agent for the preparation of a pharmaceutical composition... Agent: K.f. Ross P.C.

20090130235 - Method for marketing vibration medicine products: It is disclosed a method for marketing vibration medicine products. The method includes getting an original liquid vibration medicine product, producing a powder vibration medicine product, providing that powder vibration medicine product for blending inside a food or drink entity to get a new entity, and marketing the new entity... Agent: Dr. Mark M. Friedman C/o Bill Polkinghorn - Discovery Dispatch

20090130237 - Process of making purified extract of scutellaria barbata d. don: An extract of Scutellaria barbata D. Don is effective in the arrest of cancer cell growth in the G1 phase, the induction of apoptosis in cancer cells and the shrinking of solid cancers. The extract may be prepared as a pharmaceutical composition for administration to mammals for the treatment of... Agent: Wilson Sonsini Goodrich & Rosati

20090130238 - Composition for preventing and treating hangover: There is provided a composition for preventing and treating katzenjammers comprising at least one extract selected from the group consisting of a Rosa roxburghi extract, an Engelgarditia chrysolepsis HANCE extract, a Nelumbo nucifera extract and a combination thereof as an active ingredient.... Agent: Casimir Jones, S.c.

20090130239 - Method for preventing or treating edema or dermatitis using glehnia littoralis fr. schmidt et miquel extract: The present invention relates to a method for preventing or treating edema or dermatitis using Glehnia littoralis Fr. Schmidt et Miquel extract. The Glehnia littoralis Fr. Schmidt et Miquel extract extracted using water, alcohol or a mixture thereof as a solvent inhibits production or secretion of cytokine regulators, the inflammatory... Agent: Merchant & Gould PC

20090123365 - Multifunctional nanostructures, methods of synthesizing thereof, and methods of use thereof: A nanostructure and methods of synthesizing same. In one embodiment, the nanostructure includes a nanospecies, a hydrophobic protection structure including at least one compound selected from a capping ligand, an amphiphilic copolymer, and combinations thereof, wherein the hydrophobic protection structure encapsulates the nanospecies, and at least one histidine-tagged peptide or... Agent: Morris Manning Martin LLP

20090123366 - Targeted therapy: In order to target a diseased material in a subject, a monocyte, or monocyte-derived cell, such as a macrophage, which incorporates a magnetic material, such as a magnetic particle or a ferrofluid, preferably having a biocompatible coating, is proposed to be administered. A magnetic energy source may then be applied... Agent: Swanson & Bratschun, L.L.C.

20090123367 - Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties... Agent: K&l Gates LLP

20090123368 - Use of dkk-1 protein in the cancer diagnosis: Use of DKK-1 protein or the nucleic acid sequence in preparation of cancer diagnostic agents or kits, method to detect liver cancer with the monoclonal antibody thereof, the kit comprising anti-DKK-1 antibody or protein specific nucleic acid probes, together with a label, and method to detecting specific DKK-1 protein expression... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090123369 - Styrylpyridine derivatives and their use for binding and imaging amyloid plaques: This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a... Agent: Woodcock Washburn LLP

20090123370 - Alphavbeta6 peptide ligands and their uses: AVβ6 peptide ligands, functional variants thereof and their nucleic acids encoding them are disclosed with their uses in the treatment and imaging of AVβ6 mediated diseases.... Agent: Dann, Dorfman, Herrell & Skillman

20090123371 - Molecular signature of cancer: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.... Agent: Myers Bigel Sibley & Sajovec

20090123373 - Amyloid-imaging agents: A molecular probe for use in the detection of amyloid in a subject includes a dibenzothiazole derivative.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20090123372 - Development of molecular imaging probes for carbonic anhydrase-ix using click chemistry: The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents.... Agent: Siemens Corporation Intellectual Property Department

20090123375 - Ccr3 inhibition for ocular angiogenesis and macular degeneration: Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.... Agent: Crowell & Moring LLP Intellectual Property Group

20090123374 - Methods for determining cancer resistance to histone deacetylase inhibitors: Described herein are methods and compositions for determining whether a particular cancer is resistant to or susceptible to a histone deacetylase inhibitor or to histone deacetylase inhibitors. The methods include analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also... Agent: Wilson Sonsini Goodrich & Rosati

20090123377 - Method for testing substances or mixtures of substances,use of said method and corresponding test kits: The invention relates to a method for testing substances and mixtures of substances for toxic characteristics, to the use of said method and to corresponding test kits. The method is essentially based on the determination of a fatty acid binding protein from the liver, L-FABP. The use of said method... Agent: Connolly Bove Lodge & Hutz, LLP

20090123380 - Method of assaying satiety enhancing tastants: Compositions for enhancing satiety and weight loss in an individual, assays for assessing a tastant for enhancing satiety and weight loss, and methods of using the composition to suppress appetite and enhance weight loss are provided.... Agent: Bryan Cave, LLP

20090123379 - Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor: The present invention provides methods for determining or identifying compounds that modulate the function of an isolated retinal pericyte or blood vessel, wherein a change in the contractile state of said pericyte or blood vessel is determined in the presence of a test compound, said change indicating that the test... Agent: Knobbe Martens Olson & Bear LLP

20090123376 - Therapeutic agents with decreased toxicity: The present invention relates to therapeutic agents with reduced toxicity comprising a serum albumin binding peptide (SABP), a targeting agent and a cytotoxic agent. The present invention also relates to methods for reducing the toxicity of therapeutic agents and methods of treatment using the therapeutic agents with reduced toxicity.... Agent: Goodwin Procter LLP

20090123378 - Uses and compositions for treatment of ankylosing spondylitis: The invention provides methods, uses and compositions for the treatment of ankylosing spondylitis (AS). The invention describes methods and uses for treating ankylosing spondylitis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to reduce signs and symptoms of ankylosing spondylitis in a... Agent: Lahive & Cockfield, LLP/abbott Floor 30, Suite 3000

20090123384 - Method for magnetic resonance imaging using stimulus induced rotary saturation with a contrast agent: A method and system for producing an image of a subject with a magnetic resonance imaging (MRI) system, in which the presence of a contrast agent is detected using a spin-lock pulse sequence, is described. More specifically, a contrast agent that induces saturation of magnetic resonance signals responsive to a... Agent: Quarles & Brady LLP

20090123385 - Preparation of dispersions of particles for use as contrast agents in ultrasound imaging: A method of making a suspension of particles in a first fluid of a size suitable for responding to ultrasound, by forcing a second fluid (2) through an array of pores (30) into the first fluid (1), the pores being of substantially uniform diameter, and the pressure of the second... Agent: Philips Intellectual Property & Standards

20090123381 - Imaging and therapeutic targeting of prostate and bladder tissues: The present invention provides methods for imaging and the treatment of cancer. In certain embodiments, a polyarginine (e.g., R11) may be used to selectively image prostate or bladder cells (e.g., a metastatic prostate cancer). In other embodiments, a DOC-2/DAB2 peptide, optionally conjugated to a cell permeable peptide (e.g., R11) may... Agent: Fulbright & Jaworski L.L.P.

20090123382 - Light emitting microorganisms and cells for diagnosis and therapy of tumors: Provided are diagnostic and pharmaceutical compositions containing a microorganism or a cell containing a DNA molecule encoding a detectable protein or a protein that a detectable signal, such as a luminescent or fluorescent protein. Methods of tumor targeting and tumor imaging using the microorganisms and cells are provided. Also provided... Agent: K&l Gates LLP

20090123383 - Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates: The present invention is directed to a non-isotopic methods for the in vitro and in vivo detection of hydroxyapatite-positive cells and structures.... Agent: Goodwin Procter LLP Patent Administrator

20090123386 - Abuse resistant capsules: Hard shell capsules filled with a pharmaceutical medicament and at least one modifier, selected to prevent abuse of the medicament are described. The modifier may have a high melting point, and therefore melt at a temperature too high to inject or be insoluble in liquid, having a density less than... Agent: Nixon & Vanderhye, PC

20090123387 - Buccal, polar and non-polar spray or capsule containing cardiovascular or reneal drugs: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring... Agent: Dickstein Shapiro LLP

20090123390 - Compositions for the treatment of gastrointestinal inflammation: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.... Agent: Wilson Sonsini Goodrich & Rosati

20090123389 - Methods for modulating th17 cell development in the treatment and prevention of cellulite: This invention relates generally to methods and compositions for modulating the development of Th17 cells for use, for example, in the treatment of cellulite.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090123391 - Novel formulations: A pharmaceutical aerosol formulation includes a therapeutically effective amount of particulate medicament of formula (I) or a solvate thereof, a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane or mixtures thereof, and a biocompatible polymer comprising one or more compounds of formula (II)... Agent: 3m Innovative Properties Company

20090123388 - Prodrugs of short-chain fatty acids and treatment methods: Prodrugs made up of biologically-active short-chain fatty acids or derivatives thereof conjugated to neutral or cationic amino acids capable of intracellular transport by ATB0,+ are provided. The short-chain fatty acid or derivative thereof can be attached to the amino acid through a hydroxyl group of the amino acid to form... Agent: Greenlee Winner And Sullivan P C

20090123392 - Fragrance accords to combat the perception of body odor: o

20090123393 - Multiphase toothpaste composition: Multiphase toothpaste composition comprising a first phase disposed co-axially within a second, visually clear gel phase, the second phase comprising from 1 ppm to 100 ppm of a pigment.... Agent: Unilever Patent Group

20090123394 - Selection and use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries: New strains of Lactobacillus that have been selected for their capability of improved reduction the number of Streptococcus mutans in the mouth of mammals through inhibiting activity in combination with better binding to the oral mucins and dental plaque, thereby preventing, reducing or treating dental caries, and products derived from... Agent: Lynn E Barber

20090123395 - flavour compositions: Flavor compositions which reduce or prevent dental cavities based on the use of flavor materials found to inhibit the production of acid by micro-organisms in the oral cavity, e.g. lactic acid production from glucose by Streptococcus mutans. The compositions include at least two flavor materials from group (a) and at... Agent: Morgan Lewis & Bockius LLP

20090123396 - Anti-sensitivity,anti-caries, anti-staining, anti-plaque ultra-mild oral hygiene agent: This invention relates to a composition useful as a dentifrice comprising a surfactant agent consisting essentially of monoalkyl and dialkyl phosphate esters, wherein the ratio of monoesters to diesters is greater than 1, and optionally an abrasive agent consisting essentially of siliceous materials.... Agent: Rhodia, Inc.

20090123397 - Microbiocidal compositions: A microbiocidal composition comprising: a non-halogenated 2-alkyl-3-isothiazolone, and chlorphenesin and/or an alkane diol, wherein the alkyl group in the non-halogenated 2-alkyl-3-isothiazolone comprises 1 to 4 carbon atoms, the alkane diol comprises from 5 to 12 carbon atoms, and the hydroxyl groups of the alkane diol are vicinally substituted.... Agent: Hedman & Costigan P.C.

20090123399 - Packaged liquid edible composition comprising carotenoids: A packaged liquid edible composition comprising a blend of at least two species of fruit and/or vegetables in liquified, puree, pulp, concentrate, extract or juice form, wherein said composition is packaged in a container in an amount of a specific volume and having a specific consistency, and wherein said composition... Agent: Unilever Patent Group

20090123398 - Silicon-free hydrocarbons providing aesthetic volatility: Non-silicone-based compositions including hydrocarbons of widely different structures and origins are combined into single, stable, homogenous products with both aesthetic and volatility properties similar to a cyclopentasiloxane. The combinations are useful to cosmetic formulators as full or partial replacement products for cyclopentasiloxanes, or “volatile silicones.”... Agent: Gibson & Dernier L.L.P.

20090123400 - Compositions and methods for reducing photosensitivity associated with photodynamic therapy: The present invention provides compositions and methods for decreasing photosensitivity induced by photodynamic therapy (PDT). The compositions and methods of the present method employ porphyrin complexing molecules as agents for reducing photosensitivity.... Agent: Foley And Lardner LLP Suite 500

20090123401 - Method of predicting spot formation on the skin using spot site-accelerating genes as an indicator thereof and method of screening inhibitors of spot formation on the skin: The present invention provides a skin test method for predicting the formation of spots in the skin. This method is characterized by judging skin to be susceptible to spot formation in the case expression of genes consisting of MLSTD1, MOGAT1, FADS2, FADS1, HSD3B1, ELOVL3, BG1, PECR, FABP7, FA2H, HAO2, ALOX15B,... Agent: Foley And Lardner LLP Suite 500

20090123403 - Cosmetic composition with color and/or optical effects: The present invention relates to a cosmetic process for making up and/or caring for keratin material(s), comprising the application, on contact with a keratin material, of at least one cosmetic composition consisting of at least 50% by weight, relative to its total weight, of compound(s) approved for food use, including... Agent: Oliff & Berridge, PLC

20090123402 - Lip cosmetics: [Solving Means] A lip cosmetic of the present invention contains the following ingredients (a) to (e): (a) an oligomer produced from behenic acid, eicosane diacid, and a glycerin condensate; (b) a polyol; (c) water; (d) an ester oil composed of a carboxylic acid having 2 to 36 carbon atoms and... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090123404 - Fragrance composition: o

20090123405 - Hair shine and styling hold composition and methods of forming and using same: A hair styling and shine composition and methods of using and forming the composition are disclosed. The composition includes about 0.1 wt % to about 60 wt % of a volatile silicone, about 0.1 wt % to about 20% wt % of hair fixative resin, and about 40 wt %... Agent: The Dial Corporation

20090123406 - Organic therapeutic and cosmetic preparation: A mixture of an aqueous solution, essential oils and mechanically extracted Phaeophyte kelp cytoplasm results in an emulsion with cosmetic and therapeutic properties. The preparation may be used on human and animal hair or skin. The moisturizing properties of the kelp cytoplasm provide the aqueous solution to the hair (keratin)... Agent: Zale Patent Law

20090123407 - Mono-, di- and polyol phosphate esters in personal care formulations: A hydrophilized personal care formulation, which can be in the form of a hand or body soap (liquid or bar), lipstick, body wash, makeup remover, skin cleaner, hair conditioner, skin or hair moisturizer. The formulation employs an organophosphorus material or a mixture of an organophosphorus material, for example, mono-, di-,... Agent: Novak Druce + Quigg, LLP

20090123408 - Polymer and cosmetic preparation: h

20090123409 - Enhanced shaving compositions: A method for treating human skin comprising a shaving composition consisting of algae extract, willow bark extract, de-ionized water, propylene glycol, aloe vera, guar gum, diazolidinyl urea, and iodopropynyl butylcarbamate. The method further comprising applying the shaving composition to the skin prior to shaving the skin.... Agent: Conley Rose, P.C. David A. Rose

20090123410 - Keratotic plug removing composition: The present invention relates to a keratotic plug remover composition including a polymer compound having a salt-forming group, and (a) an amino-modified silicone and/or (b) a polyoxyalkylene/dimethyl polysiloxane block copolymer, and a sheet for removing keratotic plugs including a nonwoven fabric substrate impregnated with the above composition. The keratotic plug... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090123411 - Molecular fingerprints with enhanced identifying capability, method for preparing same and use thereof: The invention concerns a method for preparing a molecular fingerprint comprising sites for identifying at least one target molecule, said fingerprint being obtained from at least one master molecule of polymeric type, called master polymer. The invention is characterized in that said master polymer is different from the target molecule(s),... Agent: Oliff & Berridge, PLC

20090123412 - Methods and compositions for stabilizing the myocardium: The present invention provides materials and methods that can serve as a prosthetic and/or, for tissue engineer applications, as a supporting matrix in the stabilization of the myocardium.... Agent: Morgan, Lewis & Bockius LLP (sf)

20090123415 - Diagnosis, treatment, and prevention of vascular disorders using il-1 autoantibodies: Methods of detecting individuals at risk for atherosclerosis and related vascular diseases involving the detection of IL-1α autoantibodies, as well as therapeutic methods to prevent or treat atherosclerosis and related vascular disease by administering a pharmaceutical composition comprising IL-1α autoantibodies.... Agent: Banner & Witcoff, Ltd.

20090123414 - Il-15 antigen arrays and uses thereof: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen array, wherein the antigen is an IL-15 protein, an IL-15 mutein or an IL-15 fragment. More specifically, the invention provides a composition comprising a... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090123416 - Methods for the treatment of bladder cancer using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or... Agent: Jones Day

20090123413 - Use of bat monoclonal antibody for immunotherapy: The present invention relates to immunotherapy and more specifically concerns the use of immunostimulatory BAT monoclonal antibodies for treatment of a variety of immunodeficiency related diseases and disorders and malfunction or incompetence of the immune system.... Agent: Winston & Strawn LLP Patent Department

20090123418 - Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-urea to treat proliferative disease: Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Further, pharmaceutical formulations are provided. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.... Agent: Jones Day

20090123417 - Recombinant super-compound interferon and uses thereof: This invention provides a recombinant super-compound interferon (rSIFN-co) and its equivalent with changed spatial configuration, high efficacy and low side effects. Therefore, high dose of rSIFN-co may be used. One characteristic of rSIFN-co is its ability to inhibit the HBV DNA duplication and secretion of HBsAg and HBeAg in in... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090123419 - Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents: In one aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a... Agent: Wilson Sonsini Goodrich & Rosati

20090123421 - Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents: This invention relates to compositions and methods useful for activating LT-β receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-a and multiple subunits of lymphotoxin-β, which induce cytotoxic effects on tumor cells in the presence... Agent: Lahive & Cockfield, LLP / Biogen Idec Floor 30, Suite 3000

20090123422 - Method of treating idiopathic pulmonary fibrosis with aerosolized ifn-y: A method of treating idiophathic pulmonary fibrosis (IPF), comprising administering aerosolized interferon-γ in a therapeutically effective amount to achieve improved or ameliorated symptoms of IPF.... Agent: Klauber & Jackson

20090123420 - Regulation of t cell-mediated immunity by d isomers of inhibitors of indoleamine-2,3-dioxygenase: The present invention provides improved treatment methods by the administration of the non-physiologic D-isomer of an IDO inhibitor.... Agent: Mueting, Raasch & Gebhardt, P.A.

20090123423 - Hydroxyamic analogs as hepatitis c virus serine protease inhibitor: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090123425 - Macrocyclic, pyridazinone-containing hepatitis c serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090123424 - Methods of protein purification and recovery: Improved methods for purification and recovery of interferon-beta (IFN-β) and compositions comprising substantially monomeric IFN-β are provided. In one purification method, substantially purified IFN-β or variant thereof is precipitated and then dissolved in a guanidine hydrochloride (HCl) solution. Renaturation of the protein occurs by dilution with a suitable buffer. A... Agent: Novartis Corporate Intellectual Property

20090123426 - Compositions for bacterial mediated gene silencing and methods of using the same: Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating cancer off cell proliferative disorders. The bacterium... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090123427 - Method of treating a malignancy in a subject and a pharmaceutical composition for use in same: There is a disclosed a method of killing abnormal cells such as malignant cells including melanoma cells, using a virus recognising at least one of a cell adhesion molecule and a complement regulatory protein. The virus may be a member of the Picornaviridae family. Coxsackie A-group viruses have been found... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20090123428 - Pathotropic targeted gene delivery system for cancer and other disorders: Systems for pathotropic (disease-seeking) targeted gene delivery are provided, including viral particles with extremely high titers. In particular, the viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastic sites. Personalized dosing regimens are also provided to treat diseases such as... Agent: Wilson Sonsini Goodrich & Rosati

20090123439 - Diagnostic and prognosis methods for cancer stem cells: The present invention provides methods for diagnosis and prognosis of cancer stem cells (CSC) using expression analysis of one or more groups of genes, and a combination of expression analysis from a biological sample from the subject. The methods of the invention provide a method for accuracy detecting cancer stem... Agent: David S. Resnick

20090123441 - Engineered dendritic cells and uses for the treatment of cancer: This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090123440 - Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases: The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or... Agent: Morris Manning Martin LLP

20090123438 - Multivalent vaccines comprising recombinant viral vectors: The invention relates to vaccines comprising recombinant vectors, such as recombinant adenoviruses. The vectors comprise heterologous nucleic acids encoding for at least two antigens from one or more tuberculosis-causing bacilli. The invention also relates to the use of specific protease recognition sites linking antigens through which the encoded antigens are... Agent: Traskbritt, P.C.

20090123429 - Arthrospira-based compositions and uses thereof: The present invention concerns a composition comprising physiologically stressed Arthrospira maxima for use as a biocide and/or therapeutic. The invention also concerns a method for preventing or treating an infection or infestation of a subject by an organism, wherein the method comprises the step of administering to the subject an... Agent: Schmeiser, Olsen & Watts

20090123445 - Surfactin-containing compositions for controlling scab disease in agricultural products: The present invention relates to a composition for controlling scab disease in agricultural products, which comprises a compound of Formula I or a salt thereof. The present invention further relates to a method for controlling scab disease in agricultural products by using a composition for controlling scab disease, which comprises... Agent: Drinker Biddle & Reath (dc)

20090123431 - Cell/ligand marking system, wherein the marker is of eph type, cell material comprising said system, method for preparing same and proangiogenetic use: A cell/ligand specific marking system, the system being characterized in that it comprises: (a) an endothelial precursor cell (EPC) including a cell marker selected from among the group consisting of the Eph (in particular EphB4 or EphB1), and (b) a protein material of structure L-K, which consists of a ligand... Agent: Ostrolenk Faber Gerb & Soffen

20090123434 - Cellular upregulation of vegf receptor expression using nanofibrillar articles: The invention provides methods and systems for selectively upregulating the expression of a VEGF receptor in a cell using a synthetic nanofibrillar article. Exemplary embodiments relate to the upregulation of the VEGF receptor Flk-1 in endothelial cells. Cells having the selectively-upregulated VEGF receptor can be used in processes such as... Agent: Kagan Binder, PLLC

20090123433 - Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation: The present invention relates to a pharmaceutical composition comprising of preparations of human embryonic stem (hES) cells and their derivatives and methods for their transplantation into the human body, wherein transplantation results in the clinical reversal of symptoms, cure, stabilization or arrest of degeneration of a wide variety of presently... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090123436 - Cryopreservative compositions and methods: The invention relates to compositions for the cryogenic storage of biological materials and related methods. In an embodiment, the invention includes a cryopreservative composition including a chaotropic agent and a kosmotropic agent. In an embodiment, the invention includes a cryopreservative composition including urea and trimethylamine-N-oxide. In an embodiment, the invention... Agent: Pauly, Devries Smith & Deffner, L.L.C.

20090123435 - Cultured three-dimensional tissues and uses thereof: The present disclosure provides compositions of three dimensional tissue that can be administered into tissues and organs using minimally invasive methods. The three dimensional tissues elaborate a repertoire of growth factors that facilitate repair or regeneration of damaged tissues and organs.... Agent: Dechert LLP

20090123430 - Method for differentiation of stem cells: A method for the differentiation of mammalian pluripotent stem (PS) cells into a mortal multi-lineage progenitor cell population is provided which comprises culturing the pluripotent stem cells in the presence of Hyaluronan (HA). The mortal multi-lineage progenitor cell population may be a population of mesenchymal stem cells. The mortal multi-lineage... Agent: Wilmerhale/boston

20090123437 - Methods for collecting and using placenta cord blood stem cells: An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of... Agent: Kramer & Amado, P.C.

20090123432 - Novel population of hepatocytes derived via definitive endoderm (de-hep) from human blastocysts derived stem cells:

20090123442 - Expanded nk cells: The present invention relates to expanded NK cells. The NK cells have been expanded ex vivo, are activated and have a cytotoxic phenotype. The cytotoxicity against malignant cells is markedly increased compared to non-expanded NK cells. The invention also relates to a method of treatment.... Agent: Morrison & Foerster LLP

20090123443 - Method for treating colon cancer: The present invention discloses an immunotherapeutic method for treating patients suffering from colon cancer, by administering expanded tumour-reactive CD4+ helper and/or CD8+ T-lymphocytes obtainable from one or more sentinel or metinel lymph nodes draining a tumour in the colon or a metastasis arising from a tumour in the colon. The... Agent: Thorpe North & Western, LLP.

20090123444 - Compositions and methods for treatment of neoplastic disease: The present invention comprises the use of sickle cells or sickle cell precursors loaded with a therapeutic agent that localize in tumors and induce a tumoricidal response.... Agent: Central Coast Patent Agency, Inc

20090123447 - Compositions and methods to inhibit rna viral reproduction: This invention provides methods and compositions for inhibiting replication of the genome of an RNA virus in a host cell by contacting the host cell with an effective amount of an agent that produces a subtoxic concentration of hydrogen peroxide, thereby inhibiting viral replication in the host cell. Also provided... Agent: Foley & Lardner LLP

20090123446 - Use of il-1 antagonists to treat gout: Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the incidence of a gout flare is reduced or inhibited.... Agent: Regeneron Pharmaceuticals, Inc

20090123449 - Composition of biofilm control agent: The present invention provides a composition for controlling the formation of a biofilm composed of microorganisms and microorganism-producing substances or for promoting the removal of a biofilm in various fields and a method for suppressing biofilm formation and for removing a biofilm. The present invention provides a composition of a... Agent: Birch Stewart Kolasch & Birch

20090123448 - Nucleic acid molecules coding for a dextransaccharase catalysing the synthesis of dextran with alpha 1,2 osidic sidechains: The invention relates to an isolated polypeptide with an glycosyl transferase enzymatic activity for producing dextrans with .alpha.(1.fwdarw.2) sidechains, comprising at least one region for bonding to glucan and a catalytically active region situated beyond the region bonding to glucan. The invention further relates to polynucleotides coding for said enzymes... Agent: Birch Stewart Kolasch & Birch

20090123450 - Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation: The present invention provides an isolated and substantially purified recombinant human arginase having sufficiently high enzymatic activity and stability to maintain Adequate Arginine Depletion in a patient. The present invention also provides a pharmaceutical composition comprising the modified invention enzyme and method for treatment of diseases using the pharmaceutical composition.... Agent: Foley & Lardner LLP

20090123451 - Slow intraventricular delivery: Neurological diseases, including lysosomal storage diseases, can be successfully treated using intraventricular delivery of the therapeutic agents to bypass the blood-brain barrier. Similarly, diagnostic agents and anesthetic agents can be delivered to the brain in this manner. The administration can be performed slowly to achieve maximum effect. Such administration permits... Agent: Genzyme Corporation Legal Department

20090123453 - Pharmaceutical preparations and medicines capable of generating, and/or containing, thrombin: The invention relates to a pharmaceutical active ingredient preparation for producing a medicament that contains thrombin or has a thrombin-generating capacity and compositions comprising thereof. The inventive preparation contains: (A) prothrombin obtained from plasma or by means of genetic engineering (coagulation factor II), (B) coagulation factors V, VIII, IX, X... Agent: Baker Botts L.L.P.

20090123452 - Protease screening methods and proteases identified thereby: Methods for identifying modified proteases with modified substrate specificity or other properties are provided. The methods screen candidate and modified proteases by contacting them with a substrate, such as a serpin, an alpha macroglobulins or a p35 family protein or modified serpins and modified p35 family members or modified alpha... Agent: K&l Gates LLP

20090123454 - Methods for treating adhesive capsulitis: The invention relates to the discovery that collagenase injections are effective in lyse the collagenous adhesions in the shoulder and treat the disorder, adhesive capsulitis. As such, the invention relates to methods of treating or preventing adhesive capsulitis, or frozen shoulder, in a patient in need of such treatment comprising... Agent: Elmore Patent Law Group, PC

20090123455 - Slimming cosmetic composition containing a substance inducing the production of il-6: This invention relates to a slimming cosmetic composition containing at least one compound inducing the production of IL-6 by the adipocytes in the form of a mixture with an NPY antagonist and/or an α2 antagonist and with an excipient for a cosmetic preparation.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090123459 - Compositions and method for the diagnosis, prevention and treatment of alzheimer's disease: Disclosed herein are methods of diagnosing, preventing and treating Alzheimer's disease based on the use of an inhibitor for the binding of amyloid-β (Aβ) to FcγRIIb, and a method of screening the inhibitor. The inhibitor is selected from the group consisting of an FcγRIIb protein or a variant thereof, an... Agent: Klarquist Sparkman, LLP

20090123462 - Fgfr agonists: The present invention relates to the use of Fibroblast-Growth Factor Receptor (FGFR) agonists for the diagnosis, prevention and/or treatment of pathological conditions including, but not limited to hyperproliferative disorders, bone diseases and vascular diseases. Particularly, the use of FGFR-4 agonists, e.g. anti-FGFR-4 antibodies is described. Further, the invention relates to... Agent: Millen, White, Zelano & Branigan, P.C.

20090123461 - Human podocalyxin alternative-spliced forms and uses thereof: The present invention provides a method for diagnosing and detecting cancer. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in cancer (podocalyxin) and antibodies that bind podocalyxins. The present invention provides that podocalyxins are used as targets for screening agents... Agent: Celera

20090123460 - Immunostimulatory combinations: The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.... Agent: Hunton & Williams LLP Intellectual Property Department

20090123457 - Lumican proteoglycan in the diagnosis and treatment of atherosclerosis: The invention relates to methods of reducing formation of atheromas and methods of treating atherosclerotic lesions and/or atherosclerosis by reducing the amount of lumican proteglycan in the intima or an artery or in the lesion. The invention also relates to methods of identifying subjects having or at risk of having... Agent: Edwards Angell Palmer & Dodge LLP

20090123458 - Protective antigen having fluorinated histidine residues: The unnatural amino acid analogue 2-fluorohistidine (2-FHis) was incorporated into protective antigen to produce a protein which resists protonation at physiological pH by reducing the side-chain pKa. The protein structure was unperturbed by the incorporation of fluorinated histidine residues, and the heptameric (2-FHisPA63)7 could form ion conducting channels, and bind... Agent: Stinson Morrison Hecker LLP Attn: Patent Group

20090123456 - Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists: A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an α7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090123466 - Anti-cd40 monoclonal antibody: An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090123465 - Assessment of cardiac health and thrombotic risk in a patient: The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk... Agent: Bozicevic, Field & Francis LLP

20090123464 - Method for the potentiation of opioid analgesics effects on pain: According to the invention there is provided use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA combined with at least one opioid analgesic for the preparation of a medicament for treating and/or preventing pain.... Agent: Edwards Angell Palmer & Dodge LLP

20090123463 - Methods and compositions for inducing apoptosis: The C-terminal domain of focal adhesion kinase (FAK-CD) was isolated using a Baculoviral system. Using phage display techniques, a phage encoding a 12 amino-acid peptide (peptide 35) and AV3 that binds to FAK-CD were identified. The peptides were also conjugated to TAT-FITC to produce a fluorescently labeled chimeric molecule capable... Agent: Edwards Angell Palmer & Dodge LLP

20090123467 - Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders: The present invention discloses compositions which induce cross-activation of immune mediated and direct death signaling in targeted cells by exploiting the properties of a antibody/peptide-nucleic acid conjugate. The conjugate is able to simultaneously activate multiple death signaling mechanisms. Methods of using the conjugate of the present invention as an immunotherapeutic... Agent: Dla Piper LLP (us)

20090123468 - Transducible polypeptides for modifying metabolism: Methods and compositions for modifying the metabolism of a subject are provided. One embodiment provides a recombinant polypeptide having a polynucleotide-binding domain, a protein transduction domain, and a targeting domain. In a preferred embodiment, the polynucleotide-binding domain includes one or more HMG box domains.... Agent: Pabst Patent Group LLP

20090123469 - Anti-factor b antibodies and their uses: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of factor B antagonists.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090123470 - Antibodies against cancer: An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell types and may be used in an anti-cancer agent for treating cancer in a subject. The binding... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090123472 - Detection of mutations in a gene associated with resistance to viral infection, oas1: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the... Agent: Davis Wright Tremaine, LLP/seattle

20090123473 - Human bnp immunospecific antibodies: The present invention relates to antibodies that immunospecifically bind to human brain natriuretic peptide or a human brain natriuretic peptide fragment with a high binding affinity, methods for producing and selecting said antibodies, immunoassays for human brain natriuretic peptide or a human brain natriuretic peptide fragment that employ said antibodies... Agent: Paul D. Yasger Abbott Laboratories

20090123471 - T-cadherin antigen arrays and uses thereof: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The present invention provides, inter alia, a composition comprising a virus-like particle (VLP) and at least one antigen, wherein said antigen is a T-cadherin domain protein, a combination of any T-cadherin domain proteins, a... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090123474 - Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer: The invention relates to agents which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body. More specifically the invention concerns a combination of an antagonist of the biological activity of Angiopoietin-2 and an antagonist of the... Agent: Astrazeneca R&d Boston

20090123476 - Targeted binding agents directed to upar and uses thereof: Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences... Agent: Astrazeneca R&d Boston

20090123475 - Compositions and methods for detection of antibody binding to cells: The invention includes Rh(D) binding proteins, including antibodies, and DNA encoding such proteins. Methods of generating such proteins and DNAs are also included.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090123477 - Antibodies: The invention concerns an isolated monoclonal antibody, which is specific and agonistic for CTLA-4, whereby the antibody does not bind to the C″D loop of CTLA-4.... Agent: Mayer & Williams PC

20090123480 - Bivalent smac mimetics and the uses thereof: The invention relates to bivalent mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.... Agent: Casimir Jones, S.c.

20090123478 - Human antibody molecules for il-13: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.... Agent: Astrazeneca R&d Boston

20090123479 - Immunoglobulins: The present invention relates to antigen binding proteins to human IL-23, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as Rheumatoid Arthritis (RA).... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090123481 - Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins: This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also... Agent: Bozicevic, Field & Francis LLP

20090123482 - Assays for determining compounds which modulate tram phosphorylation: Disclosed are assays for the determination and quantification of the phosphorylation of TRAM (Trif-related adaptor molecule). TRAM is rapidly phosphorylated upon LPS stimulation by protein kinase C epsilon (PKCε) and that this phosphorylation is vital for TRAM to function normally. Assays suitable for detecting the state of phosphorylation of TRAM... Agent: Heller Ehrman LLP

20090123483 - Anti-ccr7 receptor antibodies for the treatment of cancer: Antibodies, or antigen-binding fragment thereof, which bind to a CCR7 receptor are capable of selectively killing, impairing migration and/or blocking dissemination of tumour cells expressing a CCR7 receptor. Use of said antibodies for killing or for inducing apoptosis of said tumour is disclosed, thus providing an alternative therapy for treatment... Agent: Intellectual Property / Technology Law

20090123484 - Methods for diagnosing and treating kidney cancer: Methods, reagents and kits for diagnosing and treating kidney cancer are disclosed. An immunoassay for detecting kidney cancer is based on the relative change of the CELSR1 protein in urine or blood compared with normal tissue. An immunohistochemical assay for detecting kidney cancer is based on the relative absence of... Agent: King & Spalding LLP

20090123485 - Antigen antibody complexes as hiv-1 vaccines: The present relation relates to antigen-antibody complexes for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic antibody-antigen complexes which are formulated into the vaccines of the present invention.... Agent: Frommer Lawrence & Haug

20090123487 - Precursors and enzymes associated with post translational modification of proteins implicated in isoform generation of pcna: The current invention provides a method for detecting the presence of a genomic or proteomic precursor(s) within a sample, wherein the precursor(s) provide an indication of the presence or the capability of expression modulation of various other proteins which may, either directly or indirectly, provide an indication, promote, and/or be... Agent: Whiteford, Taylor & Preston, LLP Attn: Gregory M Stone

20090123486 - Vaccine composition comprising an antigen and a peptide having adjuvant properties: e

20090123488 - Compositions and methods for the treatment and prophylaxis of alzheimer's disease: A self-adjuvanting immunogenic composition comprising an immunogen comprising a lipopeptide cap (R2), a universal T helper sequence (R1) and an immunodominant Aβ B cell epitope. The immunogen also comprises one or more linker sequences and/or polar charged amino acid sequences. The B cell epitope of each immunogen has an amino... Agent: Howson & Howson LLP

20090123489 - Novel immunotherapy against neuronal and brain tumors: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090123490 - Circovirus sequences associated with piglet weight loss disease (pwd): The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a... Agent: Bingham Mccutchen LLP

20090123491 - Novel method for preventing or treating m tuberculosis infection: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090123492 - Generation of new bcg vaccine strains protecting against the establishment of latent mycobacterium tuberculosis infection and reactivation from the latent or persistent state: A vaccine for treating or preventing the establishment of latent tuberculosis infections is provided. The vaccine comprises a recombinant mycobacterium that overexpresses the transcription factor DosR, at a level sufficient to induce production of the dosR regulon genes or proteins. A host to whom the vaccine is administered mounts an... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20090123493 - Composition comprising a colloidal synthetic bioresorbable vector and a viral vector: The invention relates to pharmaceutical compositions containing a colloidal synthetic bioresorbable vector which comprises at least one type of proteinic substance, to a viral vector corresponding to at least one type of proteinic substance of the synthetic vector and to a method for the prophylactic, therapeutic and diagnosis use thereof.... Agent: Oliff & Berridge, PLC

20090123494 - Momlv-based pseudovirion packaging cell line: The present invention discloses Moloney murine leukemia virus (MoMLV)-based viral packaging cell line for the production of anti-viral vaccines. The invention also includes methods of making, administering and formulating pseudovirions and replicon deficient viral particles of the invention and methods of inducing immunity.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090123495 - Immune response inducing preparations: The present invention provides a pharmaceutical composition with an adjuvant based on an apathogenic virus, together with an antigen. The adjuvant has a natural or through genetical engineering no, reduced or altered expression of an endogenous interferon antagonist or endogenous immune suppressor.... Agent: Fulbright & Jaworski L.L.P.

20090123496 - Purification of hbv antigens for use in vaccines: The present invention relates to a method for the production of a hepatitis B antigen suitable for use in a vaccine, the method comprising purification of the antigen in the presence of cysteine, to vaccines comprising such antigens.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090123497 - Chromatographic method and system for purifying a botulinum toxin: Chromatographic processes and systems for purifying a botulinum toxin from an APF fermentation medium.... Agent: Allergan, Inc.

20090123498 - Treatment of post-stroke muscle pain: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.... Agent: Allergan, Inc.

20090123499 - Vaccine: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090123500 - Active immunization using a siderophore receptor protein: The invention provides a vaccine for immunizing poultry and other animals against infection by a gram-negative bacteria, and a method of immunizing an animal using the vaccine. The vaccine may contain purified siderophore receptor proteins derived from a single strain or species of gram-negative bacteria or other organism, which are... Agent: Mueting, Raasch & Gebhardt, P.A.

20090123501 - Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines: The invention describes the use of dendritic cell vaccines, wherein SHP-1 expression or activity is modulated in the dendritic cell. In particular, the invention provides dendritic cells (DC) transduced with an SHP1-shRNA adenovirus, or dominant negative (dn-SHP-1) or constitutively active (ca-SHP-1), and pulsed with an antigen. The methods and compositions... Agent: Fulbright & Jaworski, LLP

20090123503 - Conditioned cell culture medium compositions and methods of use: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal... Agent: Wilson Sonsini Goodrich & Rosati

20090123502 - Multi-layered fondant containing chewing gum: The present invention is directed to a multi-layered chewing gum, comprising alternative layers of a chewing gum region comprising a chewing gum composition containing a gum base and a fondant, each layer being separate and discrete and co-extensive, said multilayered chewing gum comprised of at least three layers, wherein the... Agent: Scully Scott Murphy & Presser, PC

20090123504 - Olive oil formulation for pain relief: The present disclosure generally relates to methods and compositions for reducing inflammation and/or pain, and more particularly, to compositions comprising an NSAID and oleocanthal and/or a related compound. The compositions are particularly suitable for topical delivery and may be used to relieve the effects of arthritis.... Agent: Christopher M. Goff (27839) Armstrong Teasdale LLP

20090123505 - Particulate wood preservative and method for producing same: A wood preservative includes injectable particles comprising one or more sparingly soluble copper salts. The copper-based particles are sufficiently insoluble so as to not be easily removed by leaching but are sufficiently soluble to exhibit toxicity to primary organisms primarily responsible for the decay of the wood. Exemplary particles contain... Agent: Morgan Lewis & Bockius LLP

20090123506 - Method of producing protective cable sheaths, tubes and similar: The manufacturing method includes the incorporation of a rodent repellent product, (1a & 1b) specifically (saccharyde of benzyldiethyl [(2,6-xililcarbamoilmethyl)] ammonium, capsaicine derivatives of izoate N-{2-[(2,6-dimethylphenyl)amino]-2-oxoethyl}-n,n-diethylbenzenmethanamine, (e)-8-methyl-N-vainilla-6-nonenamide, derivatives of oleoresine, capsaicinoids in an LDPE vehicular resin), in a solid form of pellets (1a), or in powder (1b) in any composition of... Agent: The Nath Law Group

20090123507 - Metal oxide nanoparticles coated with specific n-acylaminomethylene phosphonates: The present invention relates to new metal oxide nanoparticles coated with specific phosphonates, to the use of these nanoparticles as antimicrobials, especially in the home and personal care areas, to the production of such nanoparticles as well as to the new phosphonates and the corresponding process of production.... Agent: Joann Villamizar Ciba Corporation/patent Department

20090123509 - Biodegradable colloidal gels as moldable tissue engineering scaffolds: A colloid gel can include a plurality of positive charged particles mixed and associated with a plurality of negative charged particles so as to form a three-dimensional matrix having a plurality of pores defined by and disposed between the particles. The three-dimensional matrix can have shear thinning under shear and... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090123511 - Biomaterial derived from vertebrate liver tissue: A tissue graft composition comprising liver basement membrane is described. The graft composition can be implanted to replace or induce the repair of damaged or diseased tissues.... Agent: Barnes & Thornburg LLP

20090123508 - Implantable drug depot for intrathecal drug delivery system for pain management: The present disclosure provides an intrathecally-implantable depot having a biodegradable core for extended release of pain-relieving drug into the intrathecal space over at time period of at least a month. The present disclosure further provides methods for preparing a self-contained intrathecally-implantable depot and methods for continuously relieving pain in a... Agent: Kenyon & Kenyon LLP

20090123510 - Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening: The invention provides methods and compositions for reducing or inhibiting bone resorption, osteoclast differentiation and stimulation and the loosening of medical prostheses by administering a compound or agent that modulates an adenosine receptor such as the adenosine A2A receptor, in particular, an agonist of an adenosine A2A receptor. The invention... Agent: Klauber & Jackson

20090123513 - Antimicrobial biguanide metal complexes: A compound comprising a metal species and a biologically acceptable ligand, wherein the biologically acceptable ligand comprises a biguanide moiety, and wherein the biologically acceptable ligand forms a complex with the metal species in which the metal species is stabilised in an oxidation state greater than 1+. Compositions and medical... Agent: Diana Houston Smith & Nephew, Inc.

20090123518 - Biodegradable implants with controlled bulk density: Disclosed solid water permeable implants that include a water permeable polymer and an osmotically active drug formulation that comprises a drug; wherein the solid water permeable implant has a ratio R of bulk density of the solid water permeable implant to osmotic pressure of the drug formulation wherein R is... Agent: Durect Corporation Thomas P. Mccracken

20090123516 - Drug delivery from implants using self-assembled monolayers-therapeutic sams: Disclosed are medical devices comprising one or more surfaces, one or more SAM molecules attached to the one or more surfaces of the medical device, and one or more therapeutic agents attached to the one or more self-assembled monolayer molecules. Also disclosed are medical devices comprising one or more surfaces,... Agent: Fulbright & Jaworski L.L.P.

20090123514 - Electropolymerizable monomers and polymeric coatings on implantable devices prepared therefrom: Conductive surfaces of e.g., implantable devices, coated with electropolymerized polymers having active substances attached thereto are disclosed. Electropolymerizable monomers designed and used for obtaining such conductive surfaces and processes, devices and methods for attaching the electropolymerized polymers to conductive surfaces are also disclosed. The polymers, processes and devices presented herein... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090123517 - Medical devices for releasing therapeutic agent and methods of making the same: An implantable medical device for releasing therapeutic agent having a medical device body and a plurality of reservoir-defining structures disposed on a surface of the body. A reservoir can be defined by the reservoir-defining structures and therapeutic agent may be located in the reservoir. A cover may extend over the... Agent: Kenyon & Kenyon LLP

20090123515 - Polymer coatings containing drug powder of controlled morphology: A method for depositing a coating comprising a polymer and pharmaceutical agent on a substrate, comprising the following steps: discharging at least one pharmaceutical agent in a therapeutically desirable morphology in dry powder form through a first orifice; discharging at least one polymer in dry powder form through a second... Agent: Wilson Sonsini Goodrich & Rosati

20090123512 - Quorum sensing modulators: Compounds described herein are useful in modulating bacterial quorum sensing.... Agent: Miller Canfield Paddock And Stone PLC

20090123519 - Swellable hydrogel matrix and methods: The invention provides biocompatible polymeric hydrogel matrices having excellent durability and swellability. The matrices are formed from a macromer and photo-polymer combination. The matrices can be used in association with a medical device or alone. In some methods the polymeric matrix is placed or formed at a target site in... Agent: Kagan Binder, PLLC

20090123520 - Keloid therapy: Therapeutic compositions, devices and protocols for the treatment of keloids and other abnormal scars with improved appearance and a much lower recurrence rate. A therapeutic drug delivery device comprises an injectable mixture of a fibroblast inhibitor such as corticosteroid and a slow release carrier such as milled gel sponge dispersed... Agent: Lundeen & Lundeen, PLLC

20090123521 - Medical devices having coatings for controlled therapeutic agent delivery: According to an aspect of the invention, medical devices are provided, which include a nanoparticle-derived inorganic layer disposed over a least a portion of structure that includes a substrate, and optionally, a therapeutic-agent-containing layer disposed over at least a portion of the substrate. In some embodiments, the inorganic layer is... Agent: Mayer & Williams PC

20090123522 - Medicament delivery device and a method of medicament delivery: A medicament delivery device and method of delivering a medicament is provided wherein the device is insertable into the uterine myometrium for the delivery of medicaments to the pelvic area and organs thereof, for example, the bladder, peritoneum, the vulva, vagina, fallopian tubes, ovaries, and uterus, and then to the... Agent: K&l Gates LLP

20090123524 - Packaged satiety enhancing composition: Compositions for enhancing satiety and weight loss in an individual, assays for assessing a tastant for enhancing satiety and weight loss, and methods of using the composition to suppress appetite and enhance weight loss are provided.... Agent: Bryan Cave, LLP

20090123523 - Pharmaceutical delivery system: The present invention is directed to methods and compositions for administering medicaments to large animals by enveloping a medicament within a food stuff.... Agent: Hoxie & Associates LLC

20090123525 - Adsorbent-containing hemostatic devices: The present invention utilizes a combination of a porous carrier and an adsorbent such as a molecular sieve to make a more effective hemostatic device to treat wounds in mammalian animals. These hemostatic devices contain additives that do not inhibit hemostasis.... Agent: Honeywell International Inc Patent Services

20090123526 - Transdermally absorbable preparation: A transdermally absorbable preparation that even when a drug with poor solubility in a base is added in high concentration, is stable over time and can suppress crystallization of the drug, excelling in transdermal absorbability. There is provided a transdermally absorbable preparation, comprising a base and, added thereto, at least... Agent: Wolf Greenfield & Sacks, P.C.

20090123527 - Method of inducing topical anesthesia and transdermal patch: Disclosed is a method of inducing topical anesthesia in a tissue or organ of an animal comprising providing an aqueous gel formulation comprising water, an anesthetic (e.g., lidocaine hydrochloride), a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic... Agent: Leydig Voit & Mayer, Ltd

20090123528 - Transdermal delivery of beneficial substances effected by a hostile biophysical environment: The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may... Agent: Wolf Greenfield & Sacks, P.C.

20090123533 - Compositions and methods for cancer diagnosis and therapy: The miR15 and miR16 micro RNA genes are located at 13q14 within a 30 kb region of loss characteristic of cells from certain cancers, such as cells from chronic lymphocytic leukemia or prostate cancer. Chronic lymphocytic leukemia or prostate cancer can be diagnosed by detecting a reduction in miR15 or... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090123531 - Glutathione-based delivery system: A delivery system is provided. The delivery system includes a carrier or an active compound and a glutathione or a glutathione derivative grafted thereon. The invention also provides a compound including a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene glycol (PEG) or a polyethylene glycol... Agent: Birch Stewart Kolasch & Birch

20090123530 - Liposome drug delivery: This invention comprises pharmaceutical compositions for administering a biologically active compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver biologically active compounds to the gastrointestinal tract after oral administration.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090123529 - Nucleic acid immunological composition for human metapneumovirus: There is provided an immunological composition that comprises a nucleic acid vector which includes a promoter region operably linked to a coding sequence encoding the human metapneumovirus F antigen or the human metapneumovirus G antigen. The immunological composition is useful for administering to an individual to elicit an immune response... Agent: Smart & Biggar

20090123532 - Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite: The present invention provides a complex, which comprises a cationic liposome comprising 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoylglycerol and a phospholipid as main ingredients, and an oligo nucleic acid which is carried on the liposome. Also, the present invention provides a pharmaceutical composition containing the complex to be used for treating or preventing diseases caused... Agent: Darby & Darby P.C.

20090123534 - Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof: The present invention relates to a pharmaceutical composition comprising micronized progesterone, soya bean lecithin, and at least one oil selected from the group consisting of sunflower oil, olive oil, sesame seed oil, colza oil, almond oil, to the method for the preparation thereof and to the uses thereof for treating... Agent: Foley And Lardner LLP Suite 500

20090123535 - Oral controlled release formulation for sedatives and hypnotic agents: The present invention relates to a novel controlled release dosage form that releases therapeutic amounts of a sedative or hypnotic agent rapidly after administration and maintains therapeutic levels for about eight hours after administration.... Agent: Hedman & Costigan P.C.

20090123536 - Oral pharmaceutical form of losartan: e

20090123537 - Oral dosage form of ceftriaxone and methods of use: The present invention contemplates a novel oral dosage form for the intestinal delivery of ceftriaxone sodium. The oral dosage form inhibits enteric degradation of the therapeutic compound by encapsulation within an inner core region and having an outer shell, preventing its dissolution until reaching the small intestine. Furthermore, the enzymatic... Agent: Dunlap Codding, P.C.

20090123538 - Angiotensin ii receptor antagonists: The compounds of the present invention are polymorphic crystalline forms of the compound 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid, which has the structure (I). Specifically, the compounds of the invention are selected from the group consisting of 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid of Claim 3 selected from the group consisting of 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid hydrochloride Form I, 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic... Agent: Merck And Co., Inc

20090123539 - Wet granulation using a water sequestering agent: Disclosed are tablets comprising hydrolytically stable formulations of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt (Compound 1) prepared by a wet granulation process.... Agent: Rigel Pharmaceuticals Inc.

20090123540 - Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof: A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAECD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090123541 - Pharmaceutical composition: p

20090123542 - Primary composition comprising a lipophilic bioactive compound: The invention relates to a primary composition in which at least one lipophilic bioactive compound is mixed with a whey protein, present in an amount effective to increase the bioavailability of the lipophilic bioactive compound. The invention also relates to an oral composition that contains the primary composition in a... Agent: K&l Gates LLP

20090123543 - Pharmaceutical compositions: A novel solid oral dosage form comprising a therapeutically effective amount of hydrophobic pharmacological active ingredient and at least one particle separating agent preferably selected from a class of wetting agents, prepared without or with minimum amount of a disintegrating agent. The hydrophobic pharmacological active ingredient active ingredient belongs to... Agent: Merchant & Gould PC

20090123545 - Rapid onset and short term modafinil compositions and methods of use thereof: Compositions are described that comprise a modafÊnil component that is a combination of the d- and l-enantiomers of modafinil and wherein the modafÊnil component is greater than 50% by weight d-modafÊnil for use in promoting or enhancing the state of wakefulness, alertness, and/or central nervous system stimulation in an individual.... Agent: Leon R. Yankwich Yankwich & Associates, P.C.

20090123544 - Stimulus-responsive biodegradable polymers and methods of preparation: There is presently provided a stimulus-responsive polymer comprising a biodegradable polymer backbone and a stimulus-responsive pendant group attached to the biodegradable polymer backbone, wherein the biodegradable polymer backbone comprises a poly(amino ester) or a poly(amido amine), the poly(amido amine) optionally comprising a disulfide linkage in the backbone.... Agent: Klarquist Sparkman, LLP

20090123546 - Polymer-based, sustained release drug delivery system: Disclosed is a sustained release system that includes a polymer and a pharmaceutically active agent dispersed in the polymer. The agent is in granular or particulate form, and has a rate of release from the system that is limited primarily by the rate at which the agent dissolves from the... Agent: Ropes & Gray LLP

20090123547 - Methods and compositions for regenerating connective tissue: Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well... Agent: Alston & Bird LLP

20090123550 - Corticosteroid compositions: Provided herein are methods for treating, preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.... Agent: Wilson Sonsini Goodrich & Rosati

20090123548 - Device for administering aromatherapy: A device for administering aromatherapy to a subject and the method of using the device are disclosed. The device comprises an aromatherapy composition housed within a container. The container has at least one opening or aperture through which the subject may breathe in or inhale the aromatic and volatile components... Agent: Susan Reimer Tom

20090123551 - Gastrointestinal delivery systems: Provided herein are compositions suitable for the delivery of therapeutic agents to the gastrointestinal tract. Also provided herein are methods for treating, preventing or alleviating disorders of the gastrointestinal tract, for example, those involving the esophagus, by orally administering compositions described herein.... Agent: Wilson Sonsini Goodrich & Rosati

20090123549 - Pharmaceutical compositions: A composition comprising a pharmaceutically acceptable group (2, 4, 12, 13 or 14) metal compound for the treatment of a dermatological condition involving an abnormal decrease in the cell-to-cell adhesion between epithelial cells in the epidermal barrier.... Agent: Bromberg & Sunstein LLP

20090123552 - Spheroids prepared from an isolated active principle of vegetable origin and a solution of vegetable origin containing the active principle or a precursor thereof: The invention relates to spheroids which are obtained using a method comprising the following steps consisting in: supplying an active principle of vegetable origin in an isolated form; supplying a solution of vegetable origin, containing the active principle or a precursor thereof; supplying an absorbing and adsorbing substance having plastic... Agent: Davis & Bujold, P.l.l.c.

20090123553 - Peptide nanostructures and methods of generating and using the same: A tubular or spherical nanostructure composed of a plurality of peptides, wherein each of the plurality of peptides includes no more than 4 amino acids and whereas at least one of the 4 amino acids is an aromatic amino acid.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090123554 - Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls... Agent: Davidson, Davidson & Kappel, LLC

20090123555 - Stimulateable polymer particles exhibiting reactive functions, method for the production and the use thereof: The invention relates to spherical particles formed by polymer chains containing approximately from 30 to 10000 monomer units derived from monocyclic polycyclic alkene polymerization, wherein at least one monomer unit is substituted by an R chain including ethylene polyoxide which is optionally covalently linked to the polymer units through a... Agent: Young & Thompson

20090123556 - Sustained release pharmaceutical compositions: e

20090123557 - Dietary supplement composition for blood lipid health: A method for enhancing gastrointestinal motility in humans and other mammals comprises administering a therapeutically effective amount of a composition having one or more long chain (C24-C36) primary alcohols as policosanols dispersed in one or more food-grade fats or oils, wherein the particle sizes of the alcohols are substantially less... Agent: Richard K. Warther Allen, Dyer,doppelt,milbrath & Gilchrist P.A.

20090123558 - Polarized scorpion venom solution and a method for making polarized scorpion venom solution: Various embodiments of this invention disclose a polarized dilute blue scorpion venom solution, a method for making a polarized dilute scorpion venom solution, and a method for administering dilute scorpion venom solution. The polarized dilute scorpion venom solution relieves pain, improves immune-system response, treats cancer, prevents cancer, improves quality of... Agent: Marc E. Hankin, Esq.

20090123559 - Medicine to treat drug addiction and preparation method thereof: The present invention declares a pharmaceutical extract, composition that has effect to treat drug addiction, and its preparation method and quality control method. This extract is extracted from Radix Stephaniae Epigaeae. Starting medicine material of said composition is Radix Ginseng, Radix Astragali, Rhizoma Corydalis, Radix Angelicae Sinensis and Radix Ophiopogonis;... Agent: Birch Stewart Kolasch & Birch

20090123560 - Hematopoietic stem cell proliferation inducing agent: Disclosed is a hematopoietic stem cell proliferation inducing agent which comprises a pulverized product of placenta-constituting cells as an active ingredient and can induce/proliferate a hematopoietic stem cell in the peripheral blood. Since the proliferation inducing agent can induce/proliferate a hematopoietic stem cell to increase the amount of hematopoietic stem... Agent: Birch Stewart Kolasch & Birch

20090123561 - Fungicide mixtures based on 1-methyl-pyrazol-4-ylcarboxanilides: in a synergistically effective amount, methods for controlling harmful fungi using mixtures of at least one compound I and at least one active compound II and the use of the compound(s) I with active compounds II for preparing such mixtures, and also compositions and seed comprising such mixtures.... Agent: Birch Stewart Kolasch & Birch

20090123562 - Pharmaceutical formulations of gallium salts: The present invention relates to pharmaceutical formulations containing a pharmaceutically acceptable gallium salt (such as gallium nitrate), a delivery agent, and optionally, one or more chemotherapeutic agents and/or adjunctive chemotherapeutic agents.... Agent: Emisphere Technologies, Inc. C/o Darby & Darby P.C.

20090123563 - Pharmaceutical preparations comprising insulin, zinc ions and zinc-binding ligand: Novel preparations comprising branched ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer. The preparations have a prolonged action designed for flexible injection regimes.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090123564 - Novel compositions for hair disorders and process of preparation thereof: Novel compositions for hair loss prevention and/or hair growth promotion comprising at least active agent preferably derived from natural source such as from the plant Vernonia sp., either alone or in combination with other active agent(s) and optionally one or more excipient(s) are provided. The process for the extraction of... Agent: Ladas & Parry LLP

20090123566 - Use of a phosphate adsorbent to combat vascular diseases: The invention relates to the use of an adsorption material which has been modified with polynuclear metal oxide hydroxides for influencing the calcium level and, in particular, for treating or/and preventing atherosclerotic vascular diseases or/and disturbances of bone metabolism.... Agent: Novartis Corporate Intellectual Property

20090123565 - Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto: The present invention relates to the discovery that non-traditional export of certain pro-inflammatory cytokines lacking a signal sequence from a cell can be inhibited by copper chelation and/or administration to the cell of a truncated form of S100A13 lacking the basic residue portion. Further, copper chelation inhibits, inter alia, neointima... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090123567 - Bisbenzisoselenazolonyl derivatives having antineoplastic, anti-inflammatory and antithrombotic activities as well as their use: The present invention relates to new bisbenzisoselenazolonyl derivatives of the following general formula (I), wherein R is C4-5-alkylene, and their pharmaceutically acceptable salts. The inventive derivatives have antineoplastic, anti-inflammatory and antithrombotic activities.... Agent: Connolly Bove Lodge & Hutz, LLP

20090123568 - Kit useful for treating tumors and lesions of the skin and the mucous membranes: The pharmaceutical preparation useful for treating a skin or mucous membrane lesion is provided. The pharmaceutical preparation including, as active ingredients, a therapeutically effective amount of trichloroacetic acid and hydrochloric acid, or trichloroacetic acid and formic acid or all three of these acids and optionally a crosslinking/fixating/preserving agent. Additional preparations... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090123569 - Coverage indicating technology for skin sealants using tannates: A composition having various color changing tannates may be used to indicate that the composition has dried. The tannates change color in contact with an acid. The composition may be, for example, a skin prep, skin sealant, food product, paint or other building material or other product that undergoes a... Agent: Kimberly-clark Worldwide, Inc. Catherine E. Wolf

20090123570 - Composition and method for treating sore throat: The present invention provides compositions and methods for treating sore throat by reducing inflammation and clearing oral-pharyngeal mucus associated with sore throat comprising hypertonic saline and menthol.... Agent: Elmore Patent Law Group, PC

20090123571 - Method of treating men with testosterone supplement and 5alpha-reductase inhibitor: A method of treating Alzheimer's disease, Parkinson's disease, sexual dysfunction or erectile dysfunction in a man by administration of a 5alpha reductase inhibitor together with a testosterone supplement is described. The method is also concerned with the use of the 5alpha reductase inhibiting compound and the testosterone supplement together with... Agent: Merck And Co., Inc

20090123573 - Admixture of extracts of plants of the genus rosmarinus and carotenoids for treating cutaneous symptoms of aging: Intimate admixtures of at least one carotenoid and at least one extract of at least one plant of the genus Rosmarinus are well suited for treating the undesirable cutaneous signs of skin aging, in particular the degradation of the skin and/or of the mucous membranes by inhibiting the activity and/or... Agent: Buchanan, Ingersoll & Rooney PC

20090123572 - Method and pharmaceutical composition for treating psoriasis, squamous cell carcinoma and/or parakeratosis by inhibiting expression of squamous cell carcinoma-related antigen: In a first aspect thereof, the present invention provides a method for treatment and/or prevention of a disease selected from the group consisting of psoriasis and squamous cell carcinoma by inhibiting the expression of squamous cell carcinoma antigen (SCCA) by cells. In another aspect thereof, the present invention provides a... Agent: Fish & Richardson PC

20090123574 - Compositions for the regression of spongiform pustules: Herbal compositions that, when used topically in a therapeutically effective amount, are safe and effective for the regression of spongiform pustules in patients exhibiting chronic inflammatory skin disorders, such as psoriasis. The compositions, which can be formulated as ointments, oils, soaps and shampoos, comprise a non-aqueous herbal extract of Wrightia... Agent: Bregen Technical Consultants L.L.C.

20090123576 - Active substance combinations of anise fruit extract and white tea extract: An active substance combination which comprises anise fruit extract and white tea extract and a cosmetic preparation comprising same. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.... Agent: Greenblum & Bernstein, P.L.C

20090123575 - Blended compositions for treatment of alzheimer's disease and other amyloidoses: Methods for treating amyloid disease in a patient wherein the method comprises administration of a therapeutically effective amount of a composition comprising Uncaria tomentosa extract, Gingko Biloba, Green Tea Extract, Grape Seed Extract and/or Curcumin.... Agent: Proteotech, Inc.

20090123577 - Liquid concentrate for preserving cosmetics: The invention relates to a liquid concentrate for preserving cosmetic products which comprises a combination of carboxylic acid salts chosen from the salts of benzoic acid, propionic acid, salicylic acid, sorbic acid, 4-hydroxybenzoic acid, dehydracetic acid, formic acid or 10-undecylenic acid and alcohols chosen from 2-phenoxyethanol, benzyl alcohol, phenethyl alcohol,... Agent: Young & Thompson

20090123578 - Skin care compositions with botanic seed oils: A topical skin care composition with a base skin care composition suitable for application to skin, and blends of botanic seed oils, prepared according to a cold press method. The base skin care composition uses a multivesicular emulsion skin care delivery system as a base skin care composition. A micelle... Agent: Briggs And Morgan P.A.

20090123579 - Method of promoting weight loss: Compositions for enhancing satiety and weight loss in an individual, assays for assessing a tastant for enhancing satiety and weight loss, and methods of using the composition to suppress appetite and enhance weight loss are provided.... Agent: Bryan Cave, LLP

20090123580 - Methods for treating obesity, insulin resistance and inducing satiety: The present invention provides a method for treating an insulin resistance disorder, treating obesity, reducing the weight and/or preventing weight gain and controlling appetite and/or inducing satiety in a subject by administering to the subject an amount of a stabilized rice bran solubilized fraction effective to treat the subject.... Agent: Townsend And Townsend And Crew, LLP

20090123581 - Collagen cross-linking agents on dental restorative treatment and preventive dentistry: The invention relates to the development of compositions and methods for increasing the amount of collagen cross-linking in a mammalian tissue. A typical composition as described herein includes at least one cross-linking agent such as a bioflavonoid compound (e.g., proanthocyanidin), a grape seed extract, a Casein Phosphopeptide-amorphous Calcium Phosphate, or... Agent: Akerman Senterfitt

20090123582 - Ameliorating agent for metabolic syndrome: The object is to provide a food-derived effective ingredient which can promote the reduction in accumulated fats or the like. Disclosed is a body fat reduction-promoting agent, a leptin production-promoting agent, an anorexigenic agent, a PAI-1 production-suppressing agent or an anti-thrombotic agent, each comprising an extract from a chestnut astringent... Agent: Edwards Angell Palmer & Dodge LLP

20090123583 - Method for obtaining fruit wax: The invention relates to a method for obtaining fruit wax from plant constituents, said method being carried out essentially using compressed C2-C4 hydrocarbons. Unlike previous extraction methods with supercritical CO2, the inventive method can be carried out at low pressures and with a reduced extraction means throughput. Residues from the... Agent: Fulbright & Jaworski, LLP

20090123584 - Therapeutic uses of tomato extracts: The present invention relates to tomato extracts or an active fraction thereof for use in preventing or inhibiting the initiation of venous thrombosis and fibrin clot formation in a vein.... Agent: Davis Wright Tremaine LLP/los Angeles

20090117032 - Imaging agents for early detection and monitoring of cardiovascular plaque: The present invention relates in part to imaging agents comprised of a targeting moiety and a label, such as a radionuclide or paramagnetic contrast agent, and methods of use thereof.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090117033 - Injectable biodegradable particles: According to an aspect of the invention, injectable polymeric particles are provided that contain a copolymer that contains a hydroxy-acid-based repeat unit selected from a mono(hydroxy acid) unit and a poly(hydroxy acid) unit, an alkyl-ether-based repeat unit selected from a mono(alkyl ether) unit and a poly(alkyl ether) unit, and an... Agent: Mayer & Williams PC

20090117031 - Methods for treating glioma: The present disclosure provides for method of treatment and/or prevention of disease states that require cystine for maintenance or progression of the disease state. In addition, methods for screening and identifying novel therapeutic agents useful in the treatment of such disease states are described. In one embodiment, the disease state... Agent: Bradley Arant Rose & White

20090117034 - Microorganisms for imaging and/or treatment of tumors: Modified viruses encoding transporter proteins and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses also can be used in diagnostic methods, such detection and imaging of tumors. The viruses also can be used in methods of treatment of diseases, such as... Agent: K&l Gates LLP

20090117035 - Temperature-sensitive liposomal formulation: A liposome contains an active agent and has a gel-phase lipid bilayer membrane comprising phospholipid and a surface active agent. The phospholipids are the primary lipid source for the lipid bilayer membrane and the surface active agent is contained in the bilayer membrane in an amount sufficient to increase the... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090117036 - Antibodies against gpr64 and uses thereof: GPR64 antibody compositions are provided. These antibodies may be used for diagnosis or treatment of cancer, especially ovarian cancer, Ewing's sarcoma, uterine cancer, and other GPR64 expressing tumor types.... Agent: Howrey LLP-ca

20090117038 - Breast endothelial cell expression patterns: To gain a better understanding of breast tumor angiogenesis, breast endothelial cells (ECs) were isolated and evaluated for gene expression patterns. When transcripts from breast ECs derived from normal and malignant breast tissues were compared, genes that were specifically elevated in tumor-associated breast endothelium were revealed. These results confirm that... Agent: Banner & Witcoff, Ltd.

20090117037 - Methods of treatment using ctla-4 antibodies: The present invention provides method of treatment using human sequence antibodies against human CTLA-4 linked to a cytotoxic agent. In particular, methods of treating cancer and autoimmune disease are provided.... Agent: Baker Botts L.L.P.

20090117039 - Charged biodegradable polymers for medical applications: In accordance with one aspect of the invention, implantable medical devices are provided which include polymeric compositions that comprise at least one type of biodegradable ionic polymer. The at least one type of biodegradable ionic polymer comprises a biodegradable polymer core and one or more ionic end groups.... Agent: Mayer & Williams PC

20090117040 - Novel pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases: The present invention relates to pharmaceutical and diagnostic compositions as well as to the use of the active substances contained therein for preparing a pharmaceutical or a diagnostic composition for the treatment or diagnosis of neurodegenerative disorders or amyloid diseases.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090117041 - Radiologic agents for monitoring alzheimer's disease progression and evaluating a response to therapy and processes for the preparation of such agents: Disclosed are certain cycloSalingenyl pyrimidine nucleoside monophosphates comprising positron emitters or gamma-emitting radiohalides, uses thereof for monitoring Alzheimer's disease progression and evaluating response to therapy and process for their preparation.... Agent: Dann, Dorfman, Herrell & Skillman

20090117042 - Imaging agents and methods of imaging naaladase or psma: The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express NAALADase and/or PSMA. In another embodiment, the invention relates to methods of imaging tissues, organs, or... Agent: Edwards Angell Palmer & Dodge LLP

20090117043 - Antibodies that specifically bind to neurokinin b: The present invention relates to antibodies and related molecules that specifically bind to neurokinin B. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including pre-eclampsia, hypertension, inflammation, asthma, gastrointestinal disorders, anxiety, depression, addiction, or pain. The invention... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090117044 - Method for quantifying the uptake of at least one radiotracer in a body region of a patient of interest to a positron emission tomography measurement: A method for quantifying the uptake of at least one radiotracer in a body region of a patient of interest to a positron emission tomography measurement is disclosed. In at least one embodiment of the method, the uptake of the radiotracer in the body region of the patient of interest... Agent: Harness, Dickey & Pierce, P.L.C

20090117045 - Soy or lentil stabilized gold nanoparticles and method for making same: The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from soy or lentil plant material or a reactive extract thereof of the plant material. The gold nanoparticles of the invention can be fabricated with an environmentally friendly method for making biocompatible stabilized gold nanoparticles. In methods of... Agent: Greer, Burns & Crain

20090117046 - Methods for evaluating genetic susceptibility and therapy for chronic inflammatory diseases: The invention discloses a knockout mouse that is homozygous for a RUNX3 null allele, as a novel model for chronic inflammatory disease. The present invention provides methods of diagnosing and assessing predisposition to chronic inflammatory diseases. The present invention further provides methods for testing agents for effectiveness in treating and/or... Agent: Winston & Strawn LLP Patent Department

20090117047 - Light emitting microorganisms and cells for diagnosis and therapy of tumors: Provided are diagnostic and pharmaceutical compositions containing a microorganism or a cell containing a DNA molecule encoding a detectable protein or a protein that a detectable signal, such as a luminescent or fluorescent protein. Methods of tumor targeting and tumor imaging using the microorganisms and cells are provided. Also provided... Agent: K&l Gates LLP

20090117048 - Light emitting microorganisms and cells for diagnosis and therapy of tumors: Provided are diagnostic and pharmaceutical compositions containing a microorganism or a cell containing a DNA molecule encoding a detectable protein or a protein that a detectable signal, such as a luminescent or fluorescent protein. Methods of tumor targeting and tumor imaging using the microorganisms and cells are provided. Also provided... Agent: K&l Gates LLP

20090117049 - Light emitting microorganisms and cells for diagnosis and therapy of tumors: Provided are diagnostic and pharmaceutical compositions containing a microorganism or a cell containing a DNA molecule encoding a detectable protein or a protein that a detectable signal, such as a luminescent or fluorescent protein. Methods of tumor targeting and tumor imaging using the microorganisms and cells are provided. Also provided... Agent: K&l Gates LLP

20090117050 - Stem cell targeting of cancer, methods and compositions therefor: Disclosed are methods of detecting and treating a cancer such as an ovarian cancer using stem cells. Detection methods include administering a plurality of labeled stem cells to a subject having, or suspected of having, a cancer; and detecting the distribution of the stem cells. In some configurations, the label... Agent: Sonnenschein Nath & Rosenthal LLP

20090117051 - Uridine dietary supplementation compliance methods and use thereof: This invention relates to determining the compliance of a subject receiving dietary supplementation with uridine or a uridine source. Specifically, the invention relates to the use of MRS for measuring an increase in brain compounds resulting from dietary supplementation with uridine or a uridine source.... Agent: Pearl Cohen Zedek Latzer, LLP

20090117052 - Enhancement agent for high intensity focused ultrasound treatment and method for screening the same: The present invention discloses an enhancement agent for high intensity focused ultrasound (HIFU) treatment, which is administered to a patient before HIFU treatment and can reduce the level of EEF at the target location to be treated with HIFU. EEF is presented by the expression: EEF=ηPt/V (unit: J/mm3), and refers... Agent: The Webb Law Firm, P.C.

20090117053 - Local delivery of 5-aminolevulinic-acid based compounds to tissues and organs for diagnostic and therapeutic purposes: In accordance with an aspect of the present invention, a 5-aminolevulinic-acid-based compound (ALA-based compound) is delivered locally to a tissue or organ within a subject's body. In another aspect, a method of diagnosis or treatment is provided which comprises: (a) locally delivering an ALA-based compound to a tissue or organ... Agent: Mayer & Williams PC

20090117055 - Disinfectant having ozone: Provided is a disinfectant which is not harmful to the human body and has sterilizing power in atmospheric conditions. Liquid paraffin or Vaseline containing ozone is applied on the human body, or medical equipment to be disinfected is dipped therein. Thus, the disinfection of medical equipment is easily and conveniently... Agent: Hyun Jong Park Park & Associates Intellectual Property Law LLC

20090117054 - Sublingual spray for the treatment of pain: This invention relates to a spray for sublingual administration, used in the treatment and management of pain, especially acute pain. Also provided are methods of treatment and management of pain, a metered dosage system for administration of the spray, and combination therapies.... Agent: Crowell & Moring LLP Intellectual Property Group

20090117056 - Probiotic oral dosage forms: Provided are probiotic compositions that have enhanced stability under various storage conditions. The stability of the probiotic compositions is enhanced through the addition of various agents and excipients. Examples of agents and excipients that may be used to enhance the stability of probiotic compositions include prebiotics, such as the sugar... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090117057 - Grape polyphenolics for platelet and bacterial control: Special extracts of grape berries and Gogi berries can be prepared by exposing fruit juices or preparations to an insoluble binding resin which is then extracted with soluble polyvinylpyrollidone. Grape and Goji extracts made in this way can be used to inhibit or control platelet aggregation. Grape extract has exceptional... Agent: Stefan Kirchanski

20090117058 - Toothpaste composition for tooth whitening: The present invention relates to a toothpaste composition having tooth whitening effect, and more specifically, to a toothpaste composition which contains hydrogen peroxide, as peroxide releasing oxygen free radicals for the whitening effect, and silica with reduced contents of metal ions, to overcome the difficulty in long-term storage due to... Agent: Clark & Brody

20090117059 - Compositions and methods of use thereof, for the treatment of oral pain, comprising cloves or extracts thereof in combination with a steroid: Provided are compositions for delivery to an individual's mouth to provide immediate as well as long-lasting pain relief, particularly after tooth extraction or other dental procedure, which include clove, a clove extract or eugenol, and optionally a steroid and other additives including an antibiotic. Kits and systems for delivery of... Agent: Morrison & Foerster LLP

20090117060 - Cosmetic process for the treatment of the skin with sun-protection products and sun-protection products combination: The invention relates to a cosmetic method, whereby skin is treated with various sun products, and to a sun product combination. The inventive method is characterized by applying, prior to intensive exposure of the skin to UV radiation, a pre-sun product, then a sun product and finally repeatedly applying an... Agent: Norris, Mclaughlin & Marcus, P.A.

20090117062 - Novel plant gene and uses thereof: A novel gene isolated from Deschampsia antarctica coding for a lipase like protein is disclosed. A system for production of recombinant enzyme is also disclosed as well as use for the enzyme in sunscreen.... Agent: Dodds & Associates

20090117061 - Skin care products containing multiple enhancers: The present invention provides a skin care product comprising at least two enhancers and at least one skin care ingredient, wherein the at least two enhancers are selected from cyclodextrin, pentasodium pentetate, phytic acid, potassium citrate, sodium citrate, potassium gluconate and sodium gluconate.... Agent: Kenyon & Kenyon LLP

20090117064 - Stable vitamin b6 derivative: e

20090117063 - Topical administration of at least one double-stranded rna oligonucleotide (dsrna): Expression of a messenger RNA which encodes a protein which is expressed by differentiated cells, notably the cells of the skin or appendages thereof, is inhibited by topically administering to said differentiated cells a thus effective amount of at least one double-stranded RNA oligonucleotide, formulated into a topically applicable, physiologically... Agent: Buchanan, Ingersoll & Rooney PC

20090117065 - Antiperspirant gel composition: An antiperspirant composition including a continuous oil phase, a disperse aqueous phase, and a residue-masking agent. The continuous oil phase comprises a water-immiscible liquid and a tack-reducing agent. And the disperse aqueous phase comprises one or more polar solvents and an antiperspirant active.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090117066 - Antiperspirant or deodorant compositions: Incorporation of a polyol humectant in an anhydrous composition containing an astringent aluminium and/or zirconium antiperspirant salt can result in grit formation and hence poor sensory properties unless the polyol is prior contacted with a perfume carrier. A simpler manufacturing process that enables the composition to retain its moisturising properties... Agent: Unilever Patent Group

20090117068 - Cosmetic compositions: The present invention relates to a solid cosmetic composition which includes a soap and/or a non-soap surfactant, a hair modification active and/or skin enhancing agent, and at least one silicone and/or mineral oil.... Agent: Traskbritt, P.C.

20090117067 - Hair product: A fragrant chemical composition for fashioning hair consisting of shea butter, glyceride, triclosan, aloe vera and menthol that combines to aid in the pressing of hair in a well conditioned and healthful manner, as well as to prevent itching typically associated with certain hair fashions such as braids and dreadlocks.... Agent: Greenberg & Lieberman, LLC

20090117069 - Sublimable composition for controlling odor: The invention relates to a sublimable composition comprising cyclododecane and adipic acid and an optional diluent promoting sublimation of the composition. The sublimable composition is provided with a fragrance which is carried into the air by the sublimable composition to ameliorate or otherwise mask objectionable odors, particularly those odors from... Agent: Invista North America S.a.r.l.

20090117070 - Methods and crosslinked polymer compositions for cartilage repair: A method of repairing damaged cartilage and soft tissue in a patient is provided using a biocompatible, non-immunogenic composition. The composition comprises a hydrophilic polymer and a plurality of crosslinkable components having reactive functional groups. The composition used in the method may be loaded with biologically active agents for delivery... Agent: Seed Intellectual Property Law Group PLLC

20090117071 - Hydrophobically modified cationic polymers and their use as cleaning aids: A cleaning composition for hard surfaces containing a polymeric compound comprising a main backbone derived from at least the following monomeric components: (I) 20 to 99.9% by weight of at least one cationic monomer according to formula (I) wherein R1 and R2 are, independently of one another, hydrogen or C1-C4... Agent: Joann Villamizar Ciba Corporation/patent Department

20090117072 - Treatment of periodontal disease: This invention relates to a method of therapeutic or prophylactic treatment of periodontal disease comprising administering to a subject in need thereof epicatechin and/or catechin and/or a polymeric compound of formula An. Also disclosed and claimed is an article of manufacture comprising the above compounds packaged within a container with... Agent: Nada Jain, P.C.

20090117073 - Use of a fusion protein targeting the ed-b fibronectin domain for treatment of atherosclerosis: The present invention relates to the use of a fusion protein comprising an antibody part which specifically recognises ED-B fibronectin, an effector part and optionally one or more fusion protein linker(s) and/or antibody linker(s), for the manufacturing of medicaments for the treatment and prevention of atherosclerosis... Agent: Millen, White, Zelano & Branigan, P.C.

20090117074 - Sulfonylpyrroles as histone deacetylase inhibitors: e

20090117075 - Temperature responsive delivery systems: There is provided a new aqueous temperature responsive delivery system made with a temperature responsive polymer and a bioadhesive which is intrinsically cationic. This system may also have an effective amount of a treating agent, which may be a medical or cosmetic agent. The bioadhesive, temperature responsive delivery system is... Agent: Dority & Manning, P.A.

20090117076 - Methods for treating tumor cells: Methods of treating a disease in a patient are disclosed that include the administration of a targeted therapy in combination with an immunotherapy. Such therapy is useful in the treatment of any disease susceptible to targeted therapy and attack by the immune system.... Agent: The Mccallum Law Firm, P. C.

20090117077 - Polyethylene glycol-interferon alpha conjugate: The present invention relates to three-branched polyethylene glycol-interferon alpha conjugate of general formula (1) wherein polyethylene glycol has an average molecular weight of from 400 to 45,000 daltons, and a pharmaceutical composition comprising the same. The bioactive polyethylene glycol-interferon alpha conjugate of general formula (1) has antiviral and antitumoral activities,... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090117078 - Crosslinked compounds and methods of making and using thereof: Described herein are crosslinked compounds useful in numerous treatments. Described herein are methods of making crosslinked compounds via (1) die oxidative coupling of two or more thiol compounds or (2) by the reaction between at least one thiol compound with at least one thiol-reactive compound.... Agent: King & Spalding LLP

20090117079 - Methods and materials for treating or preventing diseases/disorders mediated by alcohol dehydrogenase: The present disclosure relates generally to methods and materials for treating and/or preventing a disease or disorder in a subject that is mediated by alcohol dehydrogenase by administering to the subject a therapeutically effective amount of one or more agents that prevents and/or inhibits the metabolism of methanol by alcohol... Agent: K&l Gates LLP

20090117080 - Beta-galactosidase with transgalactosylating activity: The present invention concerns a new β-galactosidase with transgalactosylating activity isolated from Bifidobacterium bifidum. The β-galactosidase is capable of converting lactose to a mixture of galactooligosaccharides which are β-linked and unexpectedly produces the α-linked disaccharide galactobiose. The mixture may be incorporated into numerous food products or animal feeds for improving... Agent: Christie, Parker & Hale, LLP

20090117081 - Parvovirus methods and compositions for killing neoplastic cells: According to the invention, parvoviruses such as the adeno-associated virus Type 2 (AAV2) are found to be oncolytic, selectively mediating apoptosis in cancer cells and their precursers, while leaving healthy cells intact. The invention thus comprises a method of killing cancer and other neoplastic and preneoplastic cells by administration of... Agent: Mckee, Voorhees & Sease, P.L.C Attn: Pennsylvania State University

20090117082 - Reovirus for the treatment of cellular proliferative disorders: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the... Agent: Fish & Richardson P.C.

20090117084 - Bacteriophage and prophage proteins in cancer gene therapy: The present invention relates to the use of a polypeptide having a proliferation inhibitory activity or a cell death inducing activity on animal cells. The invention provides further means and methods to use said polypeptide and the corresponding nucleic acids sequence containing the coding regions of said polypeptide. The invention... Agent: Marger Johnson & Mccollom, P.C.

20090117088 - Cellular intervention to treat damaged myocardium: A system and method for treating damage myocardial tissue includes delivering replacement cells to the myocardium of a patient and electrically stimulating the spinal column of the patient to affect a cellular environment within the myocardium.... Agent: Medtronic, Inc.

20090117083 - Immunomodulatory alkaloids: Immunotherapy comprises administration of an alkaloid at a dose sufficient to induce IL-2 production in dendritic cells in a patient. The alkaloid induces the production of IL-2 in dendritic cells. The alkaloids need not be naturally occurring, and may be synthetic analogues or derivatives of naturally occurring counterparts. Such analogues... Agent: Heslin Rothenberg Farley & Mesiti PC

20090117087 - Methods and compositions for printing biologically compatible nanotube composites of autologous tissue: A method of carrying out an autologous tissue implant in a subject in need thereof is carried out by: (a) forming an autologous tissue implant from autologous cells collected from a subject (e.g., by ink-jet printing, the autologous cells and the scaffold, separately or together), and then (b) implanting the... Agent: Myers Bigel Sibley & Sajovec

20090117085 - Mntf differentiation and growth of stem cells: The present invention provides methods for inducing differentiation of an embryonic stem cell into a motor neuron using a motoneuronotrophic factor (MNTF) or its peptide analogues. The present invention further provides a method for isolating a population of stem cell derived motor neurons and a population of cells comprising the... Agent: Bio Technology Law Group C/o Portfolioip

20090117086 - Preparation of replicating macrophages and use in diagnosis and therapy: Provided are methods for replicating macrophages in vitro and cell culture compositions comprising replicating macrophages. Also provided are methods for preparing replicating Kupffer cells from human liver. Further provided are methods for enhancing or extending immune function in an individual suffering from a deficiency relating to a reduced number of... Agent: Mandel & Adriano

20090117089 - Glycolipids and analogues thereof as antigens for nk t cells: This invention relates to immunogenic compounds which may serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090117090 - Inhibition of glycogen synthase kinase 3 beta in arterial repair and stent re-endothelialization: A device having a kinase inhibitor for treating or preventing vascular disease in a subject and a method of treating a subject therewith, is disclosed. The device can be a stent coated with the kinase inhibitor. The kinase inhibitor can be a glycogen synthase kinase (GSK) inhibitor, such as a... Agent: Borden Ladner Gervais LLP Anne Kinsman

20090117091 - Methods for treating pompe disease: The present invention provides methods for treating Pompe disease in a subject by administering to the subject a therapeutically effective amount of a fusion protein which includes human acid alpha-glucosidase (GAA), or a fragment thereof, and a lysosomal targeting domain. The lysosomal targeting domain binds the human cation-independent mannose-6-phosphate receptor... Agent: Choate, Hall & Stewart LLP

20090117092 - Collagenolytic active enzyme containing compositions, and their use in the dental field: The invention relates to a composition comprising at least one collagenolytic active enzyme with enzymatic activity at acidic pH for drilless enzymatic caries removal. Furthermore, the present invention relates to a process of producing this collagenolytic active enzyme comprising composition and to processes of removing caries. The invention also relates... Agent: 3m Innovative Properties Company

20090117093 - Granulysin peptides and methods of use thereof: Granulysin peptides are small antimicrobial agents with potent activity. A pharmaceutical composition comprising granulysin peptides as an active agent is administered therapeutically to a patient for exfoliation, e.g. for the treatment of skin lesions.... Agent: Bozicevic, Field & Francis LLP

20090117094 - Method of making the porous carbon material and porous carbon materials produced by the method: A method for making the microporous carbon with modified pore size distribution and advanced sorption behaviour. The carbon is derived from metal or metalloid carbides. The method employs the use of oxidant in reaction medium that during the carbide conversion into carbon widens small micropores, which otherwise would be hardly... Agent: Birch Stewart Kolasch & Birch

20090117098 - Complement c1q inhibitors for the prevention and treatment of glaucoma: The invention concerns in one embodiment a method of treating glaucoma or elevated intraocular pressure comprising administering a pharmaceutically effective amount of a composition comprising a Complement C1q inhibitor. In another embodiment, the invention concerns a composition for the treatment of elevated intraocular pressure and glaucoma, the composition comprising a... Agent: Alcon

20090117100 - Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates: e

20090117099 - Extracellular histones as biomarkers for prognosis and molecular targets for therapy: Hyper-inflammatory responses can lead to a variety of diseases including sepsis. It is now shown that extracellular histones released in response to inflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death during sepsis. As such, they can be targeted pharmacologically by inhibitors, as well as used as... Agent: Fulbright & Jaworski L.L.P.

20090117095 - Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia: Provided are isolated and purified preparations of a combination of a light chain antibody gene and a heavy chain antibody gene, where the light chain and heavy chain antibody genes are the same among more than one patient with B cell chronic lymphocytic leukemia (B-CLL). Vectors comprising those genes and... Agent: Amster, Rothstein & Ebenstein LLP

20090117096 - Methods and compositions for inhibition of metastasis: This invention generally relates to methods of producing an antibody phage population having affinity for a tumor cell target expressing a metastatic phenotype. The invention further relates to antibody compositions that specifically bind to a cell surface receptor on the metastatic cell.... Agent: Fenwick & West LLP

20090117097 - Stabilizer for protein preparation comprising meglumine and use thereof: i

20090117101 - Heh4 molecules and uses thereof: The present invention provides HEH4 polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing HEH4 polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090117106 - Cancer specific glycans and use thereof: The present invention describes glycans, which are specifically expressed by certain cancer cells, tumours and other malignant tissues. The present invention describes methods to detect cancer specific glycans as well as methods for the production of reagents binding to said glycans. The invention is also directed to the use of... Agent: Birch Stewart Kolasch & Birch

20090117104 - Glp-2 mimetibodies, polypeptides, compositions, methods and uses: Mammalian GLP-2 mimetibodies, polypeptides and nucleic acids are disclosed. Methods of utilizing the mimetibodies and polypeptides to treat GLP-2 related diseases are also disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20090117105 - Humanized anti-venezuelan equine encephalitis virus recombinant antibody: A CDR grafted humanized rAb comprises a human Ig framework having CDRs from murine mAb 1A4A1 VH and VL. DNA sequences and vectors incorporating such sequences are also provided as are pharmaceutical preparations and methods of using the humanized rAbs.... Agent: Blake, Cassels & Graydon LLP

20090117103 - M-csf antibody compositions having reduced levels of endotoxin: The present invention provides for compositions of anti-M-CSF antibodies that are substantially free of endotoxin. Also provided are methods of treating M-CSF-mediated disorders with pharmaceutical formulations of anti-M-CSF antibodies having reduced endotoxin levels, including inflammatory diseases and neoplasia disorders.... Agent: Pharmacia Corporation Global Patent Department

20090117102 - Methods and compositions using cd3 agonists: Compositions of CD3 antibody and gastrin and uses thereof in the prevention and intervention of diabetes.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090117107 - Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases: The present invention relates to methods for identifying agents capable of inhibiting the expression or activity of proteins involved in the processes modulating osteoclastogenesis, which inhibition is useful in the prevention and/or treatment of bone and joint degenerative diseases and diseases involving aberrant activity or differentiation of osteoclasts. In particular,... Agent: Klauber & Jackson

20090117108 - Gene engineering recombinant anti-cea, anti-cd3, and anti-cd28 single-chain tri-specific antibody: The invention is related to a recombinant single-chain tri-specific antibody made from anti-Tumor Associated Antigen (TAA) antibody, FC interlinker, anti-CD3 antibody, HSA interlinker and anti-CD28 antibody in turn. Particularly, the invention relates to an anti-CEA, anti-CD3, anti-CD28 recombinant single-chain tri-specific antibody, CEA-scTsAb, which was constructed with three tandem antibody fragments... Agent: Jones Day

20090117110 - Method for the in vitro assessment of the progression status of an infection by an hiv virus in an individual: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease.... Agent: Fulbright & Jaworski L.L.P.

20090117109 - Methods for reducing biofilm formation in infectious bacteria: The present invention provides methods of preventing or inhibiting biofilm formation by a population of bacteria, said method comprising the administration to the population of an antibody to a lactone or lactone-derived signal molecule secreted by bacteria. The invention therefore also provides methods for the treatment of bacterial infection in... Agent: Pepper Hamilton LLP

20090117111 - Uses of anti-cd40 antibodies: Methods for treating a human patient for a cancer or pre-malignant condition that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who... Agent: Alston & Bird LLP

20090117112 - Immunomodulatory compositions and uses therefor: The poxvirus proteins designated A41L and 130L bind to three receptor-like protein tyrosine phosphatases (RPTP), leukocyte common antigen related protein (LAR), RPTP-δ, and RPTP-σ, that are present on the cell surface of immune cells. When a host is infected with the poxvirus, binding of A41L to cell surface proteins on... Agent: Seed Intellectual Property Law Group PLLC

20090117118 - Antibodies specific for sclerostin and methods for increasing bone mineralization: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density... Agent: Marshall, Gerstein & Borun LLP

20090117115 - Binary epitope antibodies and b cell superantigen immune stimulants: Provided herein are dual epitope polypeptides and electrophilic analogs thereof having a superantigenic epitope and at least one other epitope effective to induce the production of antibodies with binary specificity for the epitopes on a polypeptide antigen. Also, provided are electrophilic analogs of polyclonal B cell stimulants or lipids, polysaccharides... Agent: Benjamin Aaron Adler Adler & Associates

20090117114 - Il-17 homologous polypeptides and therapeutic uses thereof: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide... Agent: Goodwin Procter LLP

20090117113 - Immunogenic and therapeutic compositions for streptococcus pyogenes: Group A streptococcal (GAS) antigens useful for providing immunity against pyogenes infection.... Agent: Novartis Vaccines And Diagnostics Inc.

20090117116 - Immunogenic peptides and methods of use for treating and preventing cancer: Disclosed are immunogenic peptides, related fusion proteins, nucleic acids encoding the peptides or fusion proteins, conjugates, expression vectors, host cells, and antibodies. Also, disclosed are pharmaceutical compositions, vaccines for use in the treatment or prevention of cancer, e.g., alveolar rhabodomyosarcoma, methods of stimulating a T cell to kill a tumor... Agent: Leydig, Voit & Mayer, Ltd.

20090117123 - Immunopeptides of hpv e6 and e7 proteins: An immunopeptide containing a cytotoxic T lymphocyte epitope derived from HPV E6 or HPV E7 protein. The immunopeptide can be used as a component of a vaccine for enhancing immune responses against HPV or treating HPV-associated diseases. Also within the scope of this invention are a nucleic acid encoding the... Agent: Occhiuti Rohlicek & Tsao, LLP

20090117121 - Pseudomonas aeruginosa outer membrane protein pa0427: An object of the present invention is to provide a protein or peptide antigen and an antibody against it, for use in the diagnosis, prevention, or treatment of diseases associated with Pseudomonas aeruginosa. According to the present invention, there is provided a protein or peptide derived from Pseudomonas aeruginosa outer... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090117122 - Resistin antagonists and their use: Resistin antagonists, including antibodies reactive with defined epitopes, are disclosed. Methods of utilizing resistin antagonists to treat or alleviate the symptoms of the diseases with aberrant fibroblast activity including interstitial lung diseases, hypertrophic scarring, keloid scarring and scleroderma are also disclosed. Antigens useful for raising antibodies against human resistin are... Agent: Philip S. Johnson Johnson & Johnson

20090117119 - Rtef-1 variants and the use thereof for inhibition of angiogenesis: Dominant negative (DN) variants of transcriptional enhancer factor 1-related (RTEF-1) are described. DN RTEF-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription. Methods for inhibiting VEGF production and thereby treating angiogenic disorders such as cancer are described. For example, in... Agent: Fulbright & Jaworski, L.L.P.

20090117117 - Targeting abcb5 for cancer therapy: The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.... Agent: Wolf Greenfield & Sacks, P.C.

20090117120 - Transgenic animal model for alzheimer's disease: Provided is a novel APP (amyloid precursor protein) transgenic non-human animal modeling in vivo the pathophysiological effects and effects on cognitive behavior of early intraneuronal and extracellular brain parenchymal amyloid-β (Aβ) deposition and cerebral amyloid angiopathy associated with brain microhemorrhages and reduced vasoreactivity and blood flow. Furthermore, methods of screening... Agent: Cooper & Dunham, LLP

20090117124 - Anti-ige antibodies: The present invention relates to novel human antibodies specifically directed against human immunoglobulin E (anti-IgE). The present invention also relates to pharmaceutical compositions and methods for treating asthma, in particular allergic asthma, as well as other IgE-mediated disorders including allergic rhinitis and food allergies.... Agent: Ropes & Gray LLP

20090117125 - Synthesis of 8h-3a-aza-cyclopenta[a]indenes and 5,10-dihydropyrrolo[1,2-b]isoquinolines derivatives and their use as antitumor therapeutic agents: The present disclosure relates to a series of bis(hydroxymethyl) and its bis(carbamate) of 8H-3a-azacyclopenta[a]indene-1-yl and 5,10-dihydropyrrolo-[1,2-b]isoquinolines derivatives (Formula I-Formula IV) as DNA di-alkylating agents. The preliminary antitumor studies indicated that compounds disclosed herein could exhibit potent cytotoxicity in vitro and antitumor therapeutic efficacy in human tumor xenografts and could have... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090117126 - Neutralising antibody molecules having specificity for human il-17: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090117127 - Novel compounds and methods for their production: The present invention relates to 11-O-desmethylmacbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases and/or as a prophylactic pretreatment for cancer. The present invention also provides methods for... Agent: Dann, Dorfman, Herrell & Skillman

20090117128 - Anti-hpa: The present invention relates to a monoclonal antibody selectively recognizing a human platelet alloantigen, a method for detecting the presence or absence of at least one human platelet alloantigen using said antibody, a method for the production of said antibody, a pharmaceutical composition comprising said antibody, and a kit containing... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090117129 - Immunogen adherence inhibitor directed to lactobacillus organisms and method of making and using it: A microbial adherence inhibitor specific to lactic acid producing microorganisms, in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the fermentators. The inhibitor is... Agent: Westman Champlin & Kelly, P.A.

20090117130 - Kallikrein-inhibitor therapies: Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.... Agent: Lowrie, Lando & Anastasi, LLP

20090117131 - Pharmaceutical composition for the treatment or prevention of allergic diseases, use thereof, and a method for the treatment or prevention of allergic diseases: The present invention provides a pharmaceutical composition for preventing or treating allergic diseases comprising histamine and allergen-specific antibody as active ingredients. Also, the present invention provides a use of the above composition for the manufacture of medicament for preventing or treating allergic diseases. Further, the present invention provides a method... Agent: The Rafferty Patent Law Firm

20090117132 - Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment: The invention relates to administration of an anti-CTLA-4 antibody, particularly human antibodies to human CTLA-4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and MDX-010, in combination with an immunostimulatory nucleotide, i.e, CpG ODN PF3512676, for treatment... Agent: Pfizer Inc

20090117133 - Polymeric immunoglobulin fusion proteins that target low affinity fcyreceptors: The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with FcγR and which allow for the inclusion and targeting of a second protein domain to... Agent: Wood, Herron & Evans, LLP

20090117134 - Truncated egf receptor: The present invention relates to truncated EGF receptor molecules that exhibit increased binding affinities for EGFR ligands such as EGF and TGF1. The present invention also relates to methods of screening for EGF receptor ligands and methods of treatment which involve the use of these molecules.... Agent: Greenlee Winner And Sullivan P C

20090117135 - Vaccine comprising an antigen conjugated to low valency anti-cd40 or anti-cd28 antibodies: We describe a conjugate comprising an antibody and antigen wherein said conjugate has low antibody valency and including methods to prepare said conjugate.... Agent: Klarquist Sparkman, LLP

20090117139 - Lutzomyia longipalpis polypeptides and methods of use: Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing... Agent: Klarquist Sparkman, LLP

20090117137 - Peptide epitopes of apolipoprotein b: The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.... Agent: Gauthier & Connors, LLP

20090117136 - Recombinant allergen: Dander from the domestic cat (Felis domesticus) is one of the most common causes of IgE mediated allergy. The present invention relates to a recombinant folded Fel d 1 with molecular and biological properties similar to the natural counterpart and specifically a synthetic gene coding for a direct fusion of... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090117138 - Vaccine for a therapeutic or a prophylactic treatment of myasthenia gravis: Complementary peptide having at least a sequence complementary to a major immunogenic region of an acetylcholine receptor involved in myasthenia gravis, characterized in that the complementary peptide has at least a sequence SEQ. ID. NO1 with a tryptophan in position 8, carrying at least one optionally substituted hydrocarbon group. Therapeutic... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090117140 - Human papilloma virus dominant cd4 t cell epitopes and uses thereof: Provided herein are methods of determining immunodominant T cell epitopes within a protein expressed in an individual and immunotherapy directed towards a protein in an individual using these determined epitopes. The method comprises administering autologous dendritic cells pulsed with a recombinant protein to the individual, establishing T-cell lines therefrom and... Agent: Benjamin Aaron Adler Adler & Associates

20090117141 - Hiv vaccine composition: An anti-HIV vaccine composition is disclosed. The vaccine comprises an combination of immunogenic peptide mixtures, which mixtures may be prepared in a single synthesis. The composition collectively represents the in vivo variability seen in immunogenic epitopes from highly variable regions of HIV. Immunization with the vaccine elicits broadly reactive immunity... Agent: Borden Ladner Gervais LLP Gail C. Silver

20090117143 - Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090117142 - Recombinant fusobacterium necrophorum leukotoxin vaccine and preparation thereof: The F. necrophorum gene expressing leukotoxin was sequenced and cloned. The leukotoxin open reading frame (lktA) is part of a multi-gene operon containing 9,726 bp, and encoding a protein containing 3,241 amino acids with an overall molecular weight of 335,956 daltons. The protein encoded by the gene was truncated into... Agent: Polsinelli Shugart PC

20090117145 - Composition and method for enhancing immune response: A composition and method for enhancing immune response in a living organism is disclosed. In particular, the present disclosure provides an adjuvant peptide for use in raising an immune response to an antigen. The adjuvant peptide is selected from a group of peptides with an HIV-related sequence. Additionally, the adjuvant... Agent: Fulbright & Jaworski L.L.P.

20090117144 - Recombinant flu vaccines: The present invention provides compositions for use as vaccines against the influenza virus, and rapid methods of producing such compositions. The composition include i) at least one peptide derived from an influenza virus, wherein the peptide is fused to a capsid protein derived from a plant virus forming a recombinant... Agent: Traskbritt, P.C.\dow Global Technologies Inc.

20090117146 - System and method for promoting hair growth and improving hair and scalp health: A system is provided for promoting hair growth comprising one or more extracts from a steroidal alkaloid-containing plant selected from a Veratrum plant, a Buxus plant, a Holarrhena plant, a Solarium plant and a Rauwolfia plant. The system can further comprise an extract from a Pilocarpus plant and a seaweed... Agent: Mayer & Williams PC

20090117148 - Capsular polysaccharides solubilisation and combination vaccines: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The... Agent: Novartis Vaccines And Diagnostics Inc.

20090117147 - Vaccines comprising outer membrane vesicles from gram negative bacteria: The present invention relates to the field of vaccine formulation, particularly the field of novel adjuvant compositions comprising outer membrane vesicles (or blebs), and advantageous methods of detoxifying these compositions, and advantageous methods of use of such adjuvants.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090117150 - Functional mutations in respiratory syncytial virus: The present invention provides recombinant respiratory syncytial viruses that have an attenuated phenotype and that comprise one or more mutations in the viral P, M2-1 and/or M2-2 proteins, as well as live attenuated vaccines comprising such viruses and nucleic acids encoding such viruses. Recombinant RSV P, M2-1 and M2-2 proteins... Agent: Medimmune, LLC Jonathan Klein-evans

20090117149 - Novel attenuated virus strains and uses thereof: Methods and compositions concerning mutant flaviviruses with reduced virulence. In some embodiments the invention concerns nucleotide sequences that encode mutant flaviviral proteins. Viruses comprising mutant NS1 and NS4B genes display reduced virulence are provided. In further aspects of the invention, flavivirus vaccine compositions such as West Nile virus vaccines are... Agent: Fulbright & Jaworski, L.L.P.

20090117151 - Vector for anti-hpv vaccine and transformed microorganism by the vector: Expression vectors that can efficiently produce virion capsid protein, tumor-associated protein of human papillomavirus on a microbial surface. Bacterial strains harboring such surface display vectors, and the use of the bacterial strains or their extracts or purified products as complex vaccines, are also described. The surface display vectors contain one... Agent: Intellectual Property / Technology Law

20090117152 - Mycoplasma hyopneumoniae avirulent adjuvanted live vaccine: Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or ameliorating M. hyopneumoniae infection. Administration to an animal of one or two doses of an adjuvanted live avirulent M. hyopneumoniae composition disclosed herein is... Agent: Wyeth Patent Law Group

20090117153 - Disulfide trap mhc class i molecules and uses therefor: A disulfide trap, comprising an antigen peptide covalently attached to an MHC class I heavy chain molecule by a disulfide bond extending between two cysteines, is disclosed. In some configurations, a disulfide trap, such as a disulfide trap single chain trimer (dtSCT), can comprise a single contiguous polypeptide chain. Upon... Agent: Sonnenschein Nath & Rosenthal LLP

20090117154 - Synthetic polyvalent carbohydrates as components of microbicides: Inhibitors that block the DC-SIGN mediated transmission of the HIV-virus from mucosal infection sites to T-lymphocytes. In one embodiment, the inhibitors include at least one oligosaccharide chain attached to a scaffolding framework in which the number of the oligosaccharide chains attached to the scaffold can be 2, 3, 4 or... Agent: Moore & Van Allen PLLC

20090117155 - Treatment of hiv-1 by modulation of vpr activation of the m-csf promoter: Macrophage colony-stimulating factor (M-CSF) is important for human immunodeficiency virus-type 1 (HIV-1) infection, replication and survival of infected cells. The mechanism(s) by which HIV-1 infection increases M-CSF production are, however, poorly understood. Here, we report that HIV-1 Vpr enhances M-CSF promoter activity and production in primary human monocytes and macrophages.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090117156 - Gene therapy for niemann-pick disease type a: This disclosure pertains to methods and compositions for tolerizing a mammal's brain to exogenously administered acid sphingomyelinase polypeptide by first delivering an effective amount of a transgene encoding the polypeptide to the mammal's hepatic tissue and then administering an effective amount of the transgene to the mammal's central nervous system... Agent: Genzyme Corporation Legal Department

20090117157 - Methods of treating urogenital-neurological disorders using modified clostridial toxins: The present specification discloses modified Clostridial toxins, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such modified Clostridial toxins and compositions.... Agent: Allergan, Inc.

20090117159 - Pharmaceutical compositions comprising fesoterodine: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group... Agent: Kenyon & Kenyon LLP

20090117158 - Transdermal sustained release drug delivery: Provided herein are microprojections and microprojection arrays wherein a microprojection is coated with at least two layers. One layer comprises a biologically active agent, for example, a PTH agent and optionally other excipients. Another layer, which is generally, initially devoid of active agent comprises a polymer or a mix of... Agent: Edwards Angell Palmer & Dodge LLP

20090117160 - Compositions for making up keratinous materials: o

20090117161 - Semiconductor-based core-shell particles for blocking electromagnetic radiation: A plurality of particles for blocking electromagnetic radiation wherein each particle includes at least one semiconductor core encased within a shell, the semiconductor cores being of substantially uniform diameter, which diameter is selected according to the quantum size effect such that radiation incident on the particles is absorbed below a... Agent: Christie, Parker & Hale, LLP

20090117162 - Topical cosmetic compositions: Disclosed is a cosmetic composition for topical application to the skin. The cosmetic composition comprises micron-sized, polymer-coated glass ball lenses having a polymer coating on the exterior surface thereof. The polymer-coated glass ball lenses are enhanced by engineered illumination and optics, and the appearance of the skin to which the... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090117163 - Composition and method for the application of human synthetic pheromones using substance slowly releasing technological bio capsule in form of drops in clothing, underwear, jewels and like: The invention regards a composition for the application of human synthetic pheromones in clothing, underwear, jewels, and like, comprising at least three positive human substances, e.g. androstenone, androstenediol and/or androsterone, said composition being predisposed in said clothing, underwear, jewel or like in such way to be diffused by the user... Agent: Hedman & Costigan P.C.

20090117164 - Disinfectant with durable activity based on alcohol-soluble quaternary ammonium polymers and copolymers: An alcohol- or glycol-soluble, water-insoluble, disinfectant composition and a method of using the same for disinfecting and for providing a prolonged antimicrobial property to a variety of surfaces, including skin. The composition comprises at least one alcohol or glycol and an antimicrobial polymer that is capable of imparting an antimicrobial... Agent: Elman Technology Law, P.C.

20090117165 - Decontamination system and method of decontamination: In one embodiment, a pad is provided for wiping a contaminant from a contaminated surface. The pad includes a layer of non-adsorptive fabric having a first surface configured to directly contact the contaminated surface, and a second surface opposite to the first surface. The pad further includes a layer of... Agent: Cesari And Mckenna, LLP

20090117167 - Injectable capsaicin with vasocontrictor adjunctive agent: Disclosed in certain embodiments is a method for relieving pain at a site in a human or animal in need thereof, comprising administering by injection or infiltration, a dose of a capsaicinoid and coadministering a vasoconstrictor.... Agent: Davidson, Davidson & Kappel, LLC

20090117166 - Sequential coupling of biomolecule layers to polymers: A bio-mimetic or bio-implantable material based on a sequential process of coupling biomolecule layers to a polymer layer is provided. In general, the material could be based on two or more biomolecule layers starting with one of the layers covalently linked to the polymer layer via cross-linkers and the other... Agent: Lumen Patent Firm

20090117168 - Device and method for attaracting diseased cells and foreign substances: An implantable device for attracting diseased cells or foreign substances circulating within bodily fluid channels is disclosed. The device comprises a frame, an attachment means for maintaining the frame in a localized position in a body vessel, and at least one attractant on the frame, where the attractant is capable... Agent: Knobbe Martens Olson & Bear LLP

20090117169 - Methods and compositions for regulating proliferation and migration of vascular smooth muscle cells: Provided is an extracellular domain of a mammalian Fat1 (Fat1EC). Also provided is an intracellular domain of a mammalian Fat1 (Fat1IC). Additionally provided is a vector comprising a nucleic acid sequence encoding the Fat1EC. A vector comprising a nucleic acid sequence encoding the Fat1IC is further provided. Also, a vascular... Agent: Amster, Rothstein & Ebenstein LLP

20090117170 - Segmented device for the delayed release of molecules in a tangential direction through thin films and uses thereof: o

20090117171 - Compositions and methods for treatment of macular degeneration and related conditions: The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. The methods comprise administering a composition comprising a compound that is an antagonist of a G protein coupled receptor, e.g., the C5a receptor, to... Agent: Choate, Hall & Stewart LLP

20090117172 - Oral delivery vehicle and material: Compositions for an oral delivery vehicle are described as well as methods for their manufacture and administration. The oral delivery vehicles can be made in any size or shape and can further comprise a medicament or other substance or object to be orally delivered. The vehicle can, for example, take... Agent: Gardner Groff Greenwald & Villanueva. PC

20090117173 - Antimicrobial glaze and poreclain enamel via double layer glaze with high zinc content: A cost-effective and practical antimicrobial glaze system and glazing process is disclosed herein. The antimicrobial glaze/enamel may comprise at least two layers: a base layer and a top layer. The base layer may contain a typical or normal glaze widely used in sanitary ware, having a low level of zinc... Agent: Marilyn Matthes Mrogan Frommer Lawrence & Hang

20090117174 - Modified sorbitan siloxane compositions and use thereof: The present disclosure generally relates to personal care compositions and wipes. More particularly, the disclosure relates to compositions and wipes for imparting a perceivable aesthetic feel to the skin of a user. To achieve the perceivable aesthetic feel, a modified sorbitan siloxane is incorporated into the compositions and wipes.... Agent: Christopher M. Goff (27839) Armstrong Teasdale LLP

20090117175 - Hemostatic compositions and therapeutic regimens: The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to treat wounds. More specifically the present invention relates to hemostatic compositions that reduce the need for, and cost of, nursing care of patients with chronic wounds by reducing the frequency... Agent: Jones Day

20090117176 - Anticancer treatments: A method of treating the human body for cancer comprises administering an effective therapeutic amount of a Pegylated Liposomal form of the anthracycline Doxorubicin (“PLD”), in combination with an effective therapeutic amount of ET-743... Agent: King & Spalding

20090117177 - Echogenic microbubbles and microemulsions for ultrasound-enhanced nanoparticle-mediated delivery of agents: Described are methods and compositions for treating tumors, such as drug-sensitive tumors, inoperable tumors, poorly vascularized tumors, and multidrug resistant tumors, by intravenous or direct intratumoral injection of compositions comprising microemulsions and polymeric micelle-encapsulated biologically active agents. The methods and compositions also include microemulsions converting into microbubbles in situ upon... Agent: Alan J. Howarth

20090117178 - Peptide epitopes of apolipoprotein b: The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies.... Agent: Gauthier & Connors, LLP

20090117179 - Sidna against influenza virus: Silencing of Influenza virus RNA can be achieved by siDNA. These are oligodeoxynucleotides having an antisense-strand homologous to the viral RNA and a second strand, partially complementary to the antisense-strand. The two strands are preferentially linked by a linker (eg 4 thymidines). Triple-helix formation with the target RNA is a... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20090117180 - Stable digestive enzyme compositions: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090117182 - Intraorally rapidly disintegrating tablet: m

20090117181 - Tablet comprising fluvastatin and carmellose calcium: The present invention relates to a fluvastatin-containing tablet, particularly a fluvastatin-containing tablet which has excellent disintegrating property and good bioavailability.... Agent: Novartis Corporate Intellectual Property

20090117183 - Oral contraceptive containing a gestagen and an estrogen combined with pharmaceutically acceptable auxiliary agents and/or excipients, but not containing lactose, and method of making same: The method produces a lactose-free oral contraceptive composition containing a combination of a gestagen and an estrogen together with one or more pharmaceutically acceptable auxiliary agents and/or excipients. The contraceptive composition is a tablet, powder, or capsule that contains the gestagen and estrogen, filler material such as microcrystalline cellulose and... Agent: Striker, Striker & Stenby

20090117184 - Use of a gestagen in combination with an estrogen and one or more pharmaceutically acceptable auxiliary agents/excipients for lactose-free oral contraception: e

20090117185 - 2-(aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of the clotting factor xa: The invention relates to 2-(aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of coagulation factor Xa. The compounds are suitable for the treatment and prophylaxis of cardiovascular and thrombotic events.... Agent: Clark & Elbing LLP

20090117186 - Trofosfamide-containing film-coated tablets and method for the production thereof: The invention at hand concerns trofosfamide containing film-coated tablets for oral application and a procedure for their production.... Agent: Baxter Healthcare Corporation

20090117189 - Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility: Polymerized drug delivery devices are described. Additionally, methods are described for producing and for using polymerized particles for use as drug delivery devices.... Agent: Bausch & Lomb Incorporated

20090117187 - Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure: A method of treatment for treating, preventing, inhibiting or reducing tissue deterioration, injury or damage due to congestive heart failure disease, or for restoring tissue adversely affected by said disease, in a subject, includes administering to a subject an effective amount of a composition including a peptide agent including amino... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090117188 - Methods of augmenting or repairing soft tissue: Methods of repairing or augmenting soft tissue in a subject are described. The methods include injecting into a subject composition comprising a biodegradable, polymerizable macromer, the macromer comprising a water soluble polymer modified with one or more biodegradable moieties; and polymerizing the macromer to provide a hydrogel, thus repairing or... Agent: Genzyme Corporation Legal Department

20090117190 - Sustained-release preparation: It is intended to provide a sustained-release pharmaceutical preparation with absorbability not dependent on pH. The sustained-release preparation is characterized by containing 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone or a salt thereof, as a pharmaceutically active ingredient, and containing a hydrogel base and an organic acid.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090117192 - Composition for transdermal absorption and formulation comprising a polymeric matrix formed therefrom: The inventive composition for transdermal absorption characterized by comprising a nonsteroidal anti-inflammatory drug as an active ingredient together with an alkali metal-containing alcohol derivative as a solubilizing agent for the active ingredient comprises a high concentration of the active ingredient while using only a small amount of the solvent, and... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090117191 - Controlled release tramadol formulations: A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.... Agent: Davidson, Davidson & Kappel, LLC

20090117193 - Compositions comprising an active agent: The present invention provides a highly dispersible formulation comprising an active agent and a dipeptide or tripeptide comprising at least two leucyl residues. The composition of the invention possesses superior aerosol properties and is thus preferred for aerosolized administration to the lung. Also provided are a method for (i) increasing... Agent: Nektar Therapeutics

20090117194 - Eukaryotic microorganisms for producing lipids and antioxidants: Disclosed are compositions and methods related to eukaryotic microorganisms that can produce unsaturated fatty acids which can be purified and use.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090117195 - Hydrophilic particles based on cationic chitosan derivatives: The present invention provides new nanoparticles and microparticles of hydrophilic character, prepared out of a cationic chitosan derivative and a polyanionic polymer.... Agent: Sturm & Fix LLP

20090117196 - Polyvinyl alcohol microspheres, injectable solutions and therapeutic uses of the same: The present invention relates to microspheres useful for embolization which comprises polyvinylalcohol. The present invention also relates to an injectable suspension suitable for embolization which comprises the polyvinylalcohol microspheres and a suitable liquid carrier. The present invention further relates to a method for prophylactic or therapeutic embolization which comprises administering... Agent: Jones Day

20090117197 - Compositions and methods for ameliorating cachexia: The invention provides preparations, formulations, kits and other products of manufacture (e.g., blister packs) comprising combinations of beneficial ingredients that are serviceable as therapies for improving states and disease symptoms such as involving inflammation, excessive sympathoneural drive, cachexia, anorexia, and anorexia-cachexia, as well as stress or anxiety related thereto, and... Agent: Vicus C/o Mofo Palo Alto

20090117198 - Visceral fat accumulation inhibitor, and agent for promoting the increase in and/or inhibiting the decrease in blood adiponectin level: Disclosed is: a visceral fat accumulation inhibitor or a beverage/food for inhibiting the accumulation of a visceral fat, which comprises a fat globule membrane component as an active ingredient; or a agent or beverage/food for promoting the increase in and/or inhibiting the decrease in the blood adiponectin level, which comprises... Agent: Young & Thompson

20090117199 - Method of treatment of cancer: A method for the treatment of cancer, particularly a metastatic melanoma or a neoplastic lesion, the method comprising intralesional administration of a hydrophilic vehicle comprising 4,5,6,7-Tetrachloro-2′,4′,5′,7′-tetraiodofluorescein, or a physiologically acceptable salt thereof, at a concentration of about 0.1 w/v % up to about 20 w/v % and an electrolyte comprising... Agent: Cook Alex Ltd

20090117200 - Fungicide composition comprising a phosphorous acid derivative, a mandelamide type compound and a further fungicide compound: The invention relates to active compound combinations, in particular within a fungicide composition, which comprise a phosphorous acid derivative (phosphonate or phosphite derivative), a compound of the mandelamide type like mandipropamid and a further fungicide compound. Such combinations are very highly suitable for controlling phytopathogenic fungi.... Agent: Ostrolenk Faber Gerb & Soffen

20090117201 - Multi-purpose acid compositions: The invention relates to solutions containing acidic compositions that have a pH of less than 1, are non-caustic to human tissue and are safe for human ingestion. These compositions may be used as the sole or major component of solutions such as cleansers, pharmaceuticals, food preservatives and disinfectants. The acidic... Agent: Christie, Parker & Hale, LLP

20090117202 - Formulations containing a non-oxidative biocide and a source of active halogen and use thereof in water treatment: Novel formulations containing a non-oxidative biocide, such as DBNPA, and a source of an in situ produced active biocide, such as a concentrated aqueous solution of an inorganic halide salt, are disclosed. These novel formulations are particularly effective in the treatment of water, and are characterized by high stability, desirable... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090117203 - Kit for cancer treatment and pharmaceutical composition for cancer treatment: v

20090117204 - Benzoisoselenazole derivatives with anti-inflammation, antivirus and antithrombosis activity and their use: The present invention relates to new bisbenzisoselenazolonyl derivatives of the following general formulae (I), (II) or (III) and their pharmaceutically acceptable salts. The inventive derivatives have antineoplastic, anti-inflammatory and antithrombotic activities.... Agent: Connolly Bove Lodge & Hutz, LLP

20090117205 - Quinolone-containing medicinal composition: molar ratio of the component (B) to component (A) (the multivalent compound/component (B)) is 0.01 to 0.7. A pharmaceutical solution adapted for intravascular administration containing the quinolone compound at a therapeutically sufficient amount is provided, and this solution exhibits reduced toxicity even when the multivalent metal compound were incorporated at... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090117206 - Preservative and additive for food and feed: A preservative and additive for food and feed. One aspect of the invention concerns various acidified clays and minerals as food or feed additive to kill, or inhibit the growth of, harmful microorganisms and to inactivate mycotoxins, such as aflatoxins, present as contaminants in human foods and animal feeds. Another... Agent: T Ling Chwang Jackson Walker

20090117207 - Methods and compositions for treatment of poison-caused pathology: A method of treating a poison-caused pathology in an individual subject is described which includes administering a pharmaceutical composition including a therapeutically effective amount of a chloride current modulator, a therapeutically effective amount of an exogenous oxygen carrier, or a combination of a therapeutically effective amount of a chloride current... Agent: U S Army Research Laboratory Attn Amsrl Cs Cc Ip

20090117208 - Amino acid composition and supplementary liquid containing the same: An amino acid composition comprises alanine, arginine, aspartic acid, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and glutamine. The amino acid composition of the present invention has such an effect that it can improve the action of promoting the process wherein the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090117209 - Andrographis paniculata extract: An extract of Andrographis paniculata extract containing andrographolide, 14-deoxyandrographolide, 14-deoxy-11,12-dehydroandrographolide, neoandrographolide, polysacchlorides, and flavanoids. Also disclosed is a pharmaceutical composition containing such an extract and its use for treating inflammatory bowel disease.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090117210 - Andrographis paniculata extract: An extract of Andrographis paniculata extract containing andrographolide, 14-deoxyandrographolide, 14-deoxy-11,12-dehydroandrographolide, neoandrographolide, polysacchorides, and flavanoids. Also disclosed is a pharmaceutical composition containing such an extract and its use for treating inflammatory bowel disease.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090117211 - Compositions and methods for stimulating synthesis of pro-collagen or collagen and hyaluronic acid: The present invention relates to a method that is useful for improving the appearance, texture and/or moisture of skin. In particular, the methods of the present invention comprise administering a composition comprising Chia Seed oil, Opuntia Ficus Indica extract, or both to stimulate collagen or hyaluronic acid synthesis, or decrease... Agent: In Re: 28533 Brinks, Hofer, Gilson & Lione

20090117212 - Tobacco cultivar aob 176 and products therefrom: The present invention relates to a novel tobacco cultivar designated AOB 176, which has low to intermediate nicotine content. The invention provides seeds of the cultivar AOB 176, plants and parts thereof of the cultivar AOB 176, a tissue culture derived from the cultivar AOB 176, hybrids produced from cultivar... Agent: Myers Bigel Sibley & Sajovec

20090117213 - Stable solutions having antiviral, antibacterial and hemostatic properties and methods of making thereof: Chitosan/alcohol solutions being stable solutions that have antiviral, antibacterial and hemostatic effects and methods of making thereof. The solutions can be liquids or gels and can be delivered in variety of manners.... Agent: Ryan Kromholz & Manion, S.c.

20090117214 - Extract of fraxinus excelsior seeds and therapeutic applications therefor: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior... Agent: Orrick, Herrington & Sutcliffe, LLPIPProsecution Department

20090117215 - Extract of ceratonia siliqua leaves and pods containing polyphenols with antioxidant and antitumor activities: The use of an extract of Ceratonia siliqua leaves and pod containing polyphenols (gallic acid, (−)-epigallocatechin gallate, (−)-epicatechin gallate) with oxidant activity and potential antitumor activity, useful for the preparation of pharmaceutical compositions, dietary supplements or extemporaneous preparations for the alimentary use, as well as processes for the preparation of... Agent: Young & Thompson

20090117216 - Composition and use of phyto-percolate for treatment of disease: This invention relates generally to a method of preparation of a phyto-percolate that is derived from fresh water mixture including algae. The phyto-percolate is believed to contain an enzyme having proteolytic activity. The invention further relates to the use of the phyto-percolate in a variety of disease states.... Agent: John C. Serio Brown Rusnick Berlack Israels, LLP